<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:74.1pt;left:72.2pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">A Prospective, Multi-Center, Randomized, Triple-Blinded,  Placebo-</span></b></p>
<p style="top:92.5pt;left:76.4pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Controlled study of IL-1RA Treatment in Patients with Acute ACL </span></b></p>
<p style="top:110.9pt;left:213.7pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Tear and Painful Effusions </span></b></p>
<p style="top:129.3pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:147.7pt;left:72.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">NCT Number: </span></b><span style="font-family:Times New Roman,serif;font-size:16.0pt">NCT02930122</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:166.2pt;left:72.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:184.5pt;left:72.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Document Date:</span></b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> 03 March 2020 </span></p>
<p style="top:202.9pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:221.3pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:239.7pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:258.0pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:276.5pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:294.9pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:313.2pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:331.6pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:74.1pt;left:72.2pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">A Prospective, Multi-Center, Randomized, Triple-Blinded,  Placebo-</span></b></p>
<p style="top:92.5pt;left:76.4pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Controlled study of IL-1RA Treatment in Patients with Acute ACL </span></b></p>
<p style="top:110.9pt;left:213.7pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Tear and Painful Effusions </span></b></p>
<p style="top:129.3pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:147.7pt;left:227.3pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Short title:  EASI ACL </span></b></p>
<p style="top:166.1pt;left:306.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:184.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor:  </span></b></p>
<p style="top:184.0pt;left:144.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:184.0pt;left:180.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Austin Stone MD, PhD  </span></b></p>
<p style="top:197.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:197.8pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:197.8pt;left:144.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:197.8pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Univeristy of Kentucky </span></p>
<p style="top:211.6pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Department of Orthopaedic Surgery &amp; Sport Medicine </span></p>
<p style="top:225.4pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">760 S Limestone, Suite K401 </span></p>
<p style="top:239.2pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Lexington, KY 40536-0284 </span></p>
<p style="top:253.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:253.0pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:   (859)218-3065 </span></p>
<p style="top:266.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                    Fax:      (859) 323-2412 </span></p>
<p style="top:280.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:280.6pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:  austin.stone@uky.edu </span></p>
<p style="top:294.4pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:308.2pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Principal Investigator: Cale Jacobs, PhD </span></b></p>
<p style="top:322.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">University of Kentucky  </span></p>
<p style="top:335.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Department of Orthopaedic Surgery &amp;   </span></p>
<p style="top:349.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Sport Medicine </span></p>
<p style="top:363.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Lexington, KY 40536 </span></p>
<p style="top:377.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Phone Number:  859-797-8197 </span></p>
<p style="top:391.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Fax:    859-323-2412 </span></p>
<p style="top:404.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                        Email:  cale.jacobs@uky.edu </span></p>
<p style="top:418.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:432.9pt;left:234.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt"> </span></b></p>
<p style="top:457.3pt;left:254.6pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">IND#:  116,316 </span></b></p>
<p style="top:481.6pt;left:102.0pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Funded by: Arthritis Foundation and Sobi Pharmaceuticals </span></b></p>
<p style="top:506.1pt;left:232.2pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">Version Number:  7.0 </span></b></p>
<p style="top:524.5pt;left:258.8pt;line-height:16.0pt"><b><span style="font-family:Times New Roman,serif;font-size:16.0pt">3 March 2020</span></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:746.4pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Calibri,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:74.3pt;left:264.6pt;line-height:11.0pt"><b><span style="font-family:Times New Roman,serif;font-size:11.0pt">Table of Contents </span></b></p>
<p style="top:96.1pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">LIST OF ABBREVIATIONS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ....................................................................................................................................... 1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:108.3pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">STATEMENT OF COMPLIANCE</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................................................. 3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:120.6pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">INVESTIGATOR SIGNATURE</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................................. 4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:132.7pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">PROTOCOL SUMMARY</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................................... 5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:144.9pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">SCHEMATIC OF STUDY DESIGN</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................................................................... 7</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:157.2pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:157.2pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">KEY ROLES</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ......................................................................................................................................................... 8</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:169.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Arial,sans-serif;font-size:10.0pt">2 </span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................... 9</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:181.6pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:181.6pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Background Information</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................ 9</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:195.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:195.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rationale</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">............................................................................................................................................... 14</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:209.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:209.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Potential Risks and Benefits</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................. 15</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:223.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.3.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:223.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Known Potential Risks</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................................... 15</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:237.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.3.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:237.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Known Potential Benefits</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................. 16</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:251.7pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:251.7pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">OBJECTIVES AND PURPOSE</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................................................................... 16</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:264.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY DESIGN AND ENDPOINTS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................ 16</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:276.2pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:276.2pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Description of the Study Design</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................... 16</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:290.2pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:290.2pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY ENDPOINTS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ......................................................................................................................... 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:304.3pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4.2.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:304.3pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Primary Endpoint</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................. 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:318.3pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4.2.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:318.3pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Secondary Endpoints</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................ 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:332.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:332.4pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY ENROLLMENT AND WITHDRAWAL</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................. 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:344.6pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:344.6pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Participant Inclusion Criteria</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................ 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:358.6pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:358.6pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Participant Exclusion Criteria</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">............................................................................................................... 17</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:372.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:372.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Strategies for Recruitment and Retention</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................. 18</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:386.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:386.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Participant Withdrawal or termination</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................. 18</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:400.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.4.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:400.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reasons for Withdrawal or Termination</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................... 18</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:414.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.4.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:414.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Handling of Participant Withdrawals or termination</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................ 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:428.8pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:428.8pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Premature Termination or Suspension of Study</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................... 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:442.8pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:442.8pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY AGENT</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................................................................. 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:455.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:455.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Agent(s) and Control Description</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................. 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:469.0pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:469.0pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Acquisition</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................ 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:483.1pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:483.1pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Formulation, Appearance, Packaging, and Labeling</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................ 19</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:497.1pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:497.1pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Product Storage and Stability</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................... 20</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:511.2pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:511.2pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Preparation</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................ 20</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:525.2pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:525.2pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dosing and Administration</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................... 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:539.2pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.6</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:539.2pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Route of Administration</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................... 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:553.3pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.7</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:553.3pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Starting Dose and Dose Escalation Schedule</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................... 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:567.3pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.8</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:567.3pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dose Adjustments/Modifications/Delays</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ......................................................................... 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:581.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.9</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:581.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Duration of Therapy</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ......................................................................................................... 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:595.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.1.10</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:595.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Tracking of Dose</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................. 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:609.4pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:609.4pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study agent Accountability Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................ 21</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:623.5pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:623.5pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY PROCEDURES AND SCHEDULE</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................................................... 22</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:635.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:635.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Procedures/Evaluations</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................. 22</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:649.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.1.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:649.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study related</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................................................... 22</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:663.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.1.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:663.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Standard of care study procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................... 24</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:677.8pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:677.8pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Laboratory Procedures/Evaluations</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................................................... 24</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:691.9pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.2.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:691.9pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical Laboratory Evaluations</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ....................................................................................... 24</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:705.9pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.2.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:705.9pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Other Assays or Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................. 25</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:746.4pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Calibri,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:73.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.2.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:73.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Specimen Preparation, Handling, and Storage</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................. 26</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:87.7pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.2.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:87.7pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Specimen Shipment</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................................................... 26</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:101.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:101.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Schedule</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................................................................... 26</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:115.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.3.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:115.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Screening/enrollment</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................ 26</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:129.8pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.3.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:129.8pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Schedule of Events Table</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................. 27</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:143.8pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:143.8pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Justification for Sensitive Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:157.9pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:157.9pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Concomitant Medications, Treatments, and Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:171.9pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.6</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:171.9pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Prohibited Medications, Treatments, and Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:186.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.8</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:186.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rescue Medications, Treatments, and Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:200.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.9</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:200.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Participant Access to Study Agent At Study Closure</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:214.0pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:214.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ASSESSMENT OF SAFETY</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................................. 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:226.3pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:226.3pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Specification of Safety Parameters</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ....................................................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:240.3pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.1.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:240.3pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Definition of Adverse Events (AE)</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">................................................................................... 29</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:254.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.1.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:254.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Definition of Serious Adverse Events (SAE)</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................... 30</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:268.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.1.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:268.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Definition of Unanticipated Problems (UP)</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">...................................................................... 30</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:282.4pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:282.4pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Classification of an Adverse Event</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................................................... 30</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:296.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.2.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:296.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Severity of Event</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................. 30</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:310.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.2.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:310.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Relationship to Study Agent</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................. 31</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:324.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.2.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:324.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Expectedness</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................................... 32</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:338.5pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:338.5pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Time Period and Frequency for Event Assessment and Follow-Up</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................... 32</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:352.5pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:352.5pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reporting Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................... 33</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:366.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:366.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Adverse Event Reporting</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................. 33</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:380.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:380.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Serious Adverse Event Reporting</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................... 33</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:394.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:394.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Unanticipated Problem Reporting</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................... 35</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:408.7pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:408.7pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Events of Special Interest</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................. 36</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:422.7pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.4.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:422.7pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Reporting of Pregnancy</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................... 36</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:436.8pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:436.8pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Halting Rules</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">.............................................................................................................................. 36</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:450.8pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.6</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:450.8pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Safety Oversight</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................................... 36</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:464.8pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">9</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:464.8pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">CLINICAL MONITORING</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................................. 37</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:477.1pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">STATISTICAL CONSIDERATIONS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................. 37</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:489.3pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:489.3pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Statistical and Analytical Plans</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................................ 37</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:503.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.1.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:503.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">General Approach</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................................. 37</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:517.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.1.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:517.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Analysis of the Primary Efficacy Endpoint(s)</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................. 38</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:531.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.1.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:531.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Analysis of the Secondary Endpoint(s)</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................. 38</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:545.5pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:545.5pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Measures to Minimize Bias</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................................. 38</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:559.5pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.2.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:559.5pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Enrollment/ Randomization/ Masking Procedures</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................... 38</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:573.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.2.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:573.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Evaluation of Success of Blinding</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................... 39</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:587.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.2.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:587.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Breaking the Study Blind/Participant Code</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................... 39</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:601.5pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">11</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................. 39</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:613.8pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">12</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">QUALITY ASSURANCE AND QUALITY CONTROL</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................... 40</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:626.0pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">ETHICS/PROTECTION OF HUMAN SUBJECTS</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................ 40</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:638.2pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:638.2pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ethical Standard</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................................... 40</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:652.3pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:652.3pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Institutional Review Board</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................... 40</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:666.3pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:666.3pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Informed Consent Process</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................................... 40</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:680.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.3.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:680.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Consent/assent and Other Informational Documents Provided to Participants</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt">................. 41</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:694.4pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.3.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:694.4pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Consent Procedures and Documentation</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................... 41</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:708.4pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:708.4pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Participant and data Confidentiality</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ..................................................................................................... 41</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:746.4pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Calibri,sans-serif;font-size:9.0pt"> </span></p>
<p style="top:73.6pt;left:92.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.4.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:73.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Research Use of Stored Human Samples,Specimens or Data</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................... 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:87.7pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.5</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:87.7pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Future Use of Stored Specimens</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .......................................................................................................... 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:101.7pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">DATA HANDLING AND RECORD KEEPING</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................ 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:114.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:114.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Data Collection and Management Responsibilities</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................. 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:128.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14.2</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:128.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Records Retention</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ...................................................................................................................... 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:142.0pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14.3</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:142.0pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Protocol Deviations</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .............................................................................................................................. 42</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:156.1pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14.4</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:156.1pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Publication and Data Sharing Policy</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................... 43</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:170.0pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">15</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">STUDY ADMINISTRATION</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ............................................................................................................................. 44</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:182.2pt;left:82.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">15.1</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:182.2pt;left:130.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study Leadership</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> .................................................................................................................................. 44</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:196.3pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">16</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">CONFLICT OF INTEREST POLICY</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ................................................................................................................. 44</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:208.5pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">17 </span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">LITERATURE REFERENCES</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................... 44</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:220.8pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">18 </span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Appendixes</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> ........................................................................................................................................................... 47</span><span style="font-family:Calibri,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:232.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">1 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.6pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">LIST OF ABBREVIATIONS </span></b></p>
<p style="top:93.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:107.3pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ACL </span></p>
<p style="top:107.3pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Anterior cruciate ligament (ACL) </span></p>
<p style="top:121.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">AE </span></p>
<p style="top:121.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Adverse Event </span></p>
<p style="top:135.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CFR </span></p>
<p style="top:135.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Code of Federal Regulations </span></p>
<p style="top:150.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CRF </span></p>
<p style="top:150.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Case Report Form </span></p>
<p style="top:164.5pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CIOMS </span></p>
<p style="top:164.5pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Council for International Organizations of Medical Science </span></p>
<p style="top:178.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CLIA </span></p>
<p style="top:178.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical Laboratory Improvement Amendments </span></p>
<p style="top:193.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CMP </span></p>
<p style="top:193.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical Monitoring Plan </span></p>
<p style="top:207.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CMS </span></p>
<p style="top:207.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Center for Medicare and Medicaid Services </span></p>
<p style="top:221.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">COMP </span></p>
<p style="top:221.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Cartilage oligomeric protein </span></p>
<p style="top:235.9pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CSQ </span></p>
<p style="top:235.9pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Coping Strategies Questionnaire </span></p>
<p style="top:250.3pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CTXII </span></p>
<p style="top:250.3pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Collagen Type II </span></p>
<p style="top:264.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DHHS </span></p>
<p style="top:264.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Department of Health and Human Services </span></p>
<p style="top:278.9pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DSMB </span></p>
<p style="top:278.9pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Data Safety Monitoring Board </span></p>
<p style="top:293.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">eCRF </span></p>
<p style="top:293.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Electronic Case Report Forms </span></p>
<p style="top:307.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FDA </span></p>
<p style="top:307.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Food and Drug Administration </span></p>
<p style="top:321.7pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FDAAA </span></p>
<p style="top:321.7pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Food and Drug Administration Amendments Act of 2007 </span></p>
<p style="top:336.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FFR </span></p>
<p style="top:336.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Federal Finance Report </span></p>
<p style="top:350.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">GAG </span></p>
<p style="top:350.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">glycomsaminoglycan </span></p>
<p style="top:364.7pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">GCP </span></p>
<p style="top:364.7pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Good Clinical Practice </span></p>
<p style="top:379.0pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">GLP </span></p>
<p style="top:379.0pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Good Laboratory Practice </span></p>
<p style="top:393.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">GMP </span></p>
<p style="top:393.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Good Manufacturing Practice </span></p>
<p style="top:407.5pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">HIPAA </span></p>
<p style="top:407.5pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Health Insurance Portability and Accountability Act </span></p>
<p style="top:421.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IB </span></p>
<p style="top:421.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator&#x2019;s Brochure </span></p>
<p style="top:436.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ICH </span></p>
<p style="top:436.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">International Conference on Harmonisation </span></p>
<p style="top:450.5pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ICH E6 </span></p>
<p style="top:450.5pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">International Conference on Harmonisation Guidance for Industry, Good </span></p>
<p style="top:464.3pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical Practice: Consolidated Guidance </span></p>
<p style="top:478.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ICMJE </span></p>
<p style="top:478.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">International Committee of Medical Journal Editors </span></p>
<p style="top:492.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IKDC </span></p>
<p style="top:492.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">International Knee Documentation Committee </span></p>
<p style="top:507.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1ra </span></p>
<p style="top:507.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Interleukin 1 receptor antagonist </span></p>
<p style="top:521.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IND </span></p>
<p style="top:521.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigational New Drug Application </span></p>
<p style="top:535.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IRB </span></p>
<p style="top:535.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Institutional Review Board </span></p>
<p style="top:550.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ISO </span></p>
<p style="top:550.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">International Organization for Standardization </span></p>
<p style="top:564.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS </span></p>
<p style="top:564.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Knee Injury and Osteoarthritis Outcome Score </span></p>
<p style="top:578.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">LSMEANS </span></p>
<p style="top:578.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Least-squares means </span></p>
<p style="top:592.9pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MedDRA </span></p>
<p style="top:592.9pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Medical Dictionary for Regulatory Activities </span></p>
<p style="top:607.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MOON </span></p>
<p style="top:607.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Multicenter, Orthopaedic Outcome Network </span></p>
<p style="top:621.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MOP </span></p>
<p style="top:621.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Manual of Procedures </span></p>
<p style="top:635.9pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI </span></p>
<p style="top:635.9pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Magnetic Resonance Imaging </span></p>
<p style="top:650.2pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MSDS </span></p>
<p style="top:650.2pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Material Safety Data Sheet </span></p>
<p style="top:664.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">NIH </span></p>
<p style="top:664.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">National Institutes of Health </span></p>
<p style="top:678.7pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">NIH IC </span></p>
<p style="top:678.7pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">NIH Institute and Center </span></p>
<p style="top:693.0pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">NtxI </span></p>
<p style="top:693.0pt;left:131.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:693.0pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Collagen Type I </span></p>
<p style="top:693.0pt;left:534.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">2 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:74.0pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">OA </span></p>
<p style="top:74.0pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Osteoarthritis </span></p>
<p style="top:88.3pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">OHRP  </span></p>
<p style="top:88.3pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Office for Human Research Protections </span></p>
<p style="top:102.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PI </span></p>
<p style="top:102.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Principal Investigator </span></p>
<p style="top:117.0pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PTOA </span></p>
<p style="top:117.0pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Post-traumatic osteoarthritis </span></p>
<p style="top:131.3pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">QA </span></p>
<p style="top:131.3pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Quality Assurance </span></p>
<p style="top:145.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">QC </span></p>
<p style="top:145.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Quality Control </span></p>
<p style="top:159.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">RA </span></p>
<p style="top:159.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Rheumatoid Arthritis </span></p>
<p style="top:174.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SAE </span></p>
<p style="top:174.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Serious Adverse Event </span></p>
<p style="top:188.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SAP </span></p>
<p style="top:188.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Statistical Analysis Plan </span></p>
<p style="top:202.8pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SOC </span></p>
<p style="top:202.8pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">System Organ Class </span></p>
<p style="top:217.1pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SOP </span></p>
<p style="top:217.1pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Standard Operating Procedure </span></p>
<p style="top:231.4pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">UP </span></p>
<p style="top:231.4pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Unanticipated Problem </span></p>
<p style="top:245.6pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">US </span></p>
<p style="top:245.6pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">United States </span></p>
<p style="top:259.9pt;left:77.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">XO </span></p>
<p style="top:259.9pt;left:149.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Xanthine Oxidase </span></p>
<p style="top:277.3pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:292.4pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:292.4pt;left:216.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">3 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.8pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">STATEMENT OF COMPLIANCE </span></b></p>
<p style="top:90.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:114.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:126.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The trial will be carried out in accordance with Good Clinical Practice (GCP) as required by the </span></p>
<p style="top:138.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">following (use applicable regulations depending on study location and sponsor requirements; </span></p>
<p style="top:150.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">examples follow): &#x2022; United States (US) Code of Federal Regulations (CFR) applicable to clinical </span></p>
<p style="top:162.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part </span></p>
<p style="top:174.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">812) &#x2022; ICH E6 All key personnel (all individuals responsible for the design and conduct of this </span></p>
<p style="top:186.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">trial) have completed Human Subjects Protection Training. </span></p>
<p style="top:198.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:210.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:222.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor: _______ _Austin Stone, MD,PhD______________________ </span></p>
<p style="top:234.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                 Print/Type Name  </span></p>
<p style="top:246.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:258.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:270.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Signed: _____________________________________ Date: ______________ </span></p>
<p style="top:282.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                             Signature </span></p>
<p style="top:294.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:306.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:318.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:330.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:342.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:354.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:366.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">4 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:74.2pt;left:72.0pt;line-height:16.0pt"><b><span style="font-family:Arial,sans-serif;font-size:16.0pt">INVESTIGATOR SIGNATURE </span></b></p>
<p style="top:103.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">I, the undersigned Investigator, have read the following protocol and agree to conduct the study </span></p>
<p style="top:117.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in compliance with the protocol, International Conference on Harmonization (ICH) Good </span></p>
<p style="top:131.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical Practice (GCP), Good Laboratory Practice (GLP) and all applicable regulatory </span></p>
<p style="top:145.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">requirements. </span></p>
<p style="top:165.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">I, the undersigned Investigator, agree:  </span></p>
<p style="top:185.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">To assume responsibility for the proper conduct of the study and not to deviate from the </span></p>
<p style="top:199.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">procedures described in the protocol. </span></p>
<p style="top:220.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">I am thoroughly familiar with the investigational product(s) as described in the protocol, </span></p>
<p style="top:234.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator&#x2019;s Brochure and any other relevant information sources provided to me. </span></p>
<p style="top:254.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">I am aware of and will conduct the study in compliance with the protocol, ICH GCP </span></p>
<p style="top:268.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">guidelines and all applicable regulatory requirements. </span></p>
<p style="top:289.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">I agree to permit monitoring and auditing of the study by the Sponsor and its designates, and </span></p>
<p style="top:303.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inspection by appropriate regulatory authority (ies). </span></p>
<p style="top:323.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">I agree to ensure that all persons assisting with the conduct of the study are properly qualified </span></p>
<p style="top:337.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">for their function. </span></p>
<p style="top:357.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:377.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator Name &amp; Signature: </span></b></p>
<p style="top:395.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:407.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Principal Investigator: __ Cale Jacobs, PhD _______________________________________ </span></p>
<p style="top:419.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                         Print/Type Name  </span></p>
<p style="top:431.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:443.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:455.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Signed: _____________________________________ Date: ______________ </span></p>
<p style="top:467.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                             Signature </span></p>
<p style="top:479.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:491.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:503.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:515.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:528.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:528.9pt;left:216.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff"> </span></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">5 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.8pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">PROTOCOL SUMMARY </span></b></p>
<p style="top:90.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:102.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Title: </span></b></p>
<p style="top:90.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:105.2pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A Prospective, Multicenter, Randomized, Triple-Blinded, Placebo-</span></p>
<p style="top:121.2pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Controlled study of IL-1RA Treatment in Patients with Acute ACL </span></p>
<p style="top:137.3pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Tear and Painful Effusions </span></p>
<p style="top:150.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Pr&#xe9;cis: </span></b></p>
<p style="top:150.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This study aims to establish efficacy and timing of administration, to </span></p>
<p style="top:162.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reduce post-injury pain, decrease inflammatory biomarkers in ACL </span></p>
<p style="top:174.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injured patients undergoing ACL reconstruction and correlate </span></p>
<p style="top:186.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">function, patient reported outcomes and MRI findings at 1 years after </span></p>
<p style="top:198.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ACL injury.  The study population will include 40 subjects, ages 14-</span></p>
<p style="top:210.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">40 who will be randomized into 2 groups (20 subjects per group).  </span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#44536a"> </span></p>
<p style="top:222.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Objectives: </span></b></p>
<p style="top:234.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:222.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1. Test the efficacy of a treatment protocol using IL-1ra and knee </span></p>
<p style="top:234.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">arthrocentesis to alleviate inflammation related knee pain and </span></p>
<p style="top:246.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">improve patient-reported outcomes (PRO) following ACL rupture. </span></p>
<p style="top:258.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.  Determine if intra-articular IL-1ra therapy improves levels of a </span></p>
<p style="top:270.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">panel of inflammatory, meniscus and cartilage metabolism, and </span></p>
<p style="top:282.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">oxidative stress biomarkers as measured in synovial fluid, serum and </span></p>
<p style="top:294.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">urine from patients immediately after ACL injury (baseline, 2 weeks </span></p>
<p style="top:306.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">after injury and at 1 and 2 years after surgery). </span></p>
<p style="top:318.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">3.  Answer the question if MRI T1rho changes correlate with </span></p>
<p style="top:330.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">synovial biomarker levels and show predictive value for the overall </span></p>
<p style="top:342.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subject patient outcome at 2 years</span><span style="font-family:SegoeUIHistoric,sans-serif;font-size:11.0pt">.</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:357.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Endpoint </span></b></p>
<p style="top:357.0pt;left:198.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Primary endpoint :</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">    </span></p>
<p style="top:369.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Change in Patient reported outcomes as measured by KOOS-</span></p>
<p style="top:381.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Symptoms  </span></p>
<p style="top:393.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:405.0pt;left:198.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Secondary endpoints</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">:  </span></p>
<p style="top:417.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS QOL,  </span></p>
<p style="top:429.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS-pain,  </span></p>
<p style="top:441.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS-Sports/Rec,  </span></p>
<p style="top:453.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarker levels in synovial fluid, serum and urine at time of surgery </span></p>
<p style="top:465.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI T1rho changes at 2 years </span></p>
<p style="top:477.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:489.0pt;left:198.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study Stopping Criteria </span></b></p>
<p style="top:501.0pt;left:198.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:513.0pt;left:216.8pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Local intolerance of the administered Anakinra (Kineret&#xae;) or </span></p>
<p style="top:525.0pt;left:234.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">any sign of allergic response. </span></p>
<p style="top:537.0pt;left:216.8pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Development of signs and symptoms before the second time </span></p>
<p style="top:549.0pt;left:234.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">point preventing the second administration of the study drug. </span></p>
<p style="top:561.0pt;left:216.8pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Any patient reported and drug related SAE after the first or </span></p>
<p style="top:573.0pt;left:234.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">second administration of the study drug. </span></p>
<p style="top:585.0pt;left:216.8pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Diagnosis with any condition as outlined in the exclusion </span></p>
<p style="top:597.0pt;left:234.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">criteria during the course of the</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">initial 2 weeks of study </span></p>
<p style="top:609.0pt;left:234.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">enrollment.</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:621.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Population: </span></b></p>
<p style="top:621.0pt;left:202.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study population will include up to 40 subjects within 28 days </span></p>
<p style="top:633.0pt;left:202.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">following of injury.  The study is open to male and female </span></p>
<p style="top:645.0pt;left:202.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participants who are between the ages of 14 and 40, who have ACL </span></p>
<p style="top:657.0pt;left:202.4pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">tears. Participants will be enrolled at the University of Kentucky. </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">6 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phase: </span></b></p>
<p style="top:72.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2 </span></p>
<p style="top:84.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Number of Sites </span></b></p>
<p style="top:96.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">enrolling </span></b></p>
<p style="top:108.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">participants: </span></b></p>
<p style="top:84.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1 (University of Kentucky) </span></p>
<p style="top:96.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:120.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Description of Study </span></b></p>
<p style="top:132.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Agent : </span></b></p>
<p style="top:120.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1ra (Kineret&#xae;, anakinra), supplied by Sobi Pharmaceuticals,  is a </span></p>
<p style="top:132.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recombinant, nonglycosylated form of human interleukin-1 receptor </span></p>
<p style="top:144.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">antagonist (IL-1Ra).  Kineret&#xae; consists of 153 amino acids and has a </span></p>
<p style="top:156.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">molecular weight of 17.3 kilodaltons.  It is produced by recombinant </span></p>
<p style="top:168.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DNA technology using an </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">E coli</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> bacterial expression system.  It is </span></p>
<p style="top:180.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">available as pre-filled syringes (100 mg in 0.67 mls) and is FDA </span></p>
<p style="top:192.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">approved for daily subcutaneous injection (100 mg/day) for treatment </span></p>
<p style="top:204.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of rheumatoid arthritis (age &gt; 10).  A total of 1.5 ml (150 mg) will be </span></p>
<p style="top:216.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injected intra-articularly after synovial fluid aspiration &apos;to dryness&apos; </span></p>
<p style="top:228.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">once between 1 and 28 days after ACL injury</span><span style="font-family:Times New Roman,serif;font-size:11.0pt">.</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:240.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study Duration: </span></b></p>
<p style="top:240.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">24-36 months </span></p>
<p style="top:252.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participant </span></b></p>
<p style="top:264.0pt;left:77.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Duration: </span></b></p>
<p style="top:252.0pt;left:198.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2 years </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:288.0pt;left:216.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">7 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.8pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">SCHEMATIC OF STUDY DESIGN </span></b></p>
<p style="top:90.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.0pt;left:72.0pt;line-height:14.0pt"><b><span style="font-family:Times New Roman,serif;font-size:14.0pt">Flow diagram  </span></b></p>
<p style="top:116.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:129.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Prior to Enrollment   </span></b></p>
<p style="top:141.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:153.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:165.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:177.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:189.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:201.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:213.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:225.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 1 </span></b></p>
<p style="top:237.7pt;left:72.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:108.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:144.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:180.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:216.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:252.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:288.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:324.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:360.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:396.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:432.0pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:467.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:237.7pt;left:503.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:249.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:249.7pt;left:107.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:261.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:273.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:285.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:297.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:309.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:321.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:333.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:345.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:357.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:369.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:381.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:393.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:405.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:417.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:429.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:441.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:453.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:465.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:477.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">    </span></b></p>
<p style="top:489.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:501.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 2  </span></b></p>
<p style="top:513.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Surgery </span></b></p>
<p style="top:525.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:537.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 3  </span></b></p>
<p style="top:549.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">4-14 days  </span></b></p>
<p style="top:561.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">After Visit 2  </span></b></p>
<p style="top:573.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:585.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 4 </span></b></p>
<p style="top:597.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">6 Mo After Visit 2 </span></b></p>
<p style="top:609.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:621.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 5 </span></b></p>
<p style="top:633.7pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">12 Mo After Visit 2 </span></b></p>
<p style="top:645.7pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:657.8pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 6 </span></b></p>
<p style="top:669.8pt;left:71.9pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">24 Mo After Visit 2 </span></b></p>
<p style="top:681.8pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:693.8pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:123.9pt;left:180.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Total 40: Obtain informed consent. Screen potential subjects by inclusion and </span></p>
<p style="top:133.9pt;left:180.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exclusion Enrollment criteria; obtain history, document. </span></p>
<p style="top:145.2pt;left:180.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:212.4pt;left:293.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">  Randomization for </span></p>
<p style="top:224.4pt;left:293.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those present within </span></p>
<p style="top:236.4pt;left:293.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Day 1-28 of injury</span></p>
<p style="top:248.4pt;left:293.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:248.4pt;left:329.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:260.4pt;left:293.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:260.4pt;left:329.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:272.4pt;left:293.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:272.4pt;left:329.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:284.4pt;left:293.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:284.4pt;left:346.6pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:284.4pt;left:372.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:296.4pt;left:327.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:306.8pt;left:355.6pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:306.8pt;left:366.5pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></b></p>
<p style="top:316.9pt;left:359.6pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">   </span></b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:288.4pt;left:263.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Group 1 </span></p>
<p style="top:299.5pt;left:256.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">20 Subjects </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.31954415,-281.64,407.32)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.32000003,0,-0,.32000003,206.36002,531)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEoAAABaCAIAAACQZFe9AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAfUlEQVR4nO3PAQ0AIAzAMO7fNCoeUrIq2OZ8bV4H7GpP1p6sPVl7
svZk7cnak7Una0/Wnqw9WXuy9mTtydqTtSdrT9aerD1Ze7L2ZO3J2pO1J2tP1p6s
PVl7svZk7cnak7Una0/Wnqw9WXuy9mTtydqTtSdrT9aerD1Ze7ILPlkAWzQsxPgA
AAAASUVORK5CYII=">
<p style="top:425.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32000003,0,-0,.32000003,206.36002,548.28)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEoAAABaCAIAAACQZFe9AAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAfUlEQVR4nO3PAQ0AIAzAMO7fNCoeUrIq2OZ8bV4H7GpP1p6sPVl7
svZk7cnak7Una0/Wnqw9WXuy9mTtydqTtSdrT9aerD1Ze7L2ZO3J2pO1J2tP1p6s
PVl7svZk7cnak7Una0/Wnqw9WXuy9mTtydqTtSdrT9aerD1Ze7ILPlkAWzQsxPgA
AAAASUVORK5CYII=">
<p style="top:438.6pt;left:180.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.31989209,0,-0,.3194788,-270.36003,427.40003)" src="data:image/png;base64,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">
<p style="top:400.2pt;left:182.3pt;line-height:10.0pt"><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Perform baseline assessments.</span></b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Refer to</span></b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">Section 7.3.2 Schedule of Events Table</span></b><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:412.2pt;left:278.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Administer initial study intervention. </span></p>
<p style="top:424.2pt;left:182.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Group 1:  Anakinra 1-28 days post-injury </span></p>
<p style="top:436.2pt;left:182.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Group 2:  Saline 1-28 days post-injury  </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.31666664,-274.91999,657.2)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31820227,0,-0,.31714285,195.6,653.2001)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFkAAAA4CAIAAAAZwcMHAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAeUlEQVR4nO3QMQ0AMAzAsJU/6V1VIGyHjSDKHNa8DviIF/EiXsSL
eBEv4kW8iBfxIl7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEv4kW8iBfx
Il7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEvcgHBygA5/xMMRwAAAABJ
RU5ErkJggg==">
<p style="top:507.4pt;left:176.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.32,-264.72,660.12008)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAABawAAAAqCAIAAADQ7YsIAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAABK0lEQVR4nO3YMQEAMAyAsNa/6brYDhIF3OwAAAAABOzvAAAAAIAX
TBAAAAAgwQQBAAAAEkwQAAAAIMEEAQAAABJMEAAAACDBBAEAAAASTBAAAAAgwQQB
AAAAEkwQAAAAIMEEAQAAABJMEAAAACDBBAEAAAASTBAAAAAgwQQBAAAAEkwQAAAA
IMEEAQAAABJMEAAAACDBBAEAAAASTBAAAAAgwQQBAAAAEkwQAAAAIMEEAQAAABJM
EAAAACDBBAEAAAASTBAAAAAgwQQBAAAAEkwQAAAAIMEEAQAAABJMEAAAACDBBAEA
AAASTBAAAAAgwQQBAAAAEkwQAAAAIMEEAQAAABJMEAAAACDBBAEAAAASTBAAAAAg
wQQBAAAAEkwQAAAAIMEEAQAAABIO1xcAK9N44/8AAAAASUVORK5CYII=">
<p style="top:505.8pt;left:225.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Refer to Section 7.3.2 Schedule of Events Table </span></b></p>
<p style="top:517.8pt;left:346.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.31989203,0,-0,.31761194,-275.96003,792.36)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31820227,0,-0,.31786666,197.67998,788.36)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFkAAABLCAIAAACUd7xoAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAl0lEQVR4nO3QMQ0AMAzAsJU/6V1VIGyHjSDKHNa8DviIF/EiXsSL
eBEv4kW8iBfxIl7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEv4kW8iBfx
Il7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEv4kW8iBfxIl7Ei3gRL+JF
vIgX8SJexIt4ES/iRbyIF7n2wQBMBXnqDAAAAABJRU5ErkJggg==">
<p style="top:613.4pt;left:178.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.32,-264.68,799.99996)" src="data:image/png;base64,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">
<p style="top:614.3pt;left:184.6pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Follow-up assessments Refer to Section 7.3.2 Schedule of Events</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:670.2pt;left:295.7pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Final Assessments </span></b></p>
<p style="top:682.2pt;left:286.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Refer to Section 7.3.2 </span></b></p>
<p style="top:694.2pt;left:286.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Schedule of Events </span></b></p>
<p style="top:706.2pt;left:319.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:286.9pt;left:380.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Group 2 </span></p>
<p style="top:297.9pt;left:373.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">20 Subjects </span></p>
<p style="top:309.0pt;left:397.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.32,-274.91999,706.6)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAABcMAAAAvCAIAAACgzEVGAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAABTUlEQVR4nO3YMQ0AMAzAsJU/6VHIV1WyEeTOPAAAAACa2Q4AAAAA
OMNJAQAAAKicFAAAAIDKSQEAAAConBQAAACAykkBAAAAqJwUAAAAgMpJAQAAAKic
FAAAAIDKSQEAAAConBQAAACAykkBAAAAqJwUAAAAgMpJAQAAAKicFAAAAIDKSQEA
AAConBQAAACAykkBAAAAqJwUAAAAgMpJAQAAAKicFAAAAIDKSQEAAAConBQAAACA
ykkBAAAAqJwUAAAAgMpJAQAAAKicFAAAAIDKSQEAAAConBQAAACAykkBAAAAqJwU
AAAAgMpJAQAAAKicFAAAAIDKSQEAAAConBQAAACAykkBAAAAqJwUAAAAgMpJAQAA
AKicFAAAAIDKSQEAAAConBQAAACAykkBAAAAqJwUAAAAgMpJAQAAAKicFAAAAIDK
SQEAAACoPl9HADDviUxtAAAAAElFTkSuQmCC">
<img style="position:absolute;transform:matrix(.31820227,0,-0,.32,195.6,702.6)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFkAAAA3CAIAAADol3HSAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAd0lEQVR4nO3QMQ0AMAzAsJU/6V1VIGyHjSDKHNa8DviIF/EiXsSL
eBEv4kW8iBfxIl7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEv4kW8iBfx
Il7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeJELhh4AONpobaAAAAAASUVO
RK5CYII=">
<p style="top:543.7pt;left:176.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.31627906,-264.72,708.51998)" src="data:image/png;base64,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">
<p style="top:542.0pt;left:182.3pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Follow-up assessments Refer to Section 7.3.2 Schedule of Events </span></b></p>
<p style="top:554.0pt;left:360.6pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.32,-273,749.95999)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.31820227,0,-0,.32,197.68003,745.95999)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFkAAAA3CAIAAADol3HSAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAd0lEQVR4nO3QMQ0AMAzAsJU/6V1VIGyHjSDKHNa8DviIF/EiXsSL
eBEv4kW8iBfxIl7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeBEv4kW8iBfx
Il7Ei3gRL+JFvIgX8SJexIt4ES/iRbyIF/EiXsSLeJELhh4AONpobaAAAAAASUVO
RK5CYII=">
<p style="top:576.2pt;left:178.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.32,0,-0,.31627906,-262.64,751.8799)" src="data:image/png;base64,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">
<p style="top:574.6pt;left:183.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Follow-up assessments Refer to Section 7.3.2 Schedule of Events </span></b></p>
<p style="top:586.6pt;left:362.2pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">8 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.8pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">1 </span></b></p>
<p style="top:75.8pt;left:108.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">KEY ROLES </span></b></p>
<p style="top:90.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor </span></b></p>
<p style="top:114.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:  Austin Stone, MD, PhD  </span></p>
<p style="top:126.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Institution Name:      University of Kentucky </span></p>
<p style="top:138.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                    760 S Limestone, Suite K401 </span></p>
<p style="top:150.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                  Lexington, KY 40536-0284 </span></p>
<p style="top:162.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:         (859) 218-3065 </span></p>
<p style="top:174.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Fax:                           (859) 323-2412 </span></p>
<p style="top:186.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                       austin.stone@uky.edu </span></p>
<p style="top:198.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:210.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:222.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Principal Investigator   </span></b></p>
<p style="top:234.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:246.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:  Cale Jacobs, PhD </span></p>
<p style="top:258.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Institution Name:      University of Kentucky  </span></p>
<p style="top:270.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                    Department of Orthopaedic Surgery and Sport Medicine </span></p>
<p style="top:282.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                  Lexington, KY 40536-0284 </span></p>
<p style="top:294.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:         (859) 797-8197 </span></p>
<p style="top:306.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Fax:                           (859) 323-2412 </span></p>
<p style="top:318.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                       cale.jacobs@uky.edu </span></p>
<p style="top:330.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:342.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Monitor</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">: </span></p>
<p style="top:354.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:   Karen Bowen, RN </span></p>
<p style="top:366.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Business Name:         Bluegrass Research Consultants, Inc </span></p>
<p style="top:378.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                     8020 Sea Hero Run </span></p>
<p style="top:390.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                   Versailles, KY 40383 </span></p>
<p style="top:402.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:          (859) 396-4655 </span></p>
<p style="top:414.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                         bowen73@windstream.net </span></p>
<p style="top:426.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:438.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor Regulatory </span></b></p>
<p style="top:450.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:462.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:  Laura Ashe </span></p>
<p style="top:474.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Business Name:        Center for Clinical and Translational Science </span></p>
<p style="top:486.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                    800 Rose Street, Pavilion H, Suite C300 </span></p>
<p style="top:498.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                  Lexington, KY 40536 </span></p>
<p style="top:510.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:         (859) 323-2782 </span></p>
<p style="top:522.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                        Laura.Ashe@uky.edu  </span></p>
<p style="top:534.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:546.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:558.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">SAE Reporting </span></b></p>
<p style="top:570.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:582.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:  Austin Stone, MD, PhD  </span></p>
<p style="top:594.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Institution Name:      University of Kentucky </span></p>
<p style="top:606.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                    760 S Limestone, Suite K401 </span></p>
<p style="top:618.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                  Lexington, KY 40536-0284 </span></p>
<p style="top:630.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:         (859) 218-3065 </span></p>
<p style="top:642.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Fax:                           (859) 323-2412 </span></p>
<p style="top:654.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                       </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#0000ff">austin.stone@uky.edu </span></i></p>
<p style="top:666.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:678.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffff00">                                             </span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:303.5pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">9 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.8pt;left:72.0pt;line-height:11.0pt"><b><span style="font-family:Calibri,sans-serif;font-size:11.0pt;color:#ffffff">2  </span></b></p>
<p style="top:75.0pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC </span></b></p>
<p style="top:87.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">RATIONALE  </span></b></p>
<p style="top:102.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:117.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.1 </span></p>
<p style="top:117.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">BACKGROUND INFORMATION  </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A majority of individuals with partial or complete rupture of the anterior cruciate ligament </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(ACL) develop post-traumatic osteoarthritis (PTOA) 5-15 years after the initial injury. The long-</span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">term consequences of PTOA include arthrofibrosis, pain, limited motion, and recurrent </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">instability.  Because ACL injuries occur most often in younger individuals (average age 14-29 </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">years), pain and other debilitating symptoms occur most often during patients&#x2019; most productive </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">years costing society upwards of 3.06 billion dollars annually [1]. Current surgical and non-</span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">surgical treatment options for ACL injury, while relatively successful in restoring function and </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">stability in the short term, do little or nothing to reduce or prevent the development of PTOA </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">later in life.  </span></p>
<p style="top:252.8pt;left:72.0pt;line-height:11.0pt"><span style="font-family:SegoeUIHistoric,sans-serif;font-size:11.0pt"> </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ACL rupture, with or without accompanying damage to nearby cartilage and bone, initiates a </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">persistent cascade of inflammation and catabolic enzyme activity leading to OA of the knee </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">joint.  We propose to disrupt the inflammation-driven cascade with recombinant Interleukin 1 </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">receptor antagonist (IL-1ra).  </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:320.0pt;left:72.0pt;line-height:2.0pt"><span style="font-family:SegoeUIHistoric,sans-serif;font-size:2.0pt"> </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1ra was chosen because it is safe, well tolerated, and has been used to treat RA, juvenile </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inflammatory arthritis, and post-surgical persistent knee effusions as well as knee stiffness.[2-4</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#0000ff">.</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">] </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Our own preliminary data suggests that IL-1ra reduces pain and improves function in patients </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">with acute knee injury and arthrofibrosis.  IL-1ra binds to the Interleukin 1 receptor and </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">nonproductively blocks the proinflammatory and cartilage catabolic activities of Interleukin 1 </span></p>
<p style="top:384.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">alpha and beta.  IL-1ra levels in synovial fluid are initially higher following acute ACL injury </span></p>
<p style="top:396.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">but vanish rather quickly.  Subsequently, IL-</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">1&#x3b2; le</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">vels rise slower in joint fluid after ACL rupture </span></p>
<p style="top:408.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and remain high for longer periods of time.  IL-1ra has had mixed results in the treatment of </span></p>
<p style="top:420.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">established OA, possibly due to its short half-life in vivo.  However, if given shortly after the </span></p>
<p style="top:432.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">initial inciting event potentially initiating the development of OA, the effectiveness may be </span></p>
<p style="top:444.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">significantly higher.   </span></p>
<p style="top:456.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:468.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Unlike primary OA, which typically strikes older individuals and develops silently over the </span></p>
<p style="top:480.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">course of many years, post-traumatic OA is thought to begin at the moment of ACL injury in </span></p>
<p style="top:492.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">many individuals. Capitalizing on the expertise and experience of our collaborative team of </span></p>
<p style="top:504.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigators, we have chosen to seize this window of opportunity and provide the field with </span></p>
<p style="top:516.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">valuable new data regarding the importance of reduction of the initial inflammatory response to </span></p>
<p style="top:528.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury in acute ACL tears.  </span></p>
<p style="top:540.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:552.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">It is estimated 250,000 injuries to the anterior cruciate ligament (ACL) occur each year (1). </span></p>
<p style="top:564.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">These injuries predominantly occur at young age (14-18 years) The incidence of these injuries in </span></p>
<p style="top:576.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kentucky alone is 108/100.000 (2), a number that is on par with the incidence of prostate cancer </span></p>
<p style="top:588.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in men in the US (125/100.000) and higher than lung cancer in the US (79/100.000)(2) A high-</span></p>
<p style="top:600.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">school soccer player has a knee injury risk of 1/50 player hours. In light of the fact that </span></p>
<p style="top:612.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">regardless of whether or not the ligament is reconstructed, at least 50% of these patients will </span></p>
<p style="top:624.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">develop post-traumatic osteoarthritis (PTOA) 10-20 years after injury. (3,4) The consequences of </span></p>
<p style="top:636.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PTOA are debilitating, often resulting in participation restrictions and activity limitations that </span></p>
<p style="top:648.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">affect thousands of individuals each year. Currently the identification of treatment interventions, </span></p>
<p style="top:660.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">prevention strategies, or changes to current treatment algorithms to delay or deter the </span></p>
<p style="top:672.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">development of post-traumatic structural damage and subsequent PTOA development is limited </span></p>
<p style="top:684.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">as the precise mechanism and risk factors for the development of PTOA following ACL injury is </span></p>
<p style="top:696.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">unknown.  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">10 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Early inflammation: </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Early inflammation leads to </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">swelling, pain and pain related muscle shut down </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">affecting recovery.</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Hemarthrosis and intra-articular </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pathogenic processes (e.g., down-regulation of </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">proteoglycan synthesis and up-regulation of matrix </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">metalloproteinases) initiate inflammation at the time </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of injury [5-7].  It is widely accepted that the </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">balance between IL-1 and IL-1Ra are critical in the </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">regulation of the pathological processes involved in </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">joint tissue breakdown [8, 9]. IL-1 levels are </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">elevated in patients with ACL rupture and correlate </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">with severity of chondral damage in a study by </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Marks [10]. Additionally, chondroprotective </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cytokine levels are decreased with increasing </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">severity of chondral damage [10]. The superficial </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cartilage layers have been shown to be more </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">susceptible to IL-1 induced damage than deeper </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">layers, in an </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">in vitro</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> study [11].  Moreover, synovial </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">fluid levels of IL-1Ra are reported to decrease </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">significantly after ACL injury, resulting in </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">relatively unopposed activity of IL-1 [12]. This </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">overall up-regulated catabolic state and inflammation leads to recurrent and painful effusions </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">which significantly hinder early rehabilitation after injury but also post-operatively. Post-injury </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pain and intra-articular effusion are a major contributing factor to extensor mechanism shut </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">down (quadriceps femoris) after injury or surgery which in itself is a significant risk factor for </span></p>
<p style="top:384.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">delayed recovery and posttraumatic OA development.  </span></p>
<p style="top:397.5pt;left:72.0pt;line-height:11.0pt"><i><span style="font-family:Times New Roman,serif;font-size:11.0pt"> </span></i></p>
<p style="top:411.6pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Development of posttraumatic </span></i></p>
<p style="top:423.6pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">OA:  </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">It is increasingly recognized </span></p>
<p style="top:435.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">that biochemical abnormalities of </span></p>
<p style="top:447.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the joint precede radiographic </span></p>
<p style="top:459.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">abnormalities of primary or </span></p>
<p style="top:471.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">secondary OA by as much as </span></p>
<p style="top:483.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">decades. A growing body of </span></p>
<p style="top:495.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">evidence strongly suggests that </span></p>
<p style="top:507.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the progression from ACL injury </span></p>
<p style="top:519.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to osteoarthritis is multifactorial, </span></p>
<p style="top:531.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">involving the interplay between </span></p>
<p style="top:543.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">biomechanical disturbances and </span></p>
<p style="top:555.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">biochemical homeostasis of </span></p>
<p style="top:567.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">articular cartilage. </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">However, </span></p>
<p style="top:579.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">unlike primary OA, post-</span></p>
<p style="top:591.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">traumatic secondary OA is </span></p>
<p style="top:603.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">initiated by intra-articular </span></p>
<p style="top:615.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pathogenic processes with a </span></p>
<p style="top:627.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">known date of onset, namely the </span></p>
<p style="top:639.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">date of joint injury.  This makes </span></p>
<p style="top:651.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">it much more amenable to early intervention than primary OA whose onset is not clearly </span></p>
<p style="top:663.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">definable at this time.  For many years, however, it was believed that the biomechanically and </span></p>
<p style="top:675.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">anatomically correct reconstruction of the ACL would restore near normal joint kinematics. </span></p>
<p style="top:687.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomechanically the knee joint can be restored to near normal knee kinematics using the latest </span></p>
<img style="position:absolute;transform:matrix(.4320707,0,-0,.43137253,123.099979,401.99873)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.3198506,0,-0,.32,-15.879944,295)" src="data:image/png;base64,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">
<p style="top:82.1pt;left:340.6pt;line-height:8.0pt"><b><span style="font-family:Times New Roman,serif;font-size:8.0pt">Figure 1:</span></b><span style="font-family:Times New Roman,serif;font-size:8.0pt"> Onset of early posttraumatic OA in a 24-year old </span></p>
<p style="top:91.4pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">patient 2 years after ACL reconstruction and partial medial </span></p>
<p style="top:100.5pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">meniscectomy. medial joint space narrowing and beginning </span></p>
<p style="top:109.7pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">subchondral sclerosis as well as mild squaring of the lateral </span></p>
<p style="top:119.0pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">femoral condyle can be seen in comparison to the opposite, </span></p>
<p style="top:128.1pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">uninjured side.  This patient ended up receiving a meniscal </span></p>
<p style="top:137.3pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">allograft transplant. </span></p>
<p style="top:146.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt"> </span></p>
<p style="top:305.9pt;left:536.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.504562,0,-0,.5043137,326.49598,101.35837)" src="data:image/jpeg;base64,
/9j/4AAQSkZJRgABAQEAlgCWAAD/2wBDAAoHBwgHBgoICAgLCgoLDhgQDg0NDh0V
FhEYIx8lJCIfIiEmKzcvJik0KSEiMEExNDk7Pj4+JS5ESUM8SDc9Pjv/wAALCAGp
AgUBAREA/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgED
AwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2Jy
ggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1
dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJ
ytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/9oACAEBAAA/APJLBwLg+471
uRK5YHmtS1Zx1Ga3LB8kZyDW9b5IGCKvIeKtR8YGatqMjrUq5HGTTsnoaCopU+8v
1rZThaibrmo2HNRsMCo+c04A07mn+nFSKeDVC7U+YDjrUIVuxp3TjOaPxo2im4Ge
tBcn6VG+0jqBVOQYYjOc1VkzggHHtUfRfmPNQy5AyT+FVTEzZMjcegrk/EeF1SPb
08kfzNZ8JDSKOlbVkTwK2IjwKtxHjHerEfPFTr0pwJz1xTwQKCw9KWM7pVGO9bkf
C0Sdu9UZs7ueRmojyMCk3YOO9TKMY9amU9vanK2efarEhzH+FcNfcXcw9HNRK3Gc
8mmPjkCs6UnJxVK4PGKoSjg+3es26bqe9Y123UVUooqa0bbOvNdBAW4INadvKwwD
zW1p7ZI45rftyOMcVfiYDvVyJwWA4xVuNuKmGex/On89DQQOxoX/AFi59a2F+7UT
96jJ56VG444NRY5qQc0uadn3NSoeKpXh+YGoO3INOXHpQQM8Uc+tNIGab3NRuPlq
jMME881SLtkk1IhU98k0yRU6n9KqSkBCFNcd4jYHU4/+uQ/maz4Rg5HrWxYnhTW1
C2evSrcZGR61aQ4+tScnk0q4H1p45OSadjipLcZuEraXoKSTIqnMDuqEepNNbG7N
TKdwqccc+tL0b61YbmIVxOpDGoXA/wBuqinoCwok247k+tZ0zYbhapzHJz2qjOcj
Pb0rLuTwaxLg/Oc1Xooqa22m4XPAJregQLj560oGUEAtmtzTRGx4bB966CFCAMGr
iKQMVahGOatx5HQmplLd+akD560gf5qljOZV+tbA+5UTkGou5pj8dKYPvU+jHNPG
MU9Kq3v3Qfeqw5p4pCRR9Ka1M6GkbpzVCY5Jx0qkyZJJNMkIA4/Cq7SsvJPFUrm4
yCB1PeuT1wsdQQ5/5Zj+ZqCLC9DzWpYOcgk1tQHp71cRguKsx896mHtQoIJqUGnA
jFT2Yzcj2FbC9qZIxyaqTMSarg569RSMDnFSIxxjpU6k7R604tz+dWR/qcVxerjG
pzcd81nk85pWORVKZeSc9Kz5W61QnYkmsy5zg5NYt1nzPrUNFFSQsPOQsO9dDCUK
ggZq9ERxhcfWtvTV6ZroICQoANX43PGauRk4z1q1GQABUgI9cVJ8uKaMZ4OKmg5n
QZ71sn7lQtUTNgmmFuKavOaeCQKC1OU09DUN79yqXmHHFAYkc0BuaXdjjFJkZ5NN
3jdTJH7VRkbORVVmANVZZCTkCqc756tj6VnTyHkKMe9c3q5P21MnOIx/M1FGcnoa
0rNv51uwsAoxmridM4q3GRtGBUw4NKGIOKfn8KevHFWrAfv2PoK1l7VDKfnNVnOV
qu3B6dKRjnjPalVsGrCuduaduyc+5q2hzEeK47XAV1ST3ArMI+brQT6cVTuX+YgV
myH5T/OqU2azbo8HnJrEuTmSoqKKVfvD61vW2Qowa0oJDkZGRXQ6YFYZU8+9bsS4
xmrkZHFXIRjPPFWo+nvU1BNJU1nzcpW4xwlV3P5VEWBqM0iHrzT+vekyacD71KhN
RXgzGaoDGKXjFITSAk9aDjFM4JpkucdazpG61TdhnrVaV2Py9qoyHHU1VuGODiub
1g4v0yf+WYP6mmQe54q5bP8ANgV0NscxjntV1TkDHSrUZ+XFWBnHWjPPSng5p4OK
vacPmc/hWnnBFV2++RmomwB61WbG7PrTWpAfm561YQ/Lz3pVPQmrsJBhI9K5PxCN
uo59VrIc4NJndz6VUuxzxWdKAF64qjOcjjis25zg+lYtwMSVFRRQv3h9a37b7grQ
t+TXRaYOlbsLEd8/WrkLKxHar0f1q1H93JqQZpaSrFgM3SmtiThKrv3qDdTScYpV
7mnZpM80oNSIeaLkZiP0rNU9qdnPemnoaTvR2pnfNMlPyGsybv2qk7AN61XlJJ9K
pyr6VWlxjk1zWtfNfoR2jH8zUKNnFW7b/WVv2TbkA9BWlH90VYiOeKtKeKCeakU0
8mtDSxlGPvWi5A+uKrHrmo2/KqxPPSkJHPY96jDcj1qyjDaKep4wO571bt+hHtXM
eJxi8hPqp/nWG4NAxjvzVe84QdiayZTyOc1TkwSe9UZlLZ45rFvEKykk5J61Xooo
X7w+tb1scoK0bc/Niuk0wfKMVsxZzVmIZar8HBq8hNSBu1BYUhIJq3pozOT6VrSf
dFVZG4xUNRsegpUJp+7ignFKGp4bFPlG6M+4rLyASPelBApC3tSbjQDkHJqPOajm
fCnHes6TOCetUpByfSq8rj05qpMx7cVUl+6a5nWji/T/AK5j+ZqKLGOTyatQkrID
1rcsHwBWvCcrU8J5q0D7UZy1SKeadnmtbTBiAH15q3KcmoO9RN1qCTgdelRnJ6VG
Tg/Wp4yfLHtUobIB7Zq5bk5wfSuc8VjEtu31FYBPIpc89Kr3ufL4rLlAPUiqj7Vb
AH4mqdxxkCsC9OZyKr0UVYVUMq/L3ra4VlCjFXrY810umjEQPrWtEeOtWYT8w5rQ
g71dU8DNPBoNFXtKGZHNaMpOcVWkbNRbsVGTzyKcjDBpQRR360vOacKmzmOsqTiV
h70m4UhbjpSFs0Z4pOKguGAQms92+U1Rckk81XkxnrVWTPNVZulcxrjEagmP+eY/
mahi+Y1ahOHHpW7YuNvIGfatiA5WrEWd/FWQCFoBw2TUgxilJxW5ZLtt1+lSMc8+
hphxn6VCTzUEgwpGfrUOByc81Hknn86niPapQeACexNXLRuQD1xWH4uX93A3+2R+
lc1wcZ4px4xUV0u6HOKyHXJ9aqzHB6fSs+45HvWHef66q9FFd74j+G95okP2+ym+
12qH5l/jUeprC6uvuKv2w5FdRYDES1pIeKswfe9a04Opqyp45qUccUopCcVo6UPl
Zver0hwKrHrUZ71G1CinDp70h9utKCe5pQTip1OUrMuflnPHWo8+1IWFNZvSnBji
mk1Bcn5KoyD5TxVF+tV5Dyc1Vk9aqTHmuc1cBtQU56Rj+ZqJPlHIqaHG8c1uWGM1
sQt2q1EMkY4qwM460D72MU8cAA5pw+ZwO5IFdDCMRD6U1jwf1pmefwqJjUEnQnHW
qxztJphOc/WpkbkD1FTDBwQatWjfvF96zvFqZs429JK5QgYyKd+GaSYfL0rHkOM8
VQnGDk81SnPFYN4f35qCiivpqIh7W4VwCpibOfpXg7hftThPuhjj860LQZcCumsl
+SrwPGAat2ucZrTg6VZU4qUc0pNNLVr6au2AH1qaTLGoypzUW3rTCpz60mOKUEgU
MeKQYA5pwb5RUsZw2Kpagu11NVgaTNMY84FPU8U0nk+lQTn5c1TkJxVF+SRVWT71
VpDgVUmNc7q4H29Tx/qx/M1ArKV9asW5QMP61tWTgHgAVr27YFXYWx1qweBmhSN+
QalwCeKltY992o9Oa3OiY9qiYn86aM8VGfvYqGQcECqhJwcHmmkgY4/OpeoJA/8A
rU9CT0HJzVyA/OCaj8SRebpDt3Uhq4okcZFPG0kAUswymP1rEnbDEdeaoTsADWdc
PwSenYVh3Dbpiaioor0zX/ib/aUB0/R7d7dZOJJmPJHtXKKMSVp2I/eCuktDgVbQ
4Jq9bH5a0oOlWlGakHFKenSgJ+tb1suy3Ue1KR1puBTQM9qYVGcYpuzApjR1G2cD
2pp596cp+WnqwBHNMv03RbvTmswN3NKTxTGPFOBwMUmeTzUFwcJVNz1zVFzhjzVW
YndVeU9KqTH3rmtZfbfp/wBcx/M1XRl4xVqFlLLwDWzZlS68YrZh6irkfBzU7Eng
Ec01M7iO9Tq52+9XtKXfMzkdOK1SR835VCxJPBpR9056VG5Xdnuahk6Hmqv97jim
8MRnNTrsCgYz2qaIKVHfiphlTgfhUuqIZdHmHcxmvPzyN36Uq847CpJTkYH0rDvT
h8YrOmI6ZyazbgnnjmsWU5lb602iir1lzdLWoP8AW4rUsR8wrobbjFXE7mr1qOK0
4asoalX5qkVOKlii3SqPetg8IAKQc8U1ulMGetNPJpcckU1hjGaY6gioHXB4pego
6HNSsPNgIPpWOQVYg8YpM1G54FOU8AmjPpUFw3yGqchwKoycZqvJ71WkPOO1U5ut
c1rODqC/9cx/M1VQ4wDVu3b5hzW1aEb1wa2Yj05qyrmrKMCQDQCN2QakRuDmtzS4
vLtQ56nmpifl/nURPFBcBe9Rs65BqFzu75+lRBGywxjFOERBA7Y7VOITtB60qoR+
tTMeM4PSra/vbNlI6givPpYyrsnQqxFQ9HA7VI/TrgZ61i6jy3HHNZsmAD2IqhdY
EZrDY5Y/Wkooq/YDN19BWmozNWtZD5hW7bHmryfdrQtcjGRWjEanU1ZQAACrCqMf
SrNogaXdjpV4+tJTT1phwRxQBxk0h47U0n1pG9KjboajORxSHgipY2GcZ61nXybJ
z6HkVULc0xzkjFOzS7uDVa4bK1UkORzVOY7TVaQ55qu/JqnMa5vWSPty54/dj+Zq
pgkcc1atwd1alu22Ra2IXBANXEbGOam3Ac9OKfE3y1Zt1aW4SMdzj8K6POyIIvpT
S3ykZ4FRZphPIA9OtJt3D+dP8s4G1f8A69LHAQec8daeEQEYABzmptwK4z0ppQNg
j19ads3RsB1xmpLVsfuz6Vx2s2nkanMBkbjuArIlOxuR82elOYswBPTNZmoDkj3r
KccnPIrPvfljPPGKwz1ooorQ03/j5P0rTTmSta0GOa2bZunrWjDnIFacI6Zq7F0z
VhOWz2q3EoGM1OzfLgVft08uMDHJ5qXmjP60h470xjzSZzikJyaaRn8KQn1ppxUb
9OKaeozSg4PA9qZexma33D7y1kHrUbH5qXcNooLYFQyklelVX5FUZj81V3PBqu1U
5eSRXN622NQUf9Mx/M1UifnA4zVu2YeZya1bYjeOorWhdRjAFW8sSKcZARipInwO
tbOixD5rhhx0FawcEkmkY5z9cVEehPtUfJGOuasxIenAqXIAI649qZkkHBPNIfu5
HrSqVMeSD/jTl+7nBqVTgNg9qYjAOvOD1rK8UW4E0U443AjNcxcRDaQRyOhquGIQ
qR0qlfhc9M5rImwCaytTO2I+9Y1FFFaOmf69j7Vpxf6z8a1bTmti14IzWpAOQfSt
GE9qupgLxViHkVoWsRmyc4QdTVg2wSdRu3LjOauL93NLn5qM5z601s0mc8Y5pnQZ
pTjFM3dabnIpP1pr4qM+5pQehz35p6kbyp6Gsa7iMMxXseRVVj83NGRilLDFQSvn
NVmPFUrg/NVdjxVd6qSHqa5jXWxqC/8AXMfzNUY2yO1XbU8Z4rTtSd+Sa1YmwBVh
ZSB1pzTYIFWrKNrmVY06t+grq4VWGJY06KPzqVR0Hr1pT948cCmMCFakjToevFWA
DgfrTyD+OKYowe9GABk0O21Rt7etORuKC/GOeaa4HQGnX0Av9KdcfvIxuFcdMgxk
j2qjJF1XP0qjdrmOsmVQG6ZrI1b/AI9ye5NYtFFFaWmf61/pWlD981q23ate3PzA
ZrWg7VoQ9RVtWqzbhnYIoySa30ja0jAXaYwMt7mmxsZGLkdasjgU0HJNCtySaRmx
jFNzikI4yaQHg0wntTOhNLzQckVCeGwaXNDN3qG4jFxCR/GvT3rEkBVyDwR1FNLY
oZuKhZs5qBzmqc554qs5qCToaqSNXL68f9PX/rmP5mqKH2q9b42gc1pW5C45IzWl
Ew9asbwVPIpiEyOAM+grp9Mt/scI3f66Tg+1akRJORz/AIVYjYkDnkU5jk8E++Ka
wJBHr3pyjCKBk/WpDkAcdaUE8UHJOf8AIpD0IPWmBiGII6UKxAI9DT17c5xSSYJ9
8VJbTBJcH7p4NYOtWn2S9ZlX93JyKxZkGSR1rNu/uGsaT71ZGsDFr/wKsSiiitPT
PvPWlD96tW26itW15kFbMQq7DwMZqylbWk24WLznBO/hcdqtSN84gjYlQeSfWp4g
qripieMiowfmwaUU1jmlprfdph68UhPXFMzyKGPf3pN3Bpj5LChc9KJOhHeomyBu
B5HWqd7bCZTLGPnH3h61ktwcUFsj6VFu+YioXNVJzk4qs5xwKhkPy1UkI5rlfEB/
4mCY/wCeY/maoxmr9ueBg1oxNwCauq52cU7zMjFa2mW4hAuJvvH7in+dbVpI0jbi
xx6mtJOFPOasqSqAnuPWpV65P1pMZPOenIpV6dD3oZhgdeDTh60p447nrTck7vak
68HJOP0pP15zTwfu46YoJx2JNRucEHpTruJdRsNjffUcH3rjrtWgk2SDBFZtye3O
MVkyffz71k6yP9Cb/eFYFFFFammdHNaEH361bbr9K2bMZkBrXi9auR461ZhUseK1
LaeSCLyUc7T+lXYMAe9WgcinFufakzuz2oHv2o6ik5zQ3SoyeOeDTCSD1pg60uSw
xSHjimk/NSr6ikfnNRP0yKru207gcGqdzCk/zAbX9u9UHUocGoGPNRsfzqlcHmq7
Hmopj8tU36GuU8RHGop/1zH8zVKMk4960YTjHFXosggVcXJAwK0rW1VFEsvpkD1q
0jtJLuPTt6CtaxGD1yK1Y/unJz24q0p7fiM05c5PcntTiecg0q8jk85prMTn60/d
gcD9acDnAx1pFO5qaWO4jHHelBBA4pATxwBzSk/MO2RTZVBX3pkcvkuSeAeDWVrl
osw85eAehHY1ylwpSTa3pWVJkOeehrM1nmyfHqK56iiitXTPuPV+D71aloc1uWI6
VrRZxgVajzge9advFtUD8TVpF2jJ61YhfnBNXQ3Ax0xS54oH61IORQeBimDjNLzi
o2AY+lRkHtTc/N0pC2BSZpH4bilXpxQeOagcnB54qq5yDzxUBPGM8jvVeVPMyCMH
+dZ7grkdxUEjYNVbjnFQECq8pPIqrIcDNcn4hOdRQ/8ATIfzNU4vvKK0rfk1dgDM
wA5J6Vs20Sxplzk9h61K0pZuT04+lWIG3YJHHpWxZyLgDmtWMjoM8dasxMOPanqw
LdacSS2RxSbjj3pCcdP1p6tlSD6cU4HHqabu2nHShn+XgYJ70itxQxwoBPfFOdhg
c9BTGk4yDxVa4kBjIxyec1D5/mwYcdflP+Nc5qdsGlfH3h0Nc5NxKay9WGbKT865
6iiitXTf9W/1q9bd61bQYAz3rfsgARWpEP1q7apukHtWrCC30FSI4LYqaJcnNWwS
QMdKfnjrThnBxTlPQU5uabjFJ7UxuhqJmwMCo1PzE0MSaMfMMd6a33jTl5NDA81X
kHymq5UEc1BIAq4zgVCWBGPSqN2hDbu561SkPY1UmIzUByQagkPNVZDgVyniA/8A
EwT/AK5j+ZqpBy+a0YTxmtfTo8kydl4FXnZsZ59c1JHgpk8HNWUYhVweO9atqQCq
9jzWpHJjGPWrUTbkxnkVIrfOvc01pSH685p5beMqec8+1REkpyep7mpUz06GpsYJ
+b6UjkbvXFNG5iRnHPBoQdcdOKV1JIwRgn8qa5OF9eaiYlV6+3Sq85LKeccVVZtm
Ezy2fwNULhSf5VzWpwiO43Do3p2NY+orus5f93Nc1RRRWrp3+pf61etuRmtizX5h
7VvWYzitOIYrStI/3e71rTGI4AB1NRL1B71cjPHzfmKuQ5CAYBzTsYJO3mngelAX
pil7Ue9IeKiclRUOeeaCFzxSbcnFPKkDgVGVw1KExzmnFcHrioZcMT/nNU344I71
UkXORn9aiCgc5qK6UGEkdqypBzmqUx5qLPFV5j6VVl6VymvnOoJ/1zH8zVW3PJ+t
acQxit21URWyDuRuIqYNkKowOvFTRgKBxxnINW4Imb7q5UH8K27C3j2ZYfMKuRp2
weuM1NGFVSAcVINwYFhjnP1qJuXznjNJvw2AcU9W3NhuPf1qyin1zjipFjbOSTRs
xxRt4Cg9+tMTIPApzAkrnjnJqN1b3PHbvTJELLlsjNV5mCrnjODwe9ZZLtKCT159
qiuIy0JIPINYupJ5luzYyRzXP3K74HX1UiuW6GiiitXT/wDUt9av23IxWxZD5h9K
37QdK0Y+grasgDbrx0qxKTgDpTVByD3q3EpJ9quISpNS7ywwR170inBp59jSEYFA
x0NNYjkVA5zxmoy3YUg4HHWpY2Oe1PkbGAR1ppK9e9G9MHFRs+WOR2zVd5OtV5WD
JuPJHWqUikHrgVCpDEjPNF0Nlm31rIkNUZyM1ATVeRucVVlrlteOb9f+uY/marW+
P1rThPQV0zxiNcEcqOPpTAEDhlBzmp0g2gF2xnnb3NadtKeFAA9lrTtZFLbSmTjn
1rQiClSxIwTTxEODnk1OIW2rnpUJjVjz2P40zywWGCDk0FgGIPTtipo5d2AQRnvU
yS4PzZH408jPQ0rr23Dp2pY0IPenqmQR1NDRHJHTPQ1TmdRtVcsW9BWfPuJO4njP
Bqi5JOOegxxTZCCHBGMgH+lZFwvyY69jXPTLgsvocVyk67Z5F9GNMoorVsP9Q31q
/bVs2OC1dBajgVooflrX09gLcA85qzIA2AKVVOcf3e9WIASoz61ZXJepCcd881Kc
EZHWmbj3pxbIqIsQTzSGTIPrUTMWpu30o5AIp6jgetPlJJx7UzgjpS4BGMU0Y3dM
8VXmccqV5x2qnI2Dx06VUl6EHk54qKJczcCkv5AIWXvmseQ8GqEpy1RHvVaTrVaY
4Fctrh/01f8ArmP5mq1ueOnetOH7oNdXNIZ7SCYAEOg6eveoYz5eZWXJx8tOVmaT
eTnH61o2pzI2DkgfnWvbhvOweOBnvmr+3a2cg85x6VOWZVB3A1O837sYPOfSoOWY
kp1/lTX5k4U7femuAetCO2Aueh4NTqcrjHWrceNuR0oJG/PHHSlVyM9OOtPJPyjJ
INQSsd6/iDz3qi28Esc/KePpVeTkFeeG7cVSuT84xjgdqjxvgLZwegrPmUeSSBzi
udul2zSfWuW1Fdt9J7nNVqKK1bHi2J960bYcCtmxX5hXQ2owoq8g+Xir9o+EAHUV
rWse/Ln+EUoHzHPBz0qxCMDpU0fGalHUU4cdBSMP1pj8YwajIyetNIxTCBjrzTAv
zcmnLndz3qdVzSS8Zpg6c05lxz2xUbcHggZqrMDvOSOKpuec7uM81WmJA6daIcqC
SABiqF425s54rPm6Gs92yajc8cVWc4NVJzxXMawf9NX/AHB/M1Xt26/WtOF/lroN
JlMmmtGT/q3yvtmpJ2JlIOflAGO1OhY9cZx+tatkF3ZHO4jt0rVthkszHALYzjNW
xuYlhz1zmpXZiyqMY7VOWbywTzz60mRn5vpS7hux1FIwGM4H0NQeYgbk5/pU0cqO
B6fTpVqBvMUgdKUnB6Zpyt0OP881JvwOOgqF8FlIAPPPtVaT5iVIJzkVSlPJGMHI
Y1XmjI7feBqEYEOcdOOlZ0rcMvUA44rnbo7riQ9ea53WU23Cv/eFZ1FFa9kMWtaV
sOhrZsRk8V0EA+UCr0Q+SrEGQ4HrW5aMFO3sRViaPBBwOacikD8alQDPvUq4zjtT
8YOOtJweDTZFGQKZt9qY4x3qLbmm7SGqQRtkYqVVIIzTZuOneowM96fxwKhkHzAm
q0wwSPWqTdW46VBNkEMOmKZ/yzPvWZcNuk4qncNhDWcx61FJnFV3Peqk7AKTXM6s
c3YP+wP5mq0J+bFaMLYUCtnRJgsssR/jXI+oq5dHF04qWM7inB6/Nj0rWtnKuVIG
M9q1YeF2HqTk4q2hXLc5OMZxT85KsCBx0NWCQYQNnJORimkFGGd2AfXNSL3Pbr70
1yMcHr+dVGUjB6jpTohkkbTirEDGNjzwTVlywK9/ekyWwMHPFWEXnJpjgYzjNQSK
xkB2461TnjIbjucdfSoXiZ4888Cq0ke2Eljxnmsm4OzzORmudn5lY9MmsXWl/do3
oax6KK2LMf6ItalqvHNbFkMMMVvwcgVdj+7VuBf3e7ua07AhiAetXpW3MFzwKk5B
4PFPXrUoxTgeeKM85pSSy54yKYTUbEcZpnc0oC9aeuMcU9CC1MucbgAKgXG7mn5x
+dQvke/NVZj+83AZAqk5+97mmn5ox7VSu5cDYtZ7cVRuWwPrVBiajlbAqo7YFUrh
+Otc9qRzcj2X+pqqpwwq7E/OK0LO48m5jlzwp5+nety/5upeeM5/CpLMs2GXGRgn
2rXhcEMcBc8g+2K1rZZJIxtHsc1dX5ZOT3xRHztywHUcjmrzBTEnfj0pqAORtXHp
zUqx4XpnnpTJIwew6d6i8ogcDj0ojUbuvWnLgPg9zVhkzgDpgdqVIwF7mpgMEHb0
qNs5OTjvUDKxdivOPXvVObKtyvHOKWzUeY6nnK1nucB1Yc5zisLVJBG5CjlqwpsA
fzrK1dc2xrCoorasx/oifSta1XIFa9mDvrcg7Vdj4FXIG/dYHY1o2QxLn2q7kF8V
N0xUg56CpBSg460dKUNTG5NRMQKQHIzRnBp4IxQj/MBRcEZqFeTTyuVNQSFguP1q
lKTz61SP3fXmpJHEVp5hGdo/OsV3LsWPU1BITtrNuWy2PSqjcnioJWycVWkPas65
bmsC8bfcE+nFQ1YjbmrkTZWuiebzypPJK/nxT7TAkwOQe1bcK5JHXH+f61tWEoiB
3jnluKtFjK7nkehxSx5IXAA59KuRhmTa3Ve1IJAOMEjP0qcOpXpj6mmn5h8oH5VG
x257Gow6lwScc1KUUSD65qTzNzkrzmpBnHtT854GQcetMfgcdhioSAVPUZqpMpJz
60yElJTx1GKpzR4Vw2cDnFcrezNNcMTnGcAelZ84ODWXqQzb/hXP0UVu2gxax/St
e3AABrVsfv1tQ8fjV2M5HvVi2bEoB6GtW1YA1bXBfOeas4yBx0qRRT+nNIT2ozxT
WYDFISSMjpVeSZFOC1NWWM/xU/dg5pyvz0605QC2fSnT9qiQcmpTwOe9VZOfbBqh
MTk88VXcHAj/AIqgv5P3CoPWstzgcCq8zfLWZM2XNVycZIqtI2Tmq0rYGay7l+Ga
sJ23OT6mkqSJuatxN8xHrW3bzDy4znpj/CtC1PI6fI2c1txAAh+cdOlaVsQky7um
MA461fj+8VBJytTABkyCcDpgVYgILgnt+tRsSu7nkE4p0eAAxPOM4p4k2n5TkHpU
Us2RjgH6VUecgH+ZNTR3AkiyCGZeuDU0cvr396njYlfepi/AOAKQnLe3am+uaruq
k46YPU1C+FHI6d6o3zkRs3QEZrkZfvt9aqTLjJxxWXfjMHFc6epooroLcYgjFa9u
oIFatguWrYh45PNXYhxUyDBzWhCwbBzz6VoQ844qyvTvUoJxzS57E0jSIPvMB+NQ
veRLwuW/SoHvWb7qBfrURldvvNUZweBSEHGcEU5JmQYb5lqwpyAynirMXAzTpTkY
zUaA44p55BzVaQE7getUZAQSSOPSoP4yWPKis29bDKB6Zqm/Sqc74U1myZxmoHPF
VmqpcPgGsa/k2xEZ61l0UqnBqzG3zqc9eK1rV/3YGeRkVtWoDEEHqP1raiPyqckA
nAHWtSMHMWQPu8VdVjnPQY9KmT5eo5H8qmQEbQO1K4HnE9iOKbkAEg5PaoXkOME8
j0qldXWw7Ry/p6Vnyu7tlmJ/pRFM0LhkOD/OtKDUIWA8w7D3yOK0YZFflGDD2Oas
B+BntTg2evBoOACoNRSEZI9BVGZ8DrWbdSgRspOQRiuekjGWFU5lwDzWZegeSa5t
uGNJRXRwj5IxWtAMYrVsRjJrXhHIJq2rYFWYUdhwpqyIpMghSMU8SyofvMKmS6m/
v1J9qmI+/SGaRurmnLHI3IU/U1Mlt3c1I0SldoWo/sz554FPW2xwBj61OkI24JH4
1WuLQp8y9O9Qxu0R9Qeoq9F8wDIRilYEDPWkVucninlsConwRz3qnPj6iqEvQgDO
Ky71v36gdlqnK2BVC5b5TVKQ9BUEpOMVWdgBWfcNnisO/k3S7R0FVaKKmQ9DWpat
nIH1FblgysjKTgDBGK27c4VOBkfzrViclYz35yauL9/OOD0q2itsVsE8VKDgDB/G
mvJnGe1QFsE4ORVO5ugvyRnc57+lVGt5zztyfrzULo6H51Iz603NOAOM449RT0JU
gqSPoauR6ncxDDN5i/7VWk1uNsCSLbU41S1K8yKPqaY+o2p5Fwn51SuL23OcTrz6
VkXV2r5VMk+p7VnEetVLg4B4rMuhww9q5uQYkYe9Norp4RxGK1YRxWtZjgVqwDLe
1aMaqnO3Le9W4ix5Bq3GpJ5JqZYcnoCKl+zIw5QGlFrEP+Wf61IIlX7qDNO2Oe2K
csbYxipY4QCCx6U+QxKelV3l64FQ+YTUituGD0PWq00JjJ7r2NMjdomBXoeoq4jr
IMqefSkbIpHwTkGo2PZuKr3B+QgDis2V9mT2rInIeYkHgVTnYZ69KoTtuOO1VGOW
zTHwTVO4bANZU74BNYUjb5Cx7mm0UU+MjODV6GQrtK9q1rSYq6sD8p9K6KwnUqo7
itmJwyDnIrQTLKCc8Cr6Sfuxx1FN6Ac1DIwUFmYBR1J4rNuL8uSkPC9N3c02zgLs
ZNpIHT61pray7emD7ig28gwGTK557g1H/ZdrISwUxkdRninrZRRjA/PNRvpqPyoI
PtVV7GRfunP14qu8bxn50YfhUZxUTkZqIgkcKT+FQtDOc4hf8qheGZRkxuPwqlLy
MVmXXK5rnLgYmb61HRXVQr8yCtSMc49a1rQYArYtVCoXP4VbTJ681oQKMc8DFWoz
x7VZTjGDUwAI5NPG0Y55pxfb070GUg8UvmEjk81G0px1psjcion4qPJzT0Y7SKsR
srDY4yDTJLLPMZBFV3t5EOehqMzXCnn5hT/tYA+dCM9hUcl5GR91vyqlPexEZG/A
7YrMu75ZRiMEH3qix4z2qlM2M1Tc5aqzkCoJG2nOao3DnBzWPqEm2M88msqiiilQ
4arkXSrtvKYiMDI7g1tWV7ErruJTnvyK6G0vYCg/fRn/AIFitSO9gUf66P8A76FS
Jq1sg4l3kdlGaG1NpP8AUw8nu/H6VXeKe4YGaYn2A4FWLewDuERCxPrW0FjtItiY
yB196ga4cthjn0zU8dyF+UgH14qXbBKOFwTUM9ocghfyqFFKd8HPOal2LJwRyajN
p1FMOnox5iRvrSiwgXkxqtMcRqMIijHXArOuCTz68Vm3JdScHmsq6RZQSAFYd6xL
kEEqetc7eAidqgorrYh861qRgZHrWraD5a2FXaqD2q3COR39atxNz7elXYTnr0qd
BipRmnbsDFJvweuaUsM5oDZPNAP5UHkZJFRk8HPNRkqD9amVAqZpokCmrMUgC9ea
lD7h8wBqJ4Y37YNRSWinocVXktFHvWbPBFGSD61i3kYinOO9VJG4qhM/WqbNz9aj
kPeqsjZNUJ3zxisLUJN0u30qpRRRRViBznrV1G5FXoMuwCjJrSt7GSTkY/AVqw6b
jqpb61q2lk+BiNvwWta30qeRQREQD3bir8ekopzLJ+AqzmK3j2xjGeCaz5piSePz
61EhGck9qecYwT+tPV8YKv8AnU0V22Tk5/SpRcK2OB9DSi5yxOxelJ9pU5+XGB2q
N5iSe3tVaSQFhzgepNRNJ27kcVUkO4e3f2rNuGPKkdDWdOmC+O/pWNfoDHuA5U/p
XN34y+ap0V18Q/erWpEApzWnacgVvLhgnHIAq1CAM9iamQCrcRqypwDxkVJ0GRQC
MUgOTjvSsSOfSjgmlOBSdvem+uelN+Tdkilkk3cdhTWX5d2KAxzxUhdwOv4Unntk
U/zfmwSKhkcc/N1rKuCXbHbNY9+4NwVHbrVCduKz5WycVAcluKimIwTVKZuKzp2w
rHNYMz75Wb1NMoooop0bYar6NwK17IY2oO+M10+nhUUcDOM10lk7YG1Ex7r1rVgk
cAfvFX2XFSeYpzukBI75zUcl3GhHTn1qnLcgt/snvUBbnOM+9NU7jhTzjvTtvzA7
u/SnI2VBPr0xUnOD1yPXtUnQZGM5pIy27jJA9aXdhyOP8ajY7u/NRHGM5yR696ZK
QoHPAqvK4JJBHA54rPm2sx45+tUpYyAecgCsmdN4kGMfKa5a+XNUDwaK7GEfvhWk
mc1qWg+UGtu1+dQe+MVeiBHOKlGd3I/Cp06cDnpVtATge1SbcgHoBS4HanBVz9aX
YCetLtUHrTdo5PNIRg8c+1RNnkd6aBk5LdO1KfmBOaCd0QGaReCCKJCQPr0qMZyC
KR3IY8jNQO7EYPBqByEhMjdB61gTPukZ/U1QuGyxqhIxLU0nCk1VmbJqpOeDWTfy
bISO5rGooooooHWrcTZA9637I70jkAzxzj2retJSArYGR61rwTvt5zgH6Cr8Fw7D
YDgdcCpPMcdTjnB96YSwIyxPvQxJXPG7P50qPznkH1p5cAkjjIpWk+Tkcn2pYygk
JAPPYVK7EgYIP0pxBY/Qdu9IoPB2nH070hJDkgEEVGx5zj9aQj5tmRwM02QHLAL1
HIqpMMs3qegFUWBdyev1qJl4Kg/rWVc4SQjHXiuR1EYbB9azT1orsYuZeK0o/WtS
16CtnTG3OUPpxWnEPkbJqWJTIOnT1qwsZBHPXrUynGDmnh+DSbyG6ilLcA0hJ4xS
hiDT9xxnNR7yDTXPPrTEGCc96cGI7cVIApGDTQB0702Q9Rmo1BPTpTGwGJI4HU1X
llY5P5VnapOx2wg8AZb61luwA5qhO4JOKptjPFROeKqOck1RuG9KxNRl3OE9KpUU
UUUUVPAe1bukzgAo3PpW5C3G3o3GQa1bZn24JHXqa0LZiMNxlW7jrVgNl8kflTmy
w+7nBzntS+gYjBzzTcbjkE8fpSg4AJyacMH8fWpFizhun49KsiJEA55x1xUm5APv
cim+dhlwc03zVcncOM857VG6xPwG70x4myGXBXGODUZRwOM56VWlRlyT0zxkVSli
KDIB/Con5i3fxBvTqKxtRbbI7elcrqIyVNZbcNikrsYf9aa0o+SBWraj5QK07KTy
7lT+FdDHGrRn1pyrg+lTKOetSIM8U4J83FNK4bp1pW6Dj8KTkLR2B9aeOnFMI5pG
WoicGpdoIzin4O3cO1MZfmz61G3WnRygDDDFRSsjMO9VJEIPXgnisa6ffOze9ULg
gDNZsnOfeoW61BI3UVVk4BNZ07dW9KwJ33zMfeo6KKKKKKfE21hWvZPsmQjpn9K6
GEnzQnXjINa9qxKgbh17itSHa/B5J7j1q0g6cYA/Wgso46j2pd6qv3ckUhnJXOAP
pSCYkbSRkGlEoyDwT9KmWQsewz0+lSK7BducgfrRuO7HoeaaxwcAexpu8kEDGaaX
wePyqWPkZUY2/wAqUsFG3njvVaQZz1xjiq0qDb2H0qpcrug9GzjNc9rGV2p3PXNc
5fjdj8ayZfvfhTK6+zyx9614l4BrUtPu/hV+BT5gOOlb9nKJguDhl4I9aumMNkjv
QFJODUyr69KegzQyYxTSBjFNYcY65pB0/lQT0pDyadjKmoivtUqD5KchHQmgrlc9
81A6DpSFPlPpVaTOelQXL+VCXPU8CsV+ATWdcnIqi/K1CQetVpF9apXD8YrJvZNk
LVjdTRRRRRRRSqcGtG2bpXS2UhkijkzyBgn6VrWbKpUAnk5rVSUrnYAPpU4ZjyT1
pybjUhTjuTmhYsLz1pDEVPbk0qrjBxnoKlUcDH+RUh4znOO1BHzAnOM5oYjd0696
jPDg44xT9pZv51MF2NjvjvTXGRznp+dV3Rs7c8Y61XKklgDx1qtKFKZY4VT0rltW
DSTvMOR39qwr0ZA9qyJxhzUVdjYJhsVswjjFaVsMYA61s29swjywwT61ZT9ywIbG
PTvWraXC3Awflb09aslNoyBQMZxUi5x/WlbkAUwgc+tNI+Wkxj6U32prckEd6UAn
p2pxX5c05OmPWlACnkU5iGUHpmq7jrxTGz0zUAGZDk8DnNZl7N5spAPyis64bqKz
ZzniqrjINQHgVUnbkis6dqxdTk5C5rPooooooooHWrts+HA7Gt3S5wknlOcI/wCh
roLRSHGeo4471rQjGNx68VbQANgnn0qQHnOBUingE889adgEUADAJFDLgHjpimnA
wafuPH6VIcHaOmRmhlGTzn/69NKcDAPA6VNHH5aMM/M1KNvfgU1yNnB5FVZGySCe
g/yKhwxyAvOOfpWZqU6plF6sMADtWOUyCGxjHOaw9VtvJIZOUb9D6Vz84/eGoa7m
zQbzx3rViXnNbemxKB5rDp0q+ZWbvx3pR97mrEJwwwSDmtqyuRcr5cmA3rTthQkN
1FPQelSbcds0xwN2T3FMIphz0pMDk00jHFOHJ9qfj5MDrSAgdaaz5YYpd3T9KbJj
dx3qMoSQoH41QvJwgMMZ5/iNZ7DArOuDyRnrVGbrj0qs/wB2qzjrVKc8msy4b5jW
DePvuD7VBRRRRRRRQOtWYj0rTt3yoPcV0+l3IuEGf9YvX/GtiNvkzgj2q9G5OCOP
U1Opzgev60rfKAO3tUiEAHjnFL6dwaRs9KYR07cVKDknnkDipgec+1J3bHQDoafs
+UHsafICWGB0FMZWVgBwAabINq5GOMmq/lNIQgBLE1BqU8dihiXDyt19q5yXLuxb
LN61WlJ24I69azb4B4JEOM9q5i4Hz9KrV31kM4Y9TWlHW5aHFuFHcVbTp06VOigD
kVJHgcdasRvsYMp5BrZRxdW4lH3wMMKUDGKcDxUUjfOMdhUec80w56mlx1pjdeKU
cCpF4GT0NMk+VTxUKklqlUHBxzTiucd6qahcfZ4/LQ/O36VkqCeTUUxwuazJzlqp
yHcarS8cVWkPFULg45rJu3wjGsFjuYn1pKKKKKKKKB1qxH1FX7ZtrY7Gti0ZoyHQ
4Yciuns5lurbzFwGH3l9Kvwnkbh1GKtxE45p7DKr2z3py5GTjkUvf2xSDkHPfNI4
5GDipNvTrVhVC5+nGadgDoM9qawCgqeKnhIcc9RweaJk4xjGCKhZOSMc0XMq6baG
UgfaJOFHoK5idt0hZjksSTmqjKxyQMZNQTRktjrgcVj3g2xsW6c1zd0MMPeqjcMa
9Ash8grSQDiteybcu3pitKBQDzUxHHFLGuTip0AFXtOm8qfa33X4NaDpt49OlMGA
hYngVWLZbPUmk5NGOOlL17UxunTminA/J9KWUDZUIGCKmRQOOtKWEaNI3AHSsK4k
86RnPc03AAqncnHArNuOCcVVPAqrKRVZu+Kz7puorF1F9sJHrWNRRRRRRRRQOtWI
xwKuQ1s2Z3IM9a1LKdrWbzBnHQj1FdNFtkRJozlHH5VPETkKeRUxBK4BxzS9VI/C
lJweKZ/CDT8AsM8+lTJ1Y+2KlJwRxSq/GOvY0x2B3Z7dqdBIEkVj0JwcelXbiPHT
8KS2iQs0r/djGTXPalcm9u2kZiFP3R6CsyTOT61By2M0x0wpPSue1NxJkIMKD19a
wbhdxAqjIMORXoNoMKK0Yxz7VpWwIwRWvbN5qYPDCrQUspGORTUHGKmC5qVOCD6V
thhNAkg6gYNRXI2wBR3NVAOetKBx+NGCeB61YGnXRAIj/WkbTbztHn8ajaxulHzQ
sB9aaIpVGDGw/CnMpOMqenpUWxgc7Wx9KegyehH1qtqcu2MRqetZIHOKVuntVC5P
zYrPmPJFVJBiqsmeagl+VKybgk5JrC1V+VWs6iiiiiiiigdatR5wKsR9a2bE8EVq
IMjPrWtod1ska3c/K3I+tbu3a30p6MAy9eTSypt4HOTmgnKnBx71GrfLzUin959B
U0S/N7EVLn5uOmOKRAM/pTHIHIHvSoAcL6HitKJvNsx3ZOPqKg1WT7Lp6wIcNIOa
5uVetVZMkZpqRZwT0HJ96qam3lx7Bw0nJ9hWBdR/ITWJcLyKz5R81ehWy/uxV+IZ
IrUgXKjFXoGMbhh1FaicgOOhpGTa+R0PNOHTGaeO1a2mOGRoj3qS7XkL6VT24OR9
KcOR700jrU6ahcx4AbIHrUg1e5H3kQ/hUi6z/ehJ+hqdNVgcZIK/UVJ9utH/AIx+
IqdSjL8u0jtVbUFRLNn2AEHriuSvHMkx54FQ446U1+lZ8w+Yk9KzZ+STVZxk1Wk+
Wqk5G3rWVccZrntRbdPj0qpRRRRRRRRQOtWoTmrMQORita1yuDjoa2I/mXinwu0c
qyDgqc110Lie3DjrgU4A5AHrT2O4fSkxknPtTCvVRT4+WOR+NWE4Jwegp2DknPYY
pxx94DqetRkfKAR34pycn8a0NOjPnbD0Zf5Vm6zP516y5+VOKx5QQ5qB1JbHrUwj
CqoYf7RPoBWDdyGe5dz0J4+lZ10nytjvWDdr81ZzjJr0K2XgCr0Q+cAVq24yAKuI
ORxV60bOY279KtMv7v6GmKPWngcVf044uRV26X98T2IqoVwOfWkA54pD1NRkelB6
Ue1OUU4qCMU1WlU4V2GPSpJ5JRbkPIzD3NYTAs5PvQQAMVFK2BWdOxNUJOpqs5AB
4qpJyc1TnPBFZVwea5u7bdcsahoooooooopV+8KsxVchB3gdq1YMbT3rVtHBQetS
4OT9a6HRJd0RjJ6HFaBXDAehpSCQPWlI+Ud+abtHHNKh547GpsHrnFTL8wA9qccY
DfpULA4X65FSxJyBjrWla4gQzt2GBWDep/pbH15qhKPmI5zx0qONNz/Skv38uzY9
DIcD6VgOOSfSqtwuVP0rBvE5+tZrr83SvQIMAjFXoB+8GTWtbjirijBzU0RKuDnp
WoMMpIHBFRbSKeF5+tWrX5TurTm+eNXqnIo3U3bg8Uwn86bjim8ZNNxxipFp685z
TgvNQag+yIisgA8c0rEdaryY79az5+AaoTZzVWTPNVZOKpXPSsq4PWuamOZmPvTK
KKKKKKKKB1FWo6uW33xWrB0NaFqcHFXCOR71paTL5dwB610JG4A0Mo6evemjIXHT
HFNPABqSIYJHGDTzyAMVPGvf1pxIzxTNh3jPep41xz71Jq0v2eygX1YZrOuhl0b1
FZ0yYY+nrSwIcNxmqOrn5kjHRVrKZarSrkc1g36Y7d6zHUFj2rvIRgir9sPnrXgH
y1bTBFSDitKzbdEMnpSsp8w04DirK/LHnFX4T5lkp9qryelMPXI6UxuT70wHOaGG
DTDkU9QTTwODUqDpWdqjZYLVAU1+uKhkGOaozjis6brVZhVaXvWfc9Kybo4RjXNP
y7fWkoooooooooHUVajq7aj5q1YB7Vdg4cVeU7lq1atsnjb3rqIDviHqKc3QYHIN
NA5yfpihxnGB9KdB1P1qUjmpUwB196PenADI9h3qxAgd1HvVXxNJtWBM981BKN0S
n2qlKOo96fCg/wAaxtQO+6b2qk68Gq0gzWPqEeQ/FYsi5ORXeRdRWjaAE1rQDjHp
VhalAyKt2LEMVq3KvzAjvSheBUr8QmrenNutSD2NNkHJFRHpTOc5pg4YinEZ/CmO
uM0sXSplAH41IlZOoMDPj0qoOKZ1aq8pySO1VZRkGsyf71V3HGaqyDIrPuRgVj3v
ELfSubPU0UUUUUUUUUDrVuI8VftAetacA9auRjjNXYzg9etTocYrp9OffEvuKssv
IBHWmgHAPvjNNcYI7elOhOCTU4+6D1py4PfkGlznA9aeFy3PtV2zX94CewrG8TPm
7Vf7oFPQ7oE5qpIvz496kTAVj7VgT/NcOfeq7A5JqvKtZd6nznjtWDKmJCPeu7iX
vWhZrk5961ohVhRUoFTWpxPWkwyg9qRM0+b7h+lTaS3319s1NKCHNQHrTH7Uzqad
0prihVx+NTgdKf0Qmsa7O6djUBFRE4zVd+hNVpB8tZtwP3ntVZ+arykYxWZcnINY
1/8A6l/pXOHrRRRRRRRRRRVqLkVpWg4xWlDxVtO1W0PANWRzXQaK+YgM1pSDGD6i
o8EgjOO9I/LLnpRHkc+/51ODxj2pRk9BTk6Y71Mv38ntV+zHDGuc19t98/PQ4qxb
8wJ+FRSriU0YAt3NYB5Yn1qFh61DIPWs29TuPSsG5QCZu1dsgwtaVkvANacYq0o5
qQCnJ8siketay/Mv1FIo5p0o+Uj2pdKbbcMPUVduBhs1WI+amMOetMIxQQMikblT
QvUVYA4qRxti/CsGc7pWPvUQqKTBHFQODioGHy81m3X36pydKqSDrVC471jX/wDx
7v8ASucooooooooooq1AcnFasAxgVoRVaj4xVpDleKsx8itrRH+Yr6VuyDcgqLAA
aojw9PTn8DTs8+1PXOc+makjHGT61LHyee4xWlaDEefeuU1dt17J9TV23H7hB9Kb
MMse3FNmG2zP0rAIqNl5+tQyLVG8TIBrBvIx5tdig7Vq2aYUVoRDmrCdc1KBS1rQ
HMQpVHz05xwc1DYNsvce9atwPlBqq1RPxzRjmkPNIRSqOeKmQdqdOcRk+grBbkn3
qM9DUT4xUJ96gfOKzroc5qhJzVd+hrOuO+Kx7/8A1D/SubPWiiiiiiiiiirFv99a
2YhwDV+LpVqMYGKtxY6etTR1q6Q+25I9RXS9Yxiom4BB71D/ABflS9uKcBk1KOMi
pAPlP1AqZB9361ow/LbZ9BmuPvDvuJG7ZrTgH7pfoKSbHP0pl6Ntmf8AdrBqNhzU
Mi/yqldDK4rHuY9z5rqU7cVr2q/KM1eiqwg4qTtS4rTszmMCpQP3lLIMiqSN5d2D
71uSjdFVVhxmonpAOKQn5s0EcUq8dqmUc028OIW+lYh6VF61E3rio24U1XY1Ruxh
aznqvLxWfcDk1j3w/dOPauZb7x+tFFFFFFFFFFWbfmRa2rfoBV6MYq1HggVZh68V
YjGDV+wYrdp78V1cXMNRSA7cmoyvT1xQThT709Blc1JjJIqRcFce9TRjPHvV+X5L
OT2Q1xsvMjfWteAfu1HtSSAEn61FqXFofpWHgUwrzULiqVyOKy5xh66WIZda2LcY
WrsY4qdR0p9OHSr1i3GKtkYeh+hrOl+WYdua3kO+AH1FVmHX2qI/pTaQnP0pe2Kc
vXmpk61DfnEDVjHpUfFRtjHFQv06VCwzVK6GQay3HNV5+mKoXHSsm7GUYe1cu/Ds
Pekoooooooooq3aD562Lbsa0IvmHvVmMVZh61YT71WbdtsqN6GuvtTmH8KbMvFMO
c8dBUZ+7jPNSxjK4qRB61IB1qxGORirV822yl/3a5BuST6mteEYQUr/dB96r6qcW
n5ViEGkNQOBVO4HBrMlHz10UH31rZg+6tW46sL90U8U4fdNW7H7xq833hSP3rPuP
9bW3bf8AHqn+7UJ6mom6U001qVelOH3qnj+9VfUf+Pdqx27VFTG6VE3SoTVO46tW
U/3qrT1Rn6Gsm6/i+lcvJ/rW+tNoooooooooHUVdteta1t0rRt/vVYSrMX3hVlPv
1Mv3x9a7Cx/1Q+lLcdv96oz0P4VGOpp6dDUw6mpF7/WrEfRfrU2p/wDIPl+lcn6f
WtiD7o+lD/dH1qrq3/Hr+IrI701+1QP3+tU5+hrMk++a/9kA">
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">11 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">anatomic ACL reconstruction techniques. However, the considerable variation in response to </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">surgical treatment even in well-controlled studies (2, 13-16) and  recent systematic reviews has </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">suggested that reconstructive surgery of the ACL or meniscus fails to protect against OA </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">development (2,4). When abnormal joint stressors and abnormal joint physiology occur together, </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the outcome is potentially even more severe (Figure 2, from Lohmander et al (2)).  This is </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">illustrated by the fact that severe meniscal damage to the knee is more likely to cause eventual </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">knee OA in patients with hand OA (evidence for a genetic predisposition to OA) compared with </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">patients without hand OA (17). </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">ACL Injury and Damage to Articular Cartilage</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">: Chondrocytes (matrix secreting cells) are </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pressure sensitive, and cannot survive compressive forces above a certain threshold, even if the </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cartilage matrix itself is not injured directly.  This threshold may often be exceeded during ACL </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injuries. Without a sufficient number of chondrocytes to maintain a scaffold, the matrix </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">eventually breaks down over time, causing pain and potential disability to the affected knee joint, </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">often many years after ACL rupture.  While the injury mechanism may lead to direct cartilage </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">damage, resulting biomechanical changes of knee function such as increased rotational </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">instability, postsurgical changes or subtle loss of range of motion may lead to progressive </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">breakdown of articular cartilage in the medial or lateral compartment and may appear as early as </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2 years after injury (18,19) as illustrated in Figure 1.  Indeed, Neuman et al. (20) reported knee </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cartilage glycosoaminoglycans changes within 2 years after ACL injury.  These changes are </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">indicative of posttraumatic OA.  </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Previous Clinical Research</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">: The IL-1ra drug we are planning to use has been previously </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">utilized in this patient population. The use of this drug is advantageous as it constitutes a </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">meaningful repurposing of an already existing drug that has been shown to be safe in this patient </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">population. </span></p>
<p style="top:387.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:SegoeUIHistoric,sans-serif;font-size:12.0pt"> </span></p>
<p style="top:400.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study 1:</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> IL-1Ra decreased pain in an open label trial of arthrofibrosis:  </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Dr. Virginia Kraus, Co-</span></p>
<p style="top:412.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator of this study, conducted two small clinical trials to test the beneficial effect of IL-</span></p>
<p style="top:424.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1ra, an inhibitor of IL-1 biological activity, in vivo.  Six patients who failed to meet entry criteria </span></p>
<p style="top:436.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">for a separate randomized trial because of age or time from injury to presentation, were entered </span></p>
<p style="top:448.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">into a small open label study in which they received 150 mg IL-1ra (anakinra, Amgen) intra-</span></p>
<p style="top:460.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">articularly for the treatment of acute ACL injury (n=2), or chronic, recurrent, arthrofibrosis </span></p>
<p style="top:472.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">following surgical lysis of adhesions (n=4). All 4 arthrofibrosis patients reported improvement in </span></p>
<p style="top:484.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">knee pain, swelling, and joint motion.  Examination by the treating physician and by physician </span></p>
<p style="top:496.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">global assessment confirmed these results.</span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">  Five out of six patients reported clinically </span></b></p>
<p style="top:508.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">significant pain relief after the treatment.  There were no other complaints related to the </span></b></p>
<p style="top:520.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">drug and no evidence of significant adverse events in any patient.</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> These results corroborate </span></p>
<p style="top:532.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">findings from animal studies and imply that adequate exposure to IL-1Ra early in the course of </span></p>
<p style="top:544.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">disease may potentially reduce pain and stiffness (21).  </span></p>
<p style="top:556.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:568.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study 2:</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> IL-1Ra decreased pain, and improved function, and lowered IL-1</span></i><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> levels in synovial </span></i></p>
<p style="top:580.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">fluid in a randomized pilot trial of ACL rupture:</span></i><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">In a second randomized trial, 11 patients with </span></p>
<p style="top:592.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">isolated ACL tears scheduled for later ACL surgery were treated with 150 mg (anakinra, Amgen; </span></p>
<p style="top:604.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">6 patients) or equal volume saline placebo (5 patients) intra-articularly within the first 30 days of </span></p>
<p style="top:616.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">acute knee injury. Mean age of participants was 24 + 4 (SD) years, (6 male, 5 female). </span></p>
<p style="top:628.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Enrollment was limited to patients under 40 years of age to try to insure the lack of underlying </span></p>
<p style="top:640.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pre-existing arthropathy. Patients were recruited a mean 15 + 7 (SD) days from injury (range 6-</span></p>
<p style="top:652.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">27 days). Self-report of pain on a Likert scale 0-10 was recorded at baseline (0), 4 days, 14 days, </span></p>
<p style="top:664.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and 28 days after treatment as well as on the day of surgery.  The standardized KOOS and IKDC </span></p>
<p style="top:676.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">questionnaires were also obtained.  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">12 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Using the non-parametric Wilcoxon signed-rank sum test, significant differences (p&lt;0.05) were </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">observed in the anakinra treated group only: Pain was reduced in the anakinra treated group of </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">patients by 23% after 4 days, improvement in Activities of Daily Living by 46%, and </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">improvement in total KOOS by 24%; in contrast the placebo group improved by only 4%, 6% </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and 7% for these outcomes, respectively. This suggests a significan early effect in this patient </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">population that is beneficial for the early rehab process prior to surgery(22). </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Synovial fluid IL-1</span></b><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> decreased over 1 month in response to a single IL-1Ra intra-articular </span></b></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">injection in our pilot trial.</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">   </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">The change with treatment (Day 0 to Day 28) in synovial fluid </span></b></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1</span></b><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> constituted the most intriguing and promising cytokine result from this pilot trial</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">.  </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> increased in all the placebo treated patients (n=4 pairs of samples available); whereas IL-</span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> decreased in 4 or 5 of the anakinra treated patients (n=5 pairs of samples available)(21).   </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study 3: </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">In order to prove that we have the </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ability to perform a high level (GCP) </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">randomized clinical trial our group has </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">performed a randomized clinical trial </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">involving ACL patients in the same study </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">design featuring identical enrollment </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(inclusion/exclusion) criteria as the one </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">proposed in this contract (MOON-AAA </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinicaltrials.gov identifier: NCT01692756). </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">In this multicenter early intervention trial </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">testing the effect of Triamcinolone </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">administration patients underwent knee joint </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">aspirations, blood draws and urine collections </span></p>
<p style="top:384.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">at three time points prior to ACL surgery. </span></p>
<p style="top:396.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PRO&#x2019;s and clinical exams were performed at all time points prior to surgery and at 4 time points </span></p>
<p style="top:408.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">post-surgery up to 6 months post-surgery.   We have successfully enrolled 3-4 patients per month </span></p>
<p style="top:420.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in the last 12 months actually exceeding the goal of 2 patients / month as initially estimated. The </span></p>
<p style="top:432.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">average time from injury to enrollment is 4.2 days with an average patient age of 18.6 years. No </span></p>
<p style="top:444.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">patients have been lost to follow-up. This trial has just completed enrollment and is in the </span></p>
<p style="top:456.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">process of data analysis (see table 1). This trial has been extraordinarily successful and was able </span></p>
<p style="top:468.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to show that the initial chondrodegradatory response, as measured in synovial fluid can be </span></p>
<p style="top:480.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">modified intraarticularly with the administration of triamcinolone acetonide.  </span></p>
<p style="top:492.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:504.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Pediatric dosing</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> -  </span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">Kineret</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#xae;,</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> was studied in a single randomized, blinded multi-center trial in </span></p>
<p style="top:516.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">86 patients with polyarticular course Juvenile Rheumatoid Arthritis (JRA; ages 2-17 years) </span></p>
<p style="top:528.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">receiving a dose of 1 mg/kg subcutaneously daily, up to a maximum dose of 100 mg. The 50 </span></p>
<p style="top:540.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">patients who achieved a clinical response after a 12-week open-label run-in were randomized to </span></p>
<p style="top:552.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">Kineret</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#xae;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> (25 patients) or placebo (25 patients), administered daily for an additional 16 weeks. </span></p>
<p style="top:564.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> </span></p>
<p style="top:576.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">A subset of these patients continued open-label treatment with Kineret</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#xae;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> for up to 1 year in a </span></p>
<p style="top:588.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">companion extension study. An adverse event profile similar to that seen in adult RA patients </span></p>
<p style="top:600.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">was observed in these studies. Pediatric use of Kineret</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#xae;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> was not recommended due to difficulty </span></p>
<p style="top:612.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">dosing the medication in smaller children requiring less than 100mg per dose and because  </span></p>
<p style="top:624.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">efficacy could not be demonstrated due to low trial enrollment. No safety issues were seen. The </span></p>
<p style="top:636.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">dosing problem will not come to bear in our patient population as we only enroll children 14 </span></p>
<p style="top:648.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121">years and older. </span></p>
<p style="top:660.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#212121"> </span></p>
<p style="top:672.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Trial Registration Number: NCT00339157. First prospective placebo controlled trial to evaluate </span></p>
<p style="top:684.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the effectiveness of IL-1Ra for SJIA. Enrolled a total of 24 patients: mean (SD) age of 9.5 (5) </span></p>
<p style="top:696.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">years; female subjects entering the study were prepubescent, sexually inactive or required to use </span></p>
<p style="top:223.7pt;left:313.6pt;line-height:11.0pt"><span style="font-family:Times New Roman,serif;font-size:11.0pt">Table 1:</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Enrollment data MOON-AAA </span></p>
<p style="top:236.8pt;left:313.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">trial </span></p>
<p style="top:371.4pt;left:515.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.31991554,0,-0,.31982965,132.43128,145.69678)" src="data:image/jpeg;base64,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">
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">13 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">effective contraception; 12 received 2 mg/kg sc daily for 1 year; 10 received placebo for one </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">month then 2 mg/kg sc daily for 11 months. Max dose 100 mg qd. Anakinra treatment was </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">effective in SJIA. They noted in the Discussion that: &quot; PK data suggested that low-weight </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">children might have benefited from a higher anakinra dosage.&quot; </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Safety:</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Between month 1 and month 12, six patients stopped treatment owing to an adverse event </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(n=2), lack of efficacy (n=2) or a disease flare (n=2). &quot;One patient was diagnosed with </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inflammatory bowel disease, a complication reported in some patients initially diagnosed with JIA </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and treated with anti-TNF agents. An additional patient experienced a sudden rise in serum </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">transaminases.&quot; Of note, patients were on concurrent corticosteroid therapy.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">39</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">An open-label retrospective observational trial of 46 SJIA patients (median age 7.6 years) who </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">received anakinra alone (n=10) or in combination with corticosteroids or remittive agents </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">including methotrexate or cyclosporine.   </span></p>
<p style="top:228.0pt;left:144.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Dose:</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &quot;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">The median starting dose of anakinra was 1.5 mg/kg/day (IQR 1.1&#x2013;2.0 mg/kg/day; </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">minimum 0.93 mg/kg/day, maximum 11.2 mg/kg/day), and subsequent dose escalation was </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">required in 24% of patients. Patients requiring dose escalation received a median initial dose of </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1.3 mg/kg/day, compared with a median initial dose of 1.6 mg/kg/day in patients who did not (</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">P </span></i></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">not significant). Among 19 patients who started with a dose &lt;1.5 mg/kg/day, 8 (42%) ultimately </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">required a higher dose. One patient received anakinra twice daily. In most patients, therapy with </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">anakinra could not be interrupted during the term of observation, but recurrent dose escalation </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(tachyphylaxis) was not observed. At the last follow-up visit, anakinra had been discontinued for </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inefficacy in 1 patient, for intolerance in 2, and because of remission in 3; 7 patients could be </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">weaned to dosing every other day, although symptoms returned if the interval exceeded 48 </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">hours.&quot; Of note, the patient who received the highest dose of anakinra monotherapy (11.2 </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">mg/kg/day intravenously administered as 5.6 mg/kg every 12 hours) was being treated in </span></p>
<p style="top:384.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">intensive care for macrophage activation syndrome, a potentially life-threatening complication of </span></p>
<p style="top:396.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SJIA. On this treatment: &quot;She improved dramatically, but her response remained partial, and at </span></p>
<p style="top:408.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the last follow-up visit, she was requiring anakinra at 2.3 mg/kg/day, abatacept, and monthly </span></p>
<p style="top:420.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pulse corticosteroids.&quot; </span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:432.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:444.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">They concluded that &quot;in general, improvement was rapid and striking.&quot; series, children older than </span></p>
<p style="top:456.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7 years were more likely to exhibit a complete response to anakinra-based therapy than those </span></p>
<p style="top:468.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ages 7 years and younger (75% versus 41%; </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">P </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">&lt; 0.05). </span></p>
<p style="top:480.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:492.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Safety:</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Five patients developed macrophage activating syndrome while on anakinra but this was </span></p>
<p style="top:504.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">believed to be due to SJIA and not anakinra. They stated: &quot;the role of anakinra as a trigger for </span></p>
<p style="top:516.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">these 5 cases cannot be determined, in no case was permanent discontinuation necessary. </span></p>
<p style="top:528.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Further, dose escalation often seemed to help control macrophage activation syndrome.&quot; </span></p>
<p style="top:540.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Injection site reactions occurred in 44% of the 45 patients with evaluable data, leading to </span></p>
<p style="top:552.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">permanent discontinuation of drug in 1 patient and transient discontinuation in several others.  </span></p>
<p style="top:564.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:576.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">There were 3 cases of serious infection. A 4-year-old child treated with anakinra at 1 mg/kg/day </span></p>
<p style="top:588.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and 6 weeks of corticosteroids developed pneumococcal bacteremia at 2 months in the setting of </span></p>
<p style="top:600.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">parainfluenza infection. Anakinra was withheld for 1 week but was restarted because of rising </span></p>
<p style="top:612.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">levels of markers of inflammation. The patient remained well during an additional 6 months of </span></p>
<p style="top:624.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">observation. An 11-year-old child treated with anakinra (1.2 mg/kg/day) and high-dose oral </span></p>
<p style="top:636.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">corticosteroids developed an infection at a healed gastric feeding tube site. Anakinra was </span></p>
<p style="top:648.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">withheld for 2 weeks but was ultimately escalated to 1.9 mg/kg/day without further complication </span></p>
<p style="top:660.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">during 21 additional months of observation. A 3-yearold child receiving anakinra at 1.7 </span></p>
<p style="top:672.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">mg/kg/day was admitted to the hospital for several days with pneumonia. No organism was </span></p>
<p style="top:684.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cultured. Anakinra was restarted after discharge.&quot; </span></p>
<p style="top:696.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">14 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Other events included two episodes of bronchitis, 1 episode of eosinophilic hepatitis requiring </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">discontinuation of anakinra, elevation of liver enzymes in 2 patients but anakinra could be </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">continued, and mild neutropenia resolved on alternate day anakinra.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">40</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:123.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.2 </span></p>
<p style="top:123.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">RATIONALE  </span></p>
<p style="top:138.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:150.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">We hypothesize that IL-1Ra administered intra-articularly during the early phase of acute ACL </span></p>
<p style="top:162.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury will provide symptomatic pain relief and decrease synovial fluid inflammatory and cartilage </span></p>
<p style="top:174.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">degradation markers.  ACL injury produces high levels of inflammatory mediators, including as </span></p>
<p style="top:186.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1, which mediate knee pain, perpetuate synovitis, and decrease functional recovery post injury </span></p>
<p style="top:198.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and post-surgically. We have designed a clinical trial that specifically tests the ability of IL-1ra to </span></p>
<p style="top:210.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">alleviate pain following acute ACL injury and potentially changes patient reported outcomes at 2 </span></p>
<p style="top:222.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">years.  </span></p>
<p style="top:234.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:246.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A total of 1 mL (150 mg) will be injected intra-articularly after synovial fluid aspiration &apos;to </span></p>
<p style="top:258.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">dryness&apos; once at study entry 1-28 days after injury depending on time of presentation).  </span></p>
<p style="top:270.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ff0000"> </span></b></p>
<p style="top:282.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Rational for including pediatric population </span></b></p>
<p style="top:294.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:306.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The specific reason for enrolling the age group of children aged 14-18 is that these children have </span></p>
<p style="top:318.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a musculoskeletal physiology like adults. </span></p>
<p style="top:330.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Their major growth plates are closed.  </span></p>
<p style="top:342.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">These patients may be treated surgically like adult patients with exactly the same surgical </span></p>
<p style="top:354.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">preparation, technique and rehabilitation as adults.  </span></p>
<p style="top:366.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Children, particularly girls, between the ages of 14 and 18 have the highest statistical risk </span></p>
<p style="top:378.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in any population of tearing their Anterior Cruciate Ligament. </span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">25,45</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:390.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Children in this age group are particularly vulnerable to the later development of </span></p>
<p style="top:402.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">osteoarthritis. Lohmander et al showed that young female soccer players in this age group </span></p>
<p style="top:414.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">developed symptomatic knee Osteoarthritis secondary to the ACL injury within 12 years </span></p>
<p style="top:426.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the injury.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">24</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt">  One could therefore argue that particularly children between completed </span></p>
<p style="top:438.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">puberty and 18 years of age have to be the patients requiring most of our concern </span></p>
<p style="top:450.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">regarding development of OA.  </span></p>
<p style="top:462.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Furman et al.</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> showed that early post-injury administration of IL-1Ra did not alter bone </span></p>
<p style="top:474.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">morphology or fracture healing after intra-articular fracture but significantly reduced </span></p>
<p style="top:486.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cartilage degradation and inflammation.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">(46)</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:498.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">The value of intraarticular IL-1 blockade when given immediately after intraarticular </span></p>
<p style="top:510.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury has been demonstrated repeatedly. In a recent publication of </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Genemaras et al.</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> the </span></p>
<p style="top:522.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">early administration of IL-1Ra could be shown to significantly down-regulate pro-</span></p>
<p style="top:534.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inflammatory Il1-</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3b2;, TNF</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">-</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3b1;) and chondrodeg</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">redatory markers ( MMP-3,ADAMTS-</span></p>
<p style="top:546.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">4,ADAMTS-5) immediately after non-destructive chondral impact injury to porcine </span></p>
<p style="top:558.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">articular cartilage</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">(45)</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt">. </span></p>
<p style="top:570.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Chevalier et al.</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> showed in 2005 that intra-articular injection of anakinra in patients with </span></p>
<p style="top:582.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">knee OA is safe </span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">(47)</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt">. It is important to realize that patients who have suffered an ACL </span></p>
<p style="top:594.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury are a substantial risk for chronic inflammatory changes leading to OA and, in fact, </span></p>
<p style="top:606.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">display these changes as early as 4 weeks after injury lasting for up to 5 years after ACL </span></p>
<p style="top:618.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury. </span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">(48,49)</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:630.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">A study performed by Brown et al. enrolled 8 patients with arthrofibrosis who were </span></p>
<p style="top:642.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">treated with intra-articular administration of 150mg of anakinra. Five of the eight </span></p>
<p style="top:654.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">enrolled patients were under the age of 24, 3 under the age of 21, and one patient aged </span></p>
<p style="top:666.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">15. None of these patients have shown any adverse events and all of them improved in </span></p>
<p style="top:678.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">their clinical outcomes. In addition the same group completed a study enrolling young </span></p>
<p style="top:690.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">patients (mean age 22+ 3) who suffered ACL injuries. This trial did also not show any </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">15 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">significant adverse events regarding safety of the drug administration. In contrary, they </span></p>
<p style="top:84.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">show improved post-injury pain scores.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">52</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">In summary</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">: We would like to argue that skeletally mature adolescents of ages 14-18 are </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">musculoskeletally no different than their 19 year old and older counterparts and therefore </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">deserve the same potential benefit that early treatment with IL-1Ra may offer older patients. We </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">find of no data to indicate that intra-articular use of IL-1Ra would have a different effect in the </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14-18 year old over the 19-40 year old. There is no in-vitro or in-vivo data indicating a </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">detrimental effect of Il-1Ra to articular cartilage or the knee joint as a whole in the dosages we </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">are intending to use. We believe that the potential benefits of this trial for this patient population </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">outweighs by far the uncertainty of unknown risks that may be associated specifically with being </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14-18 year old.  </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The Federal Drug Administration has approved daily subcutaneous injections (100 mg) to </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">patients with rheumatoid arthritis. Our goal is to sustain therapeutic levels of IL-1Ra in the joint </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">during the early phase of acute joint injury.  We hypothesize that the post injury intra-articular </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">administration of 150 mg IL-1Ra (Kineret&#xae;) will be well tolerated. </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">By slowing the initial inflammatory process after injury and preventing the significant </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">quadriceps muscle shutdown early, we aim to work towards this goal in this trial. We therefore </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">conclude that given the limited risk of local side effects and the potential large benefit that this </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study would provide to the scientific community and its potential to significantly improve and </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">alter patient care of young individuals suffering ACL injuries it is not reasonable to withhold </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pediatric patients aged 14-18 from this important trial. </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:375.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.3 </span></p>
<p style="top:375.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">POTENTIAL RISKS AND BENEFITS  </span></p>
<p style="top:390.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:404.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">2.3.1 KNOWN POTENTIAL RISKS  </span></p>
<p style="top:416.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:428.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Safety Precautions: </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participants will be followed at regular intervals by their study doctor.  </span></p>
<p style="top:440.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">During each visit participants will be evaluated for adverse events according to GCP guidelines </span></p>
<p style="top:452.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and reported accordingly to IRB and FDA regulations. </span></p>
<p style="top:464.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:476.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Risks associated with Kineret&#xae;:   </span></b></p>
<p style="top:488.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:500.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Reproductive Risks:  It is not known whether receiving Kineret&#xae; is harmful to an unborn child.  </span></p>
<p style="top:512.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Pregnancy after administration of Kineret&#xae; may involve risks to the mother, and her embryo or </span></p>
<p style="top:524.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">fetus.  Therefore, females who are capable of reproducing, must use effective contraceptive </span></p>
<p style="top:536.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">methods.  These methods must be used from the time of screening until Visit 2 during which  </span></p>
<p style="top:548.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">any remaining medication will be washed out of the joint during the surgery.  If the participant </span></p>
<p style="top:560.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">does not elect to have surgery (visit 2) contraception methods will be documented until the end </span></p>
<p style="top:572.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the study. Examples of effective birth control are:  hormonal contraceptives (the pill, implant, </span></p>
<p style="top:584.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">transdermal patch, or injection), barrier methods (condom with spermicide, diaphragm with </span></p>
<p style="top:596.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">spermicide), IUD, or a male partner had a vasectomy. </span></p>
<p style="top:608.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:620.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Lactating women:  It is not known whether this drug or its metabolites are excreted in human </span></p>
<p style="top:632.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">milk.  Because many drugs are excreted in human milk, caution should be exercised when </span></p>
<p style="top:644.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kineret&#xae; is administered to a nursing woman. </span></p>
<p style="top:656.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:668.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Limitations, potential problems, and alternatives:</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">  This study will allow for safety and </span></p>
<p style="top:680.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">efficacy assessment in patients with acute effusive knee injury.   </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">16 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Dose:  Based on our work and the work of others, we believe 150 mg dosage is </span></p>
<p style="top:84.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">appropriate.  The goal of the study is to sustain levels of IL-1Ra long enough and a high </span></p>
<p style="top:96.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">enough concentrations during the critical, early time period to be effective.  For this </span></p>
<p style="top:108.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reason, we have increased our dosage from a single injection (carried out in the </span></p>
<p style="top:120.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">preliminary study) to two injections. </span></p>
<p style="top:132.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient attrition:  Close and regular communication, particularly in the intensive first few </span></p>
<p style="top:144.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">months, will be provided to all subject participants.  Patients will be fully informed of the </span></p>
<p style="top:156.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">time commitments and need for a total of three arthrocenteses in order to recruit study </span></p>
<p style="top:168.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subjects willing to participate in the full study.  Because arthrocentesis alone can be </span></p>
<p style="top:180.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">expected to benefit subjects, education regarding direct and indirect benefits of all aspects </span></p>
<p style="top:192.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the trial will be provided.  Subjects will also receive appropriate compensation for the </span></p>
<p style="top:204.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">time and travel. </span></p>
<p style="top:217.6pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:230.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">2.3.2 KNOWN POTENTIAL BENEFITS  </span></p>
<p style="top:242.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:254.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1Ra, while potent, has had mixed results in the treatment of established OA, possibly due to </span></p>
<p style="top:266.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">its short half-life in vivo.  In this trial, we expect that an early intervention with IL-1Ra will </span></p>
<p style="top:278.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">effectively block the deleterious cascade of joint degradation events after joint injury.  We expect </span></p>
<p style="top:290.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a significant effect of IL-1Ra on post-injury pain and concomitantly an increased improvement </span></p>
<p style="top:302.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in early function. </span></p>
<p style="top:314.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:329.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">3 </span></b></p>
<p style="top:329.8pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">OBJECTIVES AND PURPOSE </span></b></p>
<p style="top:344.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:356.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Primary Objective:</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">   To assess the efficacy of using IL-1ra and knee arthrocentesis to alleviate </span></p>
<p style="top:368.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inflammation related knee pain and improve patient-reported outcomes (PRO) following ACL </span></p>
<p style="top:380.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">rupture. </span></p>
<p style="top:392.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:404.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Secondary Objectives</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">: </span></p>
<p style="top:416.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:428.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1.   To determine if intra-articular IL-1ra therapy improves levels of a panel of inflammatory, </span></p>
<p style="top:440.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">meniscus and cartilage metabolism, and oxidative stress biomarkers as measured in synovial </span></p>
<p style="top:452.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">fluid, serum and urine from patients immediately after ACL injury (baseline, 2 weeks after injury </span></p>
<p style="top:464.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and at 1 and 2 years after surgery). </span></p>
<p style="top:476.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:488.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.  To assess if MRI T1rho changes correlate with synovial biomarker levels and show predictive </span></p>
<p style="top:500.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">value for the overall subject patient outcome at 2 years </span></p>
<p style="top:512.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:527.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">4 </span></b></p>
<p style="top:527.8pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STUDY DESIGN AND ENDPOINTS </span></b></p>
<p style="top:542.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:557.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">4.1 </span></p>
<p style="top:557.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DESCRIPTION OF THE STUDY DESIGN </span></p>
<p style="top:572.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:584.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This is a phase 2, prospective, randomized, triple-blinded, placebo-controlled study of IL-1RA </span></p>
<p style="top:596.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">treatment in patients with acute ACL tear and painful effusions.  The study population will </span></p>
<p style="top:608.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">include up to 40 participants within 28 days of injury.  The study is open to male and female </span></p>
<p style="top:620.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participants  who are between the ages of 14 and 40, who have ACL tears.  Once enrolled  will </span></p>
<p style="top:632.8pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be randomized into 2 groups (20 subjects per group). </span></p>
<p style="top:645.5pt;left:72.0pt;line-height:11.0pt"><span style="font-family:Times New Roman,serif;font-size:11.0pt"> </span></p>
<p style="top:656.8pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 1</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of Anakinra (Kineret&#xae;,  IL-1ra; 150mg) 1-</span></p>
<p style="top:668.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">28 days after ACL injury.  </span></p>
<p style="top:680.8pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 2</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of saline placebo 1-28 days after ACL </span></p>
<p style="top:692.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury.  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">17 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:111.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">4.2 </span></p>
<p style="top:111.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY ENDPOINTS </span></p>
<p style="top:126.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:140.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">4.2.1 PRIMARY ENDPOINT </span></p>
<p style="top:152.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:164.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient reported outcomes as measured by KOOS-Symptoms  </span></p>
<p style="top:176.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:191.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">4.2.2 SECONDARY ENDPOINTS </span></p>
<p style="top:203.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:215.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS QOL,  </span></p>
<p style="top:227.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS-pain,  </span></p>
<p style="top:239.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS-Sports/Rec,  </span></p>
<p style="top:251.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarker levels in synovial fluid, serum and urine at time of surgery </span></p>
<p style="top:263.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI T1rho changes at 2 years </span></p>
<p style="top:275.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:290.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">5 </span></b></p>
<p style="top:290.5pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STUDY ENROLLMENT AND WITHDRAWAL </span></b></p>
<p style="top:305.5pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:322.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.1 </span></p>
<p style="top:322.1pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PARTICIPANT INCLUSION CRITERIA </span></p>
<p style="top:337.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:349.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">In order to be eligible to participate in this study, an individual must meet all of the following </span></p>
<p style="top:361.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">criteria: </span></p>
<p style="top:373.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:387.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:385.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Isolated Acute ACL Tear (1-28 days post injury) and painful effusion, with no more than </span></p>
<p style="top:397.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a clinical grade 2 MCL injury.</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:411.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:409.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Provision of signed and dated combined informed consent/HIPAA form and if a minor, a </span></p>
<p style="top:421.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">signed assent.</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:435.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:433.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Stated willingness to comply with all study procedures and availability for the duration of </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:447.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:445.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the study </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:459.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:457.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Male or female, aged 14-40 years </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:471.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:469.3pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">For females of reproductive potential: use of highly effective contraception.  </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:481.3pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Currently participating in a sporting activity </span></p>
<p style="top:493.3pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Documentation of closed growth plates as noted on the screening x-ray </span></p>
<p style="top:519.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.2 </span></p>
<p style="top:519.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PARTICIPANT EXCLUSION CRITERIA </span></p>
<p style="top:535.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:547.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">An individual who meets any of the following criteria will be excluded from participation in the </span></p>
<p style="top:559.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study: </span></p>
<p style="top:571.1pt;left:76.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:583.1pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History of underlying inflammatory disease (i.e. Rheumatoid Arthritis, Psoriatic </span></p>
<p style="top:595.1pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Arthritis etc.)  </span></p>
<p style="top:607.1pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History of having been diagnosed with hepatitis B or tuberculosis </span></p>
<p style="top:619.1pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Currently have an infections, including infection of the skin, or have signs and </span></p>
<p style="top:631.1pt;left:112.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">symptoms of an infection, including fever.  </span></p>
<p style="top:643.1pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History any abnormalities in their white blood cell counts </span></p>
<p style="top:655.1pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History of having a disease that weakens your immune system such as diabetes, cancer, </span></p>
<p style="top:667.1pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">HIV or AIDs </span></p>
<p style="top:679.1pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History of other major medical condition requiring treatment with immunosuppressant </span></p>
<p style="top:691.1pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or modulating drugs.  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">18 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">A history of chronic use of non-steroidal anti-inflammatory drugs  </span></p>
<p style="top:84.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Currently taking immunosuppressant medication, including oral and parenteral </span></p>
<p style="top:96.0pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">corticosteroids (topical and stable dose inhaled corticosteroids are acceptable) </span></p>
<p style="top:108.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Females who are pregnant or breastfeeding </span></p>
<p style="top:120.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Received a &#x201c;live&#x201d; vaccine (smallpox, MMR (measles, mumps and rubella), flu, polio, </span></p>
<p style="top:132.0pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">typhoid, chicken pox, yellow fever, herpes zoster) 1 week prior to screening or are </span></p>
<p style="top:144.0pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">scheduled to receive a &#x201c;live&#x201d; vaccine within 1 week after study injection. </span></p>
<p style="top:156.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">History of bleeding disorders or are taking any blood thinning medications, aspirin or </span></p>
<p style="top:168.0pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">other medications affecting blood clotting. </span></p>
<p style="top:180.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Previous exposure or allergic reaction to anakinra </span></p>
<p style="top:192.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Allergy to latex or tape </span></p>
<p style="top:204.0pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Allergy to Kineret or have had a reaction to any local or general anesthesia </span></p>
<p style="top:216.0pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Prior ipsilateral knee surgery  </span></p>
<p style="top:228.0pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Complete ligament tear other than the ACL </span></p>
<p style="top:240.0pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Received any investigational drug with 4 weeks of study Visit 1 </span></p>
<p style="top:252.0pt;left:94.6pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Does not have the cognitive ability to provide informed consent. </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:280.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.3 </span></p>
<p style="top:280.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STRATEGIES FOR RECRUITMENT AND RETENTION </span></p>
<p style="top:295.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:307.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participants in this trial will be recruited within 28 days from injury following a clinical </span></p>
<p style="top:319.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">appointment with one of the study&#x2019;s participating orthopaedic surgeons. </span></p>
<p style="top:331.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:343.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participants in this trial will be recruited within 28 days from injury from the Emergency </span></p>
<p style="top:355.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Department or walk-in clinics for acute injuries. </span></p>
<p style="top:367.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:379.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">No prisoners will be enrolled into the study.   </span></p>
<p style="top:391.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:403.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">We will enroll children between the ages of 14-17. Parental consent will be needed in order to </span></p>
<p style="top:415.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">enroll children into the study. </span></p>
<p style="top:427.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:439.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participants will receive $150.00 for taking part in this study.  The participant will receive </span></p>
<p style="top:451.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">$50.00 for each MRI they complete (Visit 1, Visit 5, and Visit 6).  Payment will be in the form of </span></p>
<p style="top:463.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a check which will be mailed approximately four to six weeks following the study visit.  If the </span></p>
<p style="top:475.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participant is a minor the compensation will be mailed to the minor. </span></p>
<p style="top:487.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:499.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Advertising may be used to promote this study to the public.  All advertisements and public </span></p>
<p style="top:511.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">marketing will be approved by the IRB prior to use. </span></p>
<p style="top:523.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:540.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.4 </span></p>
<p style="top:540.4pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PARTICIPANT WITHDRAWAL OR TERMINATION </span></p>
<p style="top:557.3pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Arial,sans-serif;font-size:12.0pt;color:#1f487c"> </span></i></p>
<p style="top:573.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION </span></p>
<p style="top:586.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:598.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Subjects are free to withdraw from participation in the study at any time upon request. An </span></p>
<p style="top:610.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigator may terminate participation in the study if:  </span></p>
<p style="top:622.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:634.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Any clinical adverse event (AE), laboratory abnormality, or other medical condition or </span></p>
<p style="top:646.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">situation occurs such that continued participation in the study would not be in the best </span></p>
<p style="top:658.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">interest of the participant  </span></p>
<p style="top:670.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> The participant meets an exclusion criterion (either newly developed or not previously </span></p>
<p style="top:682.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recognized) that precludes further study participation. </span></p>
<p style="top:694.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">19 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:84.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:112.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">5.4.2 HANDLING OF PARTICIPANT WITHDRAWALS OR TERMINATION </span></p>
<p style="top:124.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:136.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A subject may withdraw from the study at any time at his or her own request, or may be </span></p>
<p style="top:148.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">withdrawn at any time at the discretion of the Investigator for due to safety or scientific reasons.  </span></p>
<p style="top:160.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Reasons for discontinuation from the study at any time point will be collected.  If subject </span></p>
<p style="top:172.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">discontinues the study for any reason prior to 3-month visit, then the collected data will be </span></p>
<p style="top:184.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">evaluated but not included in the analysis and a replacement subject will be enrolled in the </span></p>
<p style="top:196.6pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study. </span></p>
<p style="top:208.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:225.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.5 </span></p>
<p style="top:225.1pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PREMATURE TERMINATION OR SUSPENSION OF STUDY </span></p>
<p style="top:240.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:252.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This study may be temporarily suspended or prematurely terminated if there is sufficient </span></p>
<p style="top:264.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reasonable cause. Written notification, documenting the reason for study suspension or </span></p>
<p style="top:276.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">termination, will be provided by the suspending or terminating party. If the study is prematurely </span></p>
<p style="top:288.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">terminated or suspended, the PI will promptly inform the IRB and will provide the reason(s) for </span></p>
<p style="top:300.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the termination or suspension.  </span></p>
<p style="top:312.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Circumstances that may warrant termination or suspension include the above mentioned stopping </span></p>
<p style="top:324.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">criteria as well as: </span></p>
<p style="top:336.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:348.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Determination of unexpected, significant, or unacceptable risk to participants </span></p>
<p style="top:360.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Demonstration of efficacy that would warrant stopping  </span></p>
<p style="top:372.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Insufficient compliance to protocol requirements  </span></p>
<p style="top:384.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Data that are not sufficiently complete and/or evaluable  </span></p>
<p style="top:396.4pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Determination of futility  </span></p>
<p style="top:408.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:420.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study may resume once concerns about safety, protocol compliance, data quality are addressed </span></p>
<p style="top:432.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and satisfy the sponsor, IRB and/or FDA. </span></p>
<p style="top:444.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:460.9pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">6 </span></b></p>
<p style="top:460.9pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STUDY AGENT </span></b></p>
<p style="top:477.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:494.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">6.1 </span></p>
<p style="top:494.5pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY AGENT(S) AND CONTROL DESCRIPTION </span></p>
<p style="top:511.3pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:527.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.1 ACQUISITION </span></p>
<p style="top:540.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:552.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Unblinded study drug will be shipped from the manufacturer Swedish Orphan Biovitrum (Sobi) </span></p>
<p style="top:564.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">directly to the site research pharmacist, after all required regulatory and legal documents have </span></p>
<p style="top:576.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">been received by the Sponsor. </span></p>
<p style="top:588.1pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:600.1pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Replacement Procedures For Investigational Medicinal Product: </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Resupply shipments or </span></p>
<p style="top:612.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">replacement of study drug will be provided by Sobi after consultation with Dr. Stone. </span></p>
<p style="top:624.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:640.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING </span></p>
<p style="top:652.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:664.7pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Formulation, Packaging and Labeling:  </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kineret&#xae; is a recombinant, nonglycosylated form of </span></p>
<p style="top:676.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">human interleukin-1 receptor antagonist (IL-1Ra).  Kineret&#xae; consists of 153 amino acids and has </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">20 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a molecular weight of 17.3 kilodaltons.  It is produced by recombinant DNA technology using an </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">E coli</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> bacterial expression system. </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kineret is supplied in single use prefilled glass syringes with 29 gauge needles as a sterile, clear, </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">colorless-to-white, preservative free solution for daily subcutaneous (SC) administration. The </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">solution may contain trace amounts of small, translucent-to-white amorphous proteinaceous </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">particles. Each prefilled glass syringe contains: 0.67 mL (100 mg) of anakinra in a solution (pH </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">mg), and sodium chloride (5.48 mg) in Water for Injection, USP. </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The prefilled syringe contains an outer rigid plastic needle shield attached to an inner needle </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">cover. The syringe or needle shield components are not made with natural rubber latex. </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Each syringe will have a label that will contain, at minimum, the protocol number, </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">contents (written as &#x201c;Kineret&#xae;&#x201d;), applicable regulatory cautions, storage conditions, route </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of administration, and a space to write in the dispensing date, subject identification number and </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subject initials.  </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:292.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.3 PRODUCT STORAGE AND STABILITY </span></p>
<p style="top:304.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:316.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The prepared syringes of Kineret or placebo will be stored in a separate, temperature controlled </span></p>
<p style="top:328.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">refrigerator at the investigative site.  </span></p>
<p style="top:340.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kineret&#xae; should be stored in the refrigerator at 2&#xb0; - 8&#xb0; C (36&#xb0; - 46&#xb0;F). </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> DO NOT FREEZE OR </span></b></p>
<p style="top:352.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">SHAKE.</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">  Protect from light. Kineret&#xae; should not be used after the expiration date unless </span></p>
<p style="top:364.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">otherwise notified by the Principal Investigator.   </span></p>
<p style="top:376.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:388.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study drug will be sent to the designated research staff at the University of Kentucky.   </span></p>
<p style="top:400.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:412.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Once a subject is identified and consented, the study coordinator will utilize the syringe </span></p>
<p style="top:424.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">corresponding to the assigned patient ID to administer the study medication.  It has been shown </span></p>
<p style="top:436.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">by HPLC analyses, that Kineret is stable for at least 4 hours at ambient temperature and in light </span></p>
<p style="top:448.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in 0.9%NaCl and in a plastic culture vial.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">38 </span></sup></p>
<p style="top:460.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:472.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The refrigerator temperature must be monitored by site personnel on a regular basis and must be </span></p>
<p style="top:484.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recorded on a temperature log sheet or recorded electronically.  In the event that the </span></p>
<p style="top:496.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">refrigerator&#x2019;s temperature goes outside the 2&#xb0; - 8&#xb0; C (36&#xb0; - 46&#xb0;F) range, the Sponsor or designee </span></p>
<p style="top:508.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">should be contacted immediately at the telephone number provided in the protocol.  Only </span></p>
<p style="top:520.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">temperature excursions outside of the acceptable range, per the Sponsor&#x2019;s procedures, are </span></p>
<p style="top:532.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reported as protocol deviations. </span></p>
<p style="top:544.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:560.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.4 PREPARATION </span></p>
<p style="top:573.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:585.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study drug will be kept in a temperature controlled environment according to the </span></p>
<p style="top:597.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">manufacturer&#x2019;s recommendations  </span></p>
<p style="top:609.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Under aseptic clean conditions, a total of 200 mg (1.34 mL) of Kineret&#xae; (concentration </span></p>
<p style="top:633.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">100mg/0.67ml) will be injected from 2 sterile original prefilled 100 mg syringes of Kineret into a </span></p>
<p style="top:645.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">sterile vial. A sterile graduated 5 mL syringe will then be used to draw 150 mg (1 mL) of Kineret </span></p>
<p style="top:657.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">for intraarticular injection into the knee. The medication must be transferred from the original </span></p>
<p style="top:669.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">prefilled Kineret syringes as the needles are intended for subcutaneous delivery and are not </span></p>
<p style="top:681.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">adequate for intra-articular knee injection. No dilution of the medication will be performed. </span></p>
<p style="top:693.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">21 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">For the placebo we will utilize 1 mL of 0.9%NACL sterile saline solution drawn up in the same </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">type of syringe as for the Kineret administration in order to maintain double blinding of the study </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigator and patients. </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The number of study syringes prepared by the designated research personnel or research </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pharmacist, per day, will depend on the number of potential enrollees or return patients requiring </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Kineret&#xae; injections that day. </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:160.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.5 DOSING AND ADMINISTRATION </span></p>
<p style="top:172.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study treatment must only be dispensed by a pharmacist or other medically qualified staff.  </span></p>
<p style="top:184.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study treatment is to be dispensed only to subjects enrolled in this study. </span></p>
<p style="top:196.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:208.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Once a subject is identified and consented, the investigator will utilize the syringe corresponding </span></p>
<p style="top:220.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to the assigned patient ID to administer the study medication.  It has been shown by HPLC </span></p>
<p style="top:232.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">analyses, that Kineret is stable for at least 4 hours at ambient temperature and in light in </span></p>
<p style="top:244.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">0.9%NaCl and in a plastic culture vial.</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">38 </span></sup></p>
<p style="top:256.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:268.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 1</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of Anakinra (Kineret&#xae;,  IL-1ra; 150mg) 1-</span></p>
<p style="top:280.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">28 days after ACL injury. </span></p>
<p style="top:292.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 2</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of saline placebo 1-28 days after ACL </span></p>
<p style="top:304.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury. </span></p>
<p style="top:316.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:332.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.6 ROUTE OF ADMINISTRATION </span></p>
<p style="top:345.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:357.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Intra-articular injection </span></p>
<p style="top:369.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:385.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.7 STARTING DOSE AND DOSE ESCALATION SCHEDULE </span></p>
<p style="top:397.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:409.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The starting dose of Kineret is 150mg.  There is no planned dose escalation. </span></p>
<p style="top:421.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:438.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.8 DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS </span></p>
<p style="top:450.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:462.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">No dose adjustments or modifications are allowed in this study. </span></p>
<p style="top:474.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:490.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.9 DURATION OF THERAPY </span></p>
<p style="top:502.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:514.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Enrolled participants will receive, based on their randomization, either Kineret or a matching </span></p>
<p style="top:526.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">saline placebo within 1-28 days after suffering an ACL injury.   </span></p>
<p style="top:538.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:550.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">If a participant discontinues the study for any reason prior to 3-month visit, then the collected </span></p>
<p style="top:562.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">data will be evaluated but not included in the analysis and a replacement participant will be </span></p>
<p style="top:574.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">enrolled in the study. </span></p>
<p style="top:586.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:603.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">6.1.10 TRACKING OF DOSE </span></p>
<p style="top:615.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:631.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">6.2 </span></p>
<p style="top:631.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY AGENT ACCOUNTABILITY PROCEDURES </span></p>
<p style="top:647.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:659.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">It is the responsibility of the Sponsor/Investigator to supervise accurate monitoring of the receipt, </span></p>
<p style="top:671.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">storage, dispensing, and accounting of all study drug according to accepted medical and </span></p>
<p style="top:683.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pharmaceutical practice, and should also comply with state and local regulations. The originals </span></p>
<p style="top:695.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of all invoices of study drug shipments must be retained. Accurate, original site records of study </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">22 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">drug inventory and dispensing must be maintained using the forms provided by the </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor/Investigator. All disposition records must be made available for inspection by the FDA, </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DSMB, monitor or designee upon request. </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Forms will be provided for the accounting of study drug and for the accounting of study drug for </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">each subject. A reason(s) must be given for any study drug that is not accounted for. Site must </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">keep all used and unused study drug in their original box until the monitor either arranges return </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to the distribution center or gives instruction on their disposal. If any unused study drug remain </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">at the end of the study, they will be accounted for at the end of the study in the presence of the </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">monitor who will provide instructions on their disposal </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:196.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">7 </span></b></p>
<p style="top:196.6pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STUDY PROCEDURES AND SCHEDULE </span></b></p>
<p style="top:213.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:230.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.1 </span></p>
<p style="top:230.2pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY PROCEDURES/EVALUATIONS </span></p>
<p style="top:245.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:260.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.1.1 STUDY RELATED   </span></p>
<p style="top:272.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:284.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Demographic information:  </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Demographic data to be collected at Visit 1 will include height, </span></p>
<p style="top:296.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">weight, date of birth, age, gender and race. </span></p>
<p style="top:308.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:320.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Medical and Medication History</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> A detailed past medical history and a list of current </span></p>
<p style="top:332.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">medication, to include prescription and over-the-counter medications, will be collected at Visit 1.  </span></p>
<p style="top:344.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Assessment of eligibility should include a review of permitted and prohibited medications. Both </span></p>
<p style="top:356.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the medical and medication history will be reviewed with the subject throughout the study for </span></p>
<p style="top:368.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">any changes in baseline history. </span></p>
<p style="top:380.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:392.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Physical examination</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> including vital signs, height, weight, BMI. All subjects must have a </span></p>
<p style="top:404.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">clinical exam that is consistent with an ACL tear at Visit 1. All subjects will have range of </span></p>
<p style="top:416.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">motion (ROM) collected at all visits. </span></p>
<p style="top:428.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:440.2pt;left:75.6pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Knee Aspiration</span></i></b><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">:  </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">All subjects undergo knee aspiration to dryness at initial encounter Visit 1 (1-</span></p>
<p style="top:452.2pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">28 days after ACL injury), Visit 2 (the time of surgery) and again at Visit  3 (4-14 days post-op).   </span></p>
<p style="top:464.2pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Should a subject be enrolled into the study and choose not to undergo ACL reconstruction, </span></p>
<p style="top:476.2pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subject will receive treatment according to this protocol but, aspiration at time of surgery will be </span></p>
<p style="top:488.2pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">omitted. </span></p>
<p style="top:500.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:512.2pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Assessment of Pain and Function &#x2013;Subject Reported Outcomes</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; The study will use the </span></p>
<p style="top:524.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">standardized subject self-report Knee Injury and Osteoarthritis Outcome Score (KOOS) </span></p>
<p style="top:536.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">instrument to assess pain and function in response to the intervention for acute ACL injury. The </span></p>
<p style="top:548.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS is a 100 item instrument that consists of 5 subscales (pain, other symptoms, function in </span></p>
<p style="top:560.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">daily living, function in sport and recreation, and knee-related quality of life). The 5 separate </span></p>
<p style="top:572.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subscales provide a complete picture of patients&apos; perceptions of their knee injury and </span></p>
<p style="top:584.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">consequences to their daily activities, etc.. KOOS includes the WOMAC osteoarthritis index, </span></p>
<p style="top:596.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">which allows for potential comparison with other earlier studies. The KOOS has high test-retest </span></p>
<p style="top:608.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reproducibility (ICC &gt; 0.75). The KOOS subscales for function in sport and recreation and knee-</span></p>
<p style="top:620.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">related quality of life have been shown to be the most sensitive subscales pre-operatively and </span></p>
<p style="top:632.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">change the most post-operatively (27).  The study will supplement the KOOS with self-reported </span></p>
<p style="top:644.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">function score assessments from the </span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">International Knee Documentation Committee</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> (IKDC</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">) form </span></p>
<p style="top:656.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">for evaluation of knee ligament injuries (28) as well as the. </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Veterans Rand 12-Item (VR-12) </span></p>
<p style="top:668.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">health survey and the Patient Acceptable Symptoms State (PASS) question.</span><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023"> The questionnaires </span></p>
<p style="top:680.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">will be assessed either via an internet based collection software that allows secure data collection </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">23 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">through a password coded entry portal or during routine clinical visits using an IPad or paper </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023">forms. Paper forms may be used during routine clinical visits or directly mailed to patients. </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#000023"> </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Specific Pain assessments</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - Pain coping strategies are important in understanding improvements </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in pain and psychological disability [46-48].  This study will use a simple Likert pain scale as a </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pain assessment tools (Figure 3). Pain catastrophizing has been identified as one of the strongest </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">predictors of pain and has been defined as &#x201c;an individual&#x2019;s tendency to focus on and exaggerate </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the threat value of painful stimuli and negatively evaluate one&#x2019;s own ability to deal with pain.&#x201d; </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">[49] Not only do individuals who catastrophize, experience more experimental pain (29-31) but </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">also, catastrophizing has been shown to account for 7% to 31% of the variance in pain ratings in </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">varied populations of patients having persistent pain.  </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI analysis</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">:</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> All subjects will undergo MRI examination following Visit 1 and subsequent </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRIs will be performed at Visits 5 and 6. Sagittal and axial MRI images will be acquired using a </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">3.0-T MRI scanner and an 1Tx/15Rx phased array knee coil. Sagittal and axial T1-weighted spin </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">echo images (FSE) will be acquired to allow semi-quantitative analysis at the conclusion of the </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study. These sequences will be followed by a sagittal high-resolution 3D dual echo steady state </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(DESS) sequence for cartilage segmentation and a sagittal combined T1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">/T2 mapping for the </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">quantification of cartilage composition. The major parameters for the DESS sequences are: FOV </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">= 140 mm, matrix = 384</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">307</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">176, resolution = 0.36</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">0.45</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">0.7 mm</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">3</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt">, time of repetition </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(TR)/time of echo (TE) = 17.6ms/6.0ms. The T1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">/T2 mapping will be acquired using a 3D </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MAPSS sequence with major parameters: FOV = 140 mm, image matrix = 320</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">160</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">24, </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">resolution = 0.44</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">0.44</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#xd7;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">4 mm</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">3</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt">, time of recovery = 1.5 seconds, bandwidth = 400 Hz/Pixel, </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">TR/TE = 7ms/3ms, time of spin lock (TSLs) = 0, 10, 40, 80 ms for T1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> mapping and preparation </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">TEs = 0, 20, 40, 60 ms for T2 mapping. The scan time will be approximately 12 minutes for the </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">combined T1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">/T2 mapping. Images will obtained with the knee in full extension.  </span></p>
<p style="top:385.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:397.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Images collected at the University of Kentucky will then be transferred digitally to the University </span></p>
<p style="top:409.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of California, San Francisco to be analyzed by Dr. Majumdar and her laboratory. Based on the </span></p>
<p style="top:421.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">high resolution DESS images, articular cartilage will be segmented using a spline-based, </span></p>
<p style="top:433.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">semiautomatic technique. The T1</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> map will be created on a voxel-by-voxel basis using </span></p>
<p style="top:445.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">established fitting routines. The segmented masks will then be overlaid on the T1</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> maps after </span></p>
<p style="top:457.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">registration between DESS and T1</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> images, and mean T1</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x3c1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">  values will be calculated for the </span></p>
<p style="top:469.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">entire tibiofemoral cartilage, medial and lateral tibial plateau, medial and lateral femoral </span></p>
<p style="top:481.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">condyles, and the patellofemoral compartment  will be calculated. </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:493.8pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:505.8pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:517.8pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">24 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:280.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.1.2 STANDARD OF CARE STUDY PROCEDURES  </span></p>
<p style="top:292.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:304.6pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Radiographic Analysis: </span></i></b></p>
<p style="top:316.6pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Plain x-ray analysis: </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">All subjects would have undergone a routine clinical x-ray analysis prior to </span></p>
<p style="top:328.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 1.   This includes bilateral x-ray views of the knee joint using a standing a/p, synaflexer </span></p>
<p style="top:340.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">standardized flexion weight bearing p/a (Synarc&#xae;), Merchant views and weight bearing lateral </span></p>
<p style="top:352.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">views. Radiographs will be assessed to determine study eligibility as open growth plates are an </span></p>
<p style="top:364.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">exclusion criteria. Plain radiographs will be reviewed for radiographic progression of joint space </span></p>
<p style="top:376.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">narrowing or osteophyte formation using the Kellgren-Lawrence classification system as well as </span></p>
<p style="top:388.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the Iwano classification for the patello-femoral joint.  </span></p>
<p style="top:400.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:412.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Previous studies have shown that that joint space narrowing measured on a standardized </span></p>
<p style="top:424.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">synaflexor platform has a high reproducibility and accuracy. At 2 years koint space narrowing </span></p>
<p style="top:436.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">has been identified in an ACL injured cohort using this system (32).  </span></p>
<p style="top:448.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:465.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.2 </span></p>
<p style="top:465.1pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">LABORATORY PROCEDURES/EVALUATIONS </span></p>
<p style="top:481.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:498.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.2.1 CLINICAL LABORATORY EVALUATIONS  </span></p>
<p style="top:510.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:522.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical Laboratory Evaluations: none </span></p>
<p style="top:534.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:546.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Pregnancy test: Female participants of child bearing potential will have a urine pregnancy test at </span></p>
<p style="top:558.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 1.  Pregnancy testing results must be negative in order for enrollment into the study.  </span></p>
<p style="top:570.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:582.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Procedure for minors: A female minor is identified as a potential candidate for the study. The </span></p>
<p style="top:594.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigator or approved study staff approach the patient and accompanying parent/guardian to </span></p>
<p style="top:606.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inform them that the patient may qualify for a study.  Both parties are informed of the study.  If </span></p>
<p style="top:618.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">interested in participating in the study, each research team will perform a pregnancy test for </span></p>
<p style="top:630.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inclusion/exclusion in correspondence with their locally approved minor pregnancy testing </span></p>
<p style="top:642.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">protocol.  </span></p>
<p style="top:654.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:666.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Non-Clinical Laboratory Evaluations: </span></p>
<p style="top:678.7pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:79.0pt;left:82.1pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Figure 3. (A) Cartilage subcompartment definition in medial (left) and lateral (right) sides. (B) </span></p>
<p style="top:92.8pt;left:82.1pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Meniscal region definition in medial (left) and lateral (right) sides. </span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">109 </span></sup></p>
<p style="top:256.1pt;left:470.0pt;line-height:11.0pt"><span style="font-family:Times New Roman,serif;font-size:11.0pt"> </span></p>
<p style="top:266.6pt;left:308.2pt;line-height:11.0pt"><span style="font-family:Times New Roman,serif;font-size:11.0pt"> </span></p>
<img style="position:absolute;transform:matrix(.6399598,0,-0,.6399598,-35.30945,80.2968)" src="data:image/jpeg;base64,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">
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">25 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sample collection including joint arthrocentesis.</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Synovial fluid will be aspirated and spun at </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">3500 RPM for 10 minutes and the supernatant will be frozen at -70&#xb0;C. Joint aspiration will be </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">performed aseptically with local anesthesia through a superolateral suprapatellar approach.  The </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">aspiration syringe will be gently removed and the study drug/placebo-containing syringe will be </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">attached, followed by injection. The supernatants will be stored, pending analysis, in the UK </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Center for Clinical and Translational Science Bioanalysis Lab.  All biomarker analyses in </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">synovial fluid, serum, and urine will be performed by co-Investigator Dr. Virginia Kraus at Duke </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">University.  </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:180.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1&#xdf;, IL-1</span></i></b><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">, IL-6 and IL-1Ra analyses</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - These cytokines will be measured in the </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">synovial fluid using the high-sensitivity Quantikine (sandwich) Immunoassays (R&amp;D).  As </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">described previously (39), the standard curve will be extended in the low range for the IL-1</span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x3b1;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">assay to further improve the specificity as we have found the standard curve of the assay to be </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reproducible and linear below the lower standard described in the procedural literature </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">accompanying the reagents.    </span></p>
<p style="top:252.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:264.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Glycosaminoglycan (GAG)</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - The S-GAG content, a marker of proteoglycan degradation, </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">will be measured in synovial fluid with the dimethyl methylene blue dye (DMMB) assay as </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">noted previously (40). Chondroitin sulfate from shark cartilage will be used as a standard </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">between 5 and 50 mg/ml.   </span></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:324.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Type II collagen (cartilage) degradation assay</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">CTX-II is derived from the C-terminal </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">crosslinked telopeptide of type II collagen. Following degradation of cartilage it is released into </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the synovial fluid, the circulation, and subsequently secreted into urine. CTX-II correlates with </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the degree of joint destruction and increases significantly within one month after ACL tear </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">P</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">=0.012)(41).  CTX-II will be measured in synovial fluid by ELISA (IDS, Herlev, Denmark </span></p>
<p style="top:384.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(42).  </span></p>
<p style="top:396.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:408.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:408.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Type I collagen (meniscus) degradation assay</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; NTX-I is derived from the N-</span></p>
<p style="top:420.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">telopeptide of type I collagen and was significantly elevated in synovial fluid after acute ACL </span></p>
<p style="top:432.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">tear (</span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">P</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">=0.008) in our pilot study (42)  We will measure NTX-I in synovial fluid by ELISA(42) In </span></p>
<p style="top:444.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">serum it is considered to be indicative of bone resorption. In synovial fluid in the setting of acute </span></p>
<p style="top:456.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">joint injury we believe it to be indicative of meniscal injury and metabolism due to the fact that </span></p>
<p style="top:468.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">meniscus is primarily a type I collagen containing tissue.  </span></p>
<p style="top:480.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:492.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:492.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Cartilage Oligomeric Matrix Protein (COMP)</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - COMP is a pentameric, anionic, </span></p>
<p style="top:504.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">noncollagenous glycoprotein and member of a thrombospondin family of extracellular proteins </span></p>
<p style="top:516.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">that was initially isolated from cartilage (43) Although other joint tissues express COMP (44), it </span></p>
<p style="top:528.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">is most abundant in articular cartilage. Serum COMP levels are representative of cartilage </span></p>
<p style="top:540.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">catabolism (45,46) and we have demonstrated that serum COMP is associated with the presence </span></p>
<p style="top:552.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and severity of radiographic OA and progression of OA [60]. COMP will be measured by </span></p>
<p style="top:564.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">sandwich ELISA (Biovendor) with mAbs 17C10 and 16F12 a recombinant COMP standard with </span></p>
<p style="top:576.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">an assay range of 0.1-32 U/L and the CV is &lt;5%. </span></p>
<p style="top:588.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:600.0pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:600.0pt;left:108.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Xanthine Oxidase (XO)</span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - generates superoxide, a powerful reactive oxygen species. </span></p>
<p style="top:612.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Synovial fluid XO is indicative of oxidative stress and increases in the first month after joint </span></p>
<p style="top:624.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury (Kraus unpublished data). It is measured by a multistep enzymatic reaction available from </span></p>
<p style="top:636.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Cayman Chemical (Ann Arbor, Michigan) whose end product resorufin, is a highly fluorescent </span></p>
<p style="top:648.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">compound that can be easily analyzed using an excitation wavelength of 520-550 nm and an </span></p>
<p style="top:660.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">emission wavelength of 585-595 nm.  </span></p>
<p style="top:672.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:688.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.2.2 OTHER ASSAYS OR PROCEDURES </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">26 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">None </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:112.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.2.3 SPECIMEN PREPARATION, HANDLING, AND STORAGE </span></p>
<p style="top:124.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:136.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Refer to the study lab processing manual </span></p>
<p style="top:148.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:164.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.2.4 SPECIMEN SHIPMENT </span></p>
<p style="top:177.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:189.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Refer to the study lab processing manual </span></p>
<p style="top:201.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:217.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.3 </span></p>
<p style="top:217.7pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY SCHEDULE </span></p>
<p style="top:232.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:249.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.3.1 SCREENING/ENROLLMENT </span></p>
<p style="top:261.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:273.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 1 Screening 1-28 days following injury)  </span></b></p>
<p style="top:285.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Obtain informed consent and assent, if necessary, of potential subjects  </span></p>
<p style="top:297.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review medical history to determine eligibility based on inclusion/exclusion criteria.  </span></p>
<p style="top:309.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Review medication history to determine eligibility based on inclusion/exclusion criteria.  </span></p>
<p style="top:321.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Perform medical examinations and collect vital signs as needed to determine eligibility  </span></p>
<p style="top:333.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   based on inclusion/exclusion criteria. All subjects must have a clinical exam that is </span></p>
<p style="top:345.5pt;left:99.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">consistent with an ACL tear. </span></p>
<p style="top:357.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Collection of urine and blood for laboratory testing. Women of child bearing potential will </span></p>
<p style="top:369.5pt;left:99.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be given a urine pregnancy test.  Test must be negative in order to enroll into the study. </span></p>
<p style="top:381.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Subjects will have the following assessments:  range of motion, knee instability </span></p>
<p style="top:393.5pt;left:99.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(Lachman&#x2019;s test) and standardized MTP-2 weight bearing x-rays.   </span></p>
<p style="top:407.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Standard questionnaires including the KOOS, IKDC, VR-12 and a Likert pain scale.</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:419.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:10.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Research knee MRI</span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:429.5pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:441.5pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Following the review of above assessment results and a review of inclusion/eclusion criteria, </span></p>
<p style="top:453.5pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subjects will be randomized into 1 of 3 treatment groups.  Following randomizing, subjects will </span></p>
<p style="top:465.5pt;left:75.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">undergo a knee aspiration and will receive their first dose study medication. </span></p>
<p style="top:477.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:489.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 2 (day of surgery or 4-6 weeks post injury) </span></b></p>
<p style="top:501.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Knee aspiration (in the operating room under anesthesia) </span></p>
<p style="top:513.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient reported outcomes (PROs) administered prior to surgery </span></p>
<p style="top:525.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS, IKDC, VR-12 and a Likert pain scale administered prior to surgery </span></p>
<p style="top:537.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarkers (urine and blood) pre-operatively </span></p>
<p style="top:549.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review for AE&#x2019;s and SAE&#x2019;s </span></p>
<p style="top:561.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">ROM will be performed prior to surgery </span></p>
<p style="top:573.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:585.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 3 (4-14 days After Visit 2  ) </span></b></p>
<p style="top:597.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Knee aspiration (if clinically indicated) </span></p>
<p style="top:609.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarkers (urine and blood) </span></p>
<p style="top:621.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review for AE&#x2019;s and SAE&#x2019;s </span></p>
<p style="top:633.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">ROM will be performed </span></p>
<p style="top:645.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:657.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 4 (6 month After Visit 2+/- 2 weeks) </span></b></p>
<p style="top:669.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient reported outcomes (PROs) administered </span></p>
<p style="top:681.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS, IKDC,  VR-12 and a Likert pain scale administered  </span></p>
<p style="top:693.5pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review for AE&#x2019;s and SAE&#x2019;s </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">27 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">ROM will be performed </span></p>
<p style="top:84.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 5 (12 monthsAfter Visit 2+/- 2 weeks) </span></b></p>
<p style="top:108.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI </span></p>
<p style="top:120.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient reported outcomes (PROs) administered </span></p>
<p style="top:132.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS, IKDC,  VR-12 and a Likert pain scale administered  </span></p>
<p style="top:144.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarkers (serum and urine only) </span></p>
<p style="top:156.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review for AE&#x2019;s and SAE&#x2019;s </span></p>
<p style="top:168.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">ROM will be performed </span></p>
<p style="top:180.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Visit 6 (24 month After Visit 2+/- 2 weeks) </span></b></p>
<p style="top:204.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI </span></p>
<p style="top:216.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Patient reported outcomes (PROs) administered </span></p>
<p style="top:228.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">KOOS, IKDC,  VR-12 and a Likert pain scale administered  </span></p>
<p style="top:240.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarkers (serum and urine only) </span></p>
<p style="top:252.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Review for AE&#x2019;s and SAE&#x2019;s </span></p>
<p style="top:264.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">ROM will be performed </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:292.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">7.3.2 SCHEDULE OF EVENTS TABLE </span></p>
<p style="top:306.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:319.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This section should capture the procedures that will be accomplished at each study visit and </span></p>
<p style="top:333.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">correspond to the descriptions in the above sections. </span></p>
<p style="top:347.5pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></p>
<p style="top:383.5pt;left:83.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Procedures </span></b></p>
<p style="top:367.9pt;left:233.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Screening </span></p>
<p style="top:379.4pt;left:233.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Visit 1) </span></p>
<p style="top:367.9pt;left:294.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit </span></p>
<p style="top:379.4pt;left:299.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">e</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:367.9pt;left:334.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit </span></p>
<p style="top:379.4pt;left:341.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">3 </span></p>
<p style="top:373.6pt;left:375.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 4 </span></p>
<p style="top:373.6pt;left:427.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 5 </span></p>
<p style="top:362.1pt;left:483.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">End of </span></p>
<p style="top:373.6pt;left:485.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study </span></p>
<p style="top:385.2pt;left:483.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 6 </span></p>
<p style="top:397.8pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Time point </span></p>
<p style="top:426.3pt;left:236.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1-28 days </span></p>
<p style="top:437.8pt;left:235.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">post injury </span></p>
<p style="top:403.4pt;left:287.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Surgery </span></p>
<p style="top:414.9pt;left:291.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">day or </span></p>
<p style="top:426.3pt;left:297.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4-6 </span></p>
<p style="top:437.8pt;left:291.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">weeks </span></p>
<p style="top:449.4pt;left:295.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">post </span></p>
<p style="top:460.9pt;left:291.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury </span></p>
<p style="top:420.7pt;left:335.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4-14 </span></p>
<p style="top:432.1pt;left:333.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">After </span></p>
<p style="top:443.6pt;left:330.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 2 </span></p>
<p style="top:409.2pt;left:369.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6  months </span></p>
<p style="top:420.7pt;left:378.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">After </span></p>
<p style="top:432.1pt;left:375.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 2 </span></p>
<p style="top:443.6pt;left:378.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(+/- 2 </span></p>
<p style="top:455.2pt;left:375.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">weeks) </span></p>
<p style="top:397.6pt;left:441.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:409.2pt;left:422.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">12  After </span></p>
<p style="top:420.7pt;left:427.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 2 </span></p>
<p style="top:432.1pt;left:429.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(+/- 2 </span></p>
<p style="top:443.6pt;left:426.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">weeks) </span></p>
<p style="top:455.1pt;left:441.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:466.6pt;left:441.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:409.2pt;left:476.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">24 months </span></p>
<p style="top:420.7pt;left:472.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">After Visit 2 </span></p>
<p style="top:432.1pt;left:485.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(+/- 4 </span></p>
<p style="top:443.6pt;left:483.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">weeks) </span></p>
<p style="top:455.1pt;left:497.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:478.8pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Informed Consent </span></p>
<p style="top:478.8pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:478.8pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:478.8pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:478.8pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:478.8pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:478.8pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:493.1pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Demographics </span></p>
<p style="top:493.1pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:493.1pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:493.1pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:493.1pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:493.1pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:493.1pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:507.4pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Medical  history </span></p>
<p style="top:507.4pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:507.4pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:507.4pt;left:340.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:507.4pt;left:385.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:507.4pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:507.4pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:521.6pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Randomization </span></p>
<p style="top:521.6pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:521.6pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:521.6pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:521.6pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:521.6pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:521.6pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:536.0pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Administer Investigational </span></p>
<p style="top:549.8pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Product </span></p>
<p style="top:542.9pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:542.9pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:542.9pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:542.9pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:542.9pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:542.9pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:564.1pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Concurrent meds </span></p>
<p style="top:564.1pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:564.1pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:564.1pt;left:340.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:564.1pt;left:385.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:564.1pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:564.1pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:578.4pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Physical Exam </span></p>
<p style="top:578.4pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:578.4pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:578.4pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:578.4pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:578.4pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:578.4pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:592.7pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Range of motion </span></p>
<p style="top:592.7pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:592.7pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:592.7pt;left:340.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:592.7pt;left:385.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:592.7pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:592.7pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:607.0pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Vital signs </span></p>
<p style="top:607.0pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:607.0pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:607.0pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:607.0pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:607.0pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:607.0pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.2pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Height </span></p>
<p style="top:621.2pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:621.2pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.2pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.2pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.2pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:621.2pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:635.6pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Weight </span></p>
<p style="top:635.6pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:635.6pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:635.6pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:635.6pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:635.6pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:635.6pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:649.9pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Questionnaires </span></p>
<p style="top:649.9pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:649.9pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:649.9pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:649.9pt;left:385.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:649.9pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:649.9pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:664.2pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Knee Aspiration </span></p>
<p style="top:664.2pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:664.2pt;left:297.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">a</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:664.2pt;left:337.9pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">h</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:664.2pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:664.2pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:664.2pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:678.5pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Biomarkers </span></p>
<p style="top:678.5pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:678.5pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:678.5pt;left:340.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:678.5pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:678.5pt;left:434.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">d</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:678.5pt;left:490.9pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">d</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Safety Lab Tests</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">b</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:692.8pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:692.8pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">28 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:95.8pt;left:83.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Procedures </span></b></p>
<p style="top:80.1pt;left:233.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Screening </span></p>
<p style="top:91.6pt;left:233.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Visit 1) </span></p>
<p style="top:80.1pt;left:294.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit </span></p>
<p style="top:91.6pt;left:299.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2</span><sup><span style="font-family:Times New Roman,serif;font-size:6.5pt">e</span></sup><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:80.1pt;left:334.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit </span></p>
<p style="top:91.6pt;left:341.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">3 </span></p>
<p style="top:85.9pt;left:375.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 4 </span></p>
<p style="top:85.9pt;left:427.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 5 </span></p>
<p style="top:74.4pt;left:483.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">End of </span></p>
<p style="top:85.9pt;left:485.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Study </span></p>
<p style="top:97.4pt;left:483.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Visit 6 </span></p>
<p style="top:110.0pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Urine pregnancy tests</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">c </span></sup></p>
<p style="top:110.0pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:110.0pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:110.0pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:110.0pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:110.0pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:110.0pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:124.3pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Adverse event evaluation </span></p>
<p style="top:124.3pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:124.3pt;left:299.5pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:124.3pt;left:340.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:124.3pt;left:385.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:124.3pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:124.3pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:138.6pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X-Ray</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">f</span></sup><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:138.6pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:138.6pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:138.6pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:138.6pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:138.6pt;left:441.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:138.6pt;left:497.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:153.0pt;left:83.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MRI</span><sup><span style="font-family:Times New Roman,serif;font-size:8.0pt">g </span></sup></p>
<p style="top:153.0pt;left:252.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:153.0pt;left:303.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:153.0pt;left:344.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:153.0pt;left:389.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:153.0pt;left:436.7pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:153.0pt;left:493.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">X </span></p>
<p style="top:166.7pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">a:    Should a subject be enrolled into the study and choose not to undergo ACL reconstruction aspiration at time of surgery will be </span></p>
<p style="top:176.0pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">omitted.    </span></p>
<p style="top:185.2pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">b:   Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, </span></p>
<p style="top:194.3pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">potassium, total protein, SGOT [AST], SGPT [ALT], sodium.  </span></p>
<p style="top:203.6pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">c:  Urine pregnancy test (women of childbearing potential). </span></p>
<p style="top:212.8pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">d:  Serum and urine only </span></p>
<p style="top:221.9pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">e.</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">  </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">Should a subject be enrolled into the study and choose not to undergo ACL reconstruction, subject will received treatment according </span></p>
<p style="top:231.2pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">to this protocol.  For subjects that do not have ACL reconstruction, the time windows will be relative to Visit 2. For example, Visit 3 will </span></p>
<p style="top:240.4pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">be 4-14 days after Visit 2 </span></p>
<p style="top:249.5pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">f.</span><span style="font-family:Times New Roman,serif;font-size:12.0pt">  </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">All subjects must have standardized MTP-2 weight bearing x-ray.  Documentation of closed growth plates at screening will be noted </span></p>
<p style="top:258.8pt;left:94.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">in the routine SOC x-ray </span></p>
<p style="top:268.0pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">g.  All subjects enrolled will have an MRI performed regardless if surgery is to be scheduled or not.  However, randomization can be </span></p>
<p style="top:277.1pt;left:94.3pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">performed prior to MRI as the MRI examination is not necessary or required to diagnose the ACL tear. </span></p>
<p style="top:286.4pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">h.  We will only perform the aspiration at Visit 3 if participants had elected to have surgery performed, and if they have fluid on their </span></p>
<p style="top:295.6pt;left:83.0pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">knee. </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">29 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.4 </span></p>
<p style="top:75.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">JUSTIFICATION FOR SENSITIVE PROCEDURES </span></p>
<p style="top:90.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not Applicable. </span></p>
<p style="top:114.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:130.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.5 </span></p>
<p style="top:130.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  </span></p>
<p style="top:145.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:157.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All concomitant prescription medications taken during study participation will be recorded on </span></p>
<p style="top:169.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the case report forms (CRFs). For this protocol, a prescription medication is defined as a </span></p>
<p style="top:181.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">medication that can be prescribed only by a properly authorized/licensed clinician. Medications </span></p>
<p style="top:193.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to be reported in the CRF are concomitant prescription medications, over-the-counter </span></p>
<p style="top:205.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">medications and non-prescription medications including herbal supplements. </span></p>
<p style="top:217.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:234.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.6 </span></p>
<p style="top:234.4pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  </span></p>
<p style="top:249.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:261.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Treatment with (list specific drugs) will not be permitted unless discussed with and approved by </span></p>
<p style="top:273.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the PI. </span></p>
<p style="top:285.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:297.6pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Immunosuppressant including oral and parenteral corticosteroids (topical and stable dose </span></p>
<p style="top:309.6pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inhaled corticosteroids are acceptable)or modulating drugs.  </span></p>
<p style="top:321.6pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Non-steroidal anti-inflammatory drugs  </span></p>
<p style="top:333.6pt;left:94.3pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Any blood thinning medications, aspirin or other medications affecting blood clotting. </span></p>
<p style="top:345.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:362.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.7 </span></p>
<p style="top:362.2pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES  </span></p>
<p style="top:377.4pt;left:112.3pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:389.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not applicable </span></p>
<p style="top:401.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:418.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.8 </span></p>
<p style="top:418.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES  </span></p>
<p style="top:433.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:445.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  Not Applicable </span></p>
<p style="top:457.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:473.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">7.9 </span></p>
<p style="top:473.8pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  </span></p>
<p style="top:490.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:504.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not applicable. </span></p>
<p style="top:518.2pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff"> </span></b></p>
<p style="top:535.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">8 </span></b></p>
<p style="top:535.0pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">ASSESSMENT OF SAFETY </span></b></p>
<p style="top:551.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:568.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.1 </span></p>
<p style="top:568.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SPECIFICATION OF SAFETY PARAMETERS </span></p>
<p style="top:583.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:600.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.1.1 DEFINITION OF ADVERSE EVENTS (AE) </span></p>
<p style="top:612.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:624.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Adverse event means any untoward medical occurrence associated with the use of an </span></p>
<p style="top:636.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). </span></p>
<p style="top:648.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:660.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:672.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:684.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">30 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) </span></p>
<p style="top:88.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:100.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Serious adverse event or serious suspected adverse reaction. An AE or suspected adverse </span></p>
<p style="top:112.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reaction is considered &quot;serious&quot; if, in the view of either the investigator or sponsor, it results in </span></p>
<p style="top:124.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization </span></p>
<p style="top:136.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or prolongation of existing hospitalization, a persistent or significant incapacity or substantial </span></p>
<p style="top:148.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. </span></p>
<p style="top:160.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Important medical events that may not result in death, be life-threatening, or require </span></p>
<p style="top:172.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">hospitalization may be considered serious when, based upon appropriate medical judgment, they </span></p>
<p style="top:184.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">may jeopardize the patient or subject and may require medical or surgical intervention to prevent </span></p>
<p style="top:196.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">one of the outcomes listed in this definition. Examples of such medical events include allergic </span></p>
<p style="top:208.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias </span></p>
<p style="top:220.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or convulsions that do not result in inpatient hospitalization, or the development of drug </span></p>
<p style="top:232.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">dependency or drug abuse. </span></p>
<p style="top:244.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:260.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP) </span></p>
<p style="top:273.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:285.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">OHRP considers unanticipated problems involving risks to participants or others to include, in </span></p>
<p style="top:297.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">general, any incident, experience, or outcome that meets </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">all</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> of the following criteria:  </span></p>
<p style="top:309.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:321.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; Unexpected in terms of nature, severity, or frequency given (a) the research procedures that  </span></p>
<p style="top:333.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   are described in the protocol-related documents, such as the IRB-approved research  </span></p>
<p style="top:345.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   protocol and informed consent document; and (b) the characteristics of the participant  </span></p>
<p style="top:357.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   population being studied;  </span></p>
<p style="top:369.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; Related or possibly related to participation in the research (&#x201c;possibly related&#x201d; means there is  </span></p>
<p style="top:381.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   a reasonable possibility that the incident, experience, or outcome may have been caused by  </span></p>
<p style="top:393.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   the procedures involved in the research); and  </span></p>
<p style="top:405.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; Suggests that the research places participants or others at a greater risk of harm (including </span></p>
<p style="top:417.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   physical, psychological, economic, or social harm) than was previously known or </span></p>
<p style="top:429.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   recognized.  </span></p>
<p style="top:441.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:453.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This study will use the OHRP definition of UP. </span></p>
<p style="top:465.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:481.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.2 </span></p>
<p style="top:481.7pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CLASSIFICATION OF AN ADVERSE EVENT </span></p>
<p style="top:498.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:515.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.2.1 SEVERITY OF EVENT </span></p>
<p style="top:527.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:539.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All AEs will be assessed by the clinician using a protocol defined grading system.  The protocol </span></p>
<p style="top:551.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">defined grading system to be used is:  </span></p>
<p style="top:563.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:575.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Mild </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2013; Events require minimal or no treatment and do not interfere with the participant&#x2019;s daily  </span></p>
<p style="top:587.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> activities. </span></p>
<p style="top:599.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Moderate</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; Events result in a low level of inconvenience or concern with the therapeutic </span></p>
<p style="top:611.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  measures. Moderate events may cause some interference with functioning.  </span></p>
<p style="top:623.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022;</span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Severe </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2013; Events interrupt a participant&#x2019;s usual daily activity and may require systemic drug  </span></p>
<p style="top:635.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  therapy or other treatment. Severe events are usually potentially life-threatening or  </span></p>
<p style="top:647.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  incapacitating. </span></p>
<p style="top:659.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:671.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:683.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">31 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.2.2 RELATIONSHIP TO STUDY AGENT </span></p>
<p style="top:88.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:100.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All AEs will have their relationship to study agent or study participation assessed with a level of </span></p>
<p style="top:112.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">specificity appropriate to the study design. The clinician&#x2019;s assessment of an AE&apos;s relationship to </span></p>
<p style="top:124.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study agent (drug) is part of the documentation process, but it is not a factor in determining what </span></p>
<p style="top:136.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">is or is not reported in the study. If there is any doubt as to whether a clinical observation is an </span></p>
<p style="top:148.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">AE, the event should be reported. All AEs must have their relationship to study agent assessed. </span></p>
<p style="top:160.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">In a clinical trial, the study product must always be suspect. To help assess, the following </span></p>
<p style="top:172.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">guidelines are used.  </span></p>
<p style="top:184.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:196.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Related</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; The AE is known to occur with the study agent, there is a reasonable possibility </span></p>
<p style="top:208.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   that the study agent caused the AE, or there is a temporal relationship between the study  </span></p>
<p style="top:220.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   agent and event. Reasonable possibility means that there is evidence to suggest a causal  </span></p>
<p style="top:232.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">   relationship between the study agent and the AE.  </span></p>
<p style="top:244.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not Related</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; There is not a reasonable possibility that the administration of the study  </span></p>
<p style="top:256.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  agent caused the event, there is no temporal relationship between the study agent and event  </span></p>
<p style="top:268.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  onset, or an alternate etiology has been established. OR For all collected AEs, the clinician </span></p>
<p style="top:280.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  who examines and evaluates the participant will determine the AE&#x2019;s causality based on  </span></p>
<p style="top:292.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  temporal relationship and his/her clinical judgment. The degree of certainty about causality  </span></p>
<p style="top:304.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  will be graded using the categories below.  </span></p>
<p style="top:316.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:328.6pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1.</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Definitely Related</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; There is clear evidence to suggest a causal relationship, and </span></p>
<p style="top:340.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">other possible contributing factors can be ruled out. The clinical event, including an </span></p>
<p style="top:352.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">abnormal laboratory test result, occurs in a plausible time relationship to drug </span></p>
<p style="top:364.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">administration and cannot be explained by concurrent disease or other drugs or </span></p>
<p style="top:376.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">chemicals. The response to withdrawal of the drug (dechallenge) should be clinically </span></p>
<p style="top:388.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">plausible. The event must be pharmacologically or phenomenologically definitive, </span></p>
<p style="top:400.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">with use of a satisfactory rechallenge procedure if necessary. </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:412.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:424.6pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2.</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Probably Related</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; There is evidence to suggest a causal relationship, and the </span></p>
<p style="top:436.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">influence of other factors is unlikely. The clinical event, including an abnormal </span></p>
<p style="top:448.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">laboratory test result,    occurs within a reasonable time after administration of the </span></p>
<p style="top:460.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">drug, is unlikely to be attributed to concurrent,  disease or other drugs or chemicals, </span></p>
<p style="top:472.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge </span></p>
<p style="top:484.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">information is not required to fulfill    this definition.  </span></p>
<p style="top:496.6pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:508.6pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">3.</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Possibly Related </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2013; There is some evidence to suggest a causal relationship (e.g., the </span></p>
<p style="top:520.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">event occurred within a reasonable time after administration of the trial medication). </span></p>
<p style="top:532.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">However, other factors may have contributed to the event (e.g., the participant&#x2019;s </span></p>
<p style="top:544.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">clinical condition, other concomitant events). Although an AE may rate only as </span></p>
<p style="top:556.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x201c;possibly related&#x201d; soon after discovery, it can be flagged as requiring more </span></p>
<p style="top:568.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">information and later be upgraded to &#x201c;probably related&#x201d; or &#x201c;definitely related,&#x201d; as </span></p>
<p style="top:580.6pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">appropriate.  </span></p>
<p style="top:594.1pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:608.4pt;left:103.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">4.</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Unlikely to be related</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> &#x2013; A clinical event, including an abnormal laboratory test </span></p>
<p style="top:620.4pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">result, whose temporal relationship to drug administration makes a causal relationship </span></p>
<p style="top:632.4pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">improbable (e.g., the event did not occur within a reasonable time after administration </span></p>
<p style="top:644.4pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the trial medication) and in which other drugs or chemicals or underlying disease </span></p>
<p style="top:656.4pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">provides plausible explanations (e.g., the participant&#x2019;s clinical condition, other </span></p>
<p style="top:668.4pt;left:121.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">concomitant treatments). </span><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:680.4pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">32 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">5.</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span></p>
<p style="top:72.0pt;left:130.6pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not Related </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2013; The AE is completely independent of study drug administration, </span></p>
<p style="top:84.0pt;left:130.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and/or evidence exists that the event is definitely related to another etiology. There </span></p>
<p style="top:96.0pt;left:130.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">must be an alternative, definitive etiology documented by the clinician </span></p>
<p style="top:108.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:124.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.2.3 EXPECTEDNESS  </span></p>
<p style="top:136.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:148.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Expected adverse reactions are AEs that are common and known to occur for the study agent </span></p>
<p style="top:160.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">being studied and should be collected in a standard, systematic format using a grading scale </span></p>
<p style="top:172.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">based on functional assessment or magnitude of reaction.  </span></p>
<p style="top:184.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:196.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">An AE or suspected adverse reaction is considered &quot;unexpected&quot; if it is not listed in the IB or is </span></p>
<p style="top:208.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">not listed at the specificity or severity that has been observed; or, if an IB is not required or </span></p>
<p style="top:220.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">available, is not consistent with the risk information described in the general investigational plan </span></p>
<p style="top:232.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or elsewhere in the protocol or the USPI, as amended. For example, under this definition, hepatic </span></p>
<p style="top:244.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">necrosis would be unexpected (by virtue of greater severity) if the IB referred only to elevated </span></p>
<p style="top:256.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would </span></p>
<p style="top:268.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be unexpected (by virtue of greater specificity) if the IB listed only cerebral vascular accidents. </span></p>
<p style="top:280.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&quot;Unexpected,&quot; as used in this definition, also refers to AEs or suspected adverse reactions that </span></p>
<p style="top:292.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">are mentioned in the IB as occurring with a class of drugs or as anticipated from the </span></p>
<p style="top:304.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pharmacological properties of the drug, but are not specifically mentioned as occurring with the </span></p>
<p style="top:316.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">particular drug under investigation.  </span></p>
<p style="top:328.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:340.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The Principal Investigator will be responsible for determining whether an AE is expected or </span></p>
<p style="top:352.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the </span></p>
<p style="top:364.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">event is not consistent with the risk information previously described for the study agent. </span></p>
<p style="top:376.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:393.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.3 </span></p>
<p style="top:393.1pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND </span></p>
<p style="top:406.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FOLLOW-UP </span></p>
<p style="top:422.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:434.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The occurrence of an AE or SAE may come to the attention of study personnel during study </span></p>
<p style="top:446.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">visits and interviews of a study participant presenting for medical care, or upon review by a </span></p>
<p style="top:458.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs </span></p>
<p style="top:470.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">will be captured on the appropriate CRF. Information to be collected includes event description, </span></p>
<p style="top:482.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">time of onset, clinician&#x2019;s assessment of severity, relationship to study product (assessed only by </span></p>
<p style="top:494.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">those with the training and authority to make a diagnosis), and time of resolution/stabilization  as </span></p>
<p style="top:506.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">well as seriousness of the event. All AEs occurring while on study must be documented </span></p>
<p style="top:518.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">appropriately regardless of relationship. All AEs will be followed to adequate resolution.  </span></p>
<p style="top:530.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:542.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Any medical condition that is present at the time that the participant is screened will be </span></p>
<p style="top:554.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">considered as baseline and not reported as an AE. However, if the study participant&#x2019;s condition </span></p>
<p style="top:566.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in </span></p>
<p style="top:578.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the data collection system throughout the study.  </span></p>
<p style="top:590.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Changes in the severity of an AE will be documented to allow an assessment of the duration of </span></p>
<p style="top:602.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the event at each level of severity to be performed. AEs characterized as intermittent require </span></p>
<p style="top:614.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">documentation of onset and duration of each episode.  </span></p>
<p style="top:626.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:638.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The PI will record all reportable events with start dates occurring any time after informed </span></p>
<p style="top:650.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study </span></p>
<p style="top:662.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs </span></p>
<p style="top:674.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">since the last visit. Events will be followed for outcome information until resolution or </span></p>
<p style="top:686.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">stabilization. </span></p>
<p style="top:698.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">33 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.4 </span></p>
<p style="top:76.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">REPORTING PROCEDURES </span></p>
<p style="top:93.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:109.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.4.1 ADVERSE EVENT REPORTING  </span></p>
<p style="top:122.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:134.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The Principal Investigator will assess the occurrence of AEs throughout the subjects&#x2019; </span></p>
<p style="top:146.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participation in the study.  Subjects will be followed for toxicity for 30 days after treatment has </span></p>
<p style="top:158.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">been discontinued or until death, whichever occurs first.  The clinical course of each event will </span></p>
<p style="top:170.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be followed until resolution, stabilization, or until it has been determined that the study treatment </span></p>
<p style="top:182.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or participation is not the cause.  </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#3366ff"> </span></i></p>
<p style="top:194.2pt;left:72.0pt;line-height:12.0pt"><i><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#3366ff"> </span></i></p>
<p style="top:206.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The investigator is responsible for ensuring that all adverse events observed by the investigator </span></p>
<p style="top:218.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">or reported by the subject, which occur after the subject has signed the informed consent, are </span></p>
<p style="top:230.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">fully recorded in the subject&#x2019;s case report form, subject&#x2019;s medical records, and/or any other </span></p>
<p style="top:242.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">institutional requirement.  Source documentation must be available to support all adverse events.  </span></p>
<p style="top:254.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:266.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A laboratory test abnormality considered clinically relevant (e.g., causing the subject to </span></p>
<p style="top:278.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">withdraw from the study), requiring treatment or causing apparent clinical manifestations, or </span></p>
<p style="top:290.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">judged relevant by the investigator, should be reported as an adverse event.   </span></p>
<p style="top:302.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:314.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The investigator will provide the following for all adverse events: </span></p>
<p style="top:326.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Description of the event </span></p>
<p style="top:338.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Date of onset and resolution </span></p>
<p style="top:350.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">seriousness of the event  </span></p>
<p style="top:362.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Attribution of relatedness to the investigational agent </span></p>
<p style="top:374.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Action taken as a result of the event </span></p>
<p style="top:386.2pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Outcome of event </span></p>
<p style="top:398.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:410.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The Principal Investigator will report adverse events to the IRB according to their policies and </span></p>
<p style="top:422.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">procedures in reporting adverse events.   </span></p>
<p style="top:434.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:450.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.4.2 SERIOUS ADVERSE EVENT REPORTING  </span></p>
<p style="top:462.7pt;left:72.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:474.7pt;left:72.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator Reporting to the FDA:   </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Adverse reactions will be reported promptly to the Food </span></p>
<p style="top:486.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and Drug Administration (FDA) via Medwatch by the Sponsor if the type of event is serious, </span></p>
<p style="top:498.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">unlisted/unexpected and possibly related to the study drug.  A clear description of the suspected </span></p>
<p style="top:510.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reaction will be provided along with an assessment as to whether the event is drug or disease </span></p>
<p style="top:522.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">related.  The Sponsor will call the FDA as soon as he/she is aware (within ten (10) working days) </span></p>
<p style="top:534.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">that an adverse reaction has occurred.  The phone number for the FDA is 301-594-5778.   </span></p>
<p style="top:546.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:558.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study sponsor will be responsible for notifying FDA of any unexpected fatal or life-</span></p>
<p style="top:570.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">threatening suspected adverse reaction as soon as possible but in no case later than 7 calendar </span></p>
<p style="top:582.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">days after the sponsor&apos;s initial receipt of the information.  </span></p>
<p style="top:594.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:606.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The Principal Investigator will complete an Internal Prompt Reporting Form within the following </span></p>
<p style="top:618.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">timelines:  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">34 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:74.0pt;left:184.4pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">EVENT </span></b></p>
<p style="top:74.0pt;left:422.5pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">TIMELINE </span></b></p>
<p style="top:88.3pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">An Unanticipated problem involving risks to </span></b></p>
<p style="top:102.1pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">subjects or others </span></b></p>
<p style="top:115.9pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  </span></p>
<p style="top:129.7pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">1. </span><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Unexpected </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">(in terms of nature, severity, or  </span></p>
<p style="top:143.5pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">frequency) given (a) the research procedures that  </span></p>
<p style="top:157.3pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">are described in the protocol-related documents,  </span></p>
<p style="top:171.1pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">such as the IRB-approved research protocol and  </span></p>
<p style="top:184.9pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">informed consent document; and  </span></p>
<p style="top:198.7pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(b) the characteristics of the subject population </span></p>
<p style="top:212.5pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> being studied;  </span></p>
<p style="top:226.3pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">2. </span><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Related or possibly related </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">to participation in the </span></p>
<p style="top:240.1pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> research; and  </span></p>
<p style="top:253.9pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">3. </span><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Suggests that the research places subjects or  </span></i></b></p>
<p style="top:267.7pt;left:81.2pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">others at a greater risk of harm </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">(including physical, </span></p>
<p style="top:281.5pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">psychological, economic, or social harm) than was </span></p>
<p style="top:295.3pt;left:81.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">previously known or recognized.  </span></p>
<p style="top:307.2pt;left:75.8pt;line-height:0.5pt"><span style="font-family:Times New Roman,serif;font-size:0.5pt"> </span></p>
<p style="top:88.3pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.1pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">If the event is life-threatening, report within  </span></p>
<p style="top:115.9pt;left:346.6pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">7 calendar days </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">of receipt of the information. </span></p>
<p style="top:129.7pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Follow-up reports for these events should be  </span></p>
<p style="top:143.5pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Submitted within 14 calendar days of receipt </span></p>
<p style="top:157.3pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of information. </span></p>
<p style="top:171.1pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  </span></p>
<p style="top:184.9pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All other events/problems must be reported </span></p>
<p style="top:198.7pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">within </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">14 calendar days </span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the investigator&#x2019;s </span></p>
<p style="top:212.5pt;left:346.6pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">receipt of the information  </span></p>
<p style="top:224.4pt;left:341.2pt;line-height:0.5pt"><span style="font-family:Times New Roman,serif;font-size:0.5pt"> </span></p>
<p style="top:309.6pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">All Research-Related Deaths </span></b></p>
<p style="top:323.4pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">(anticipated/unanticipated) </span></b></p>
<p style="top:309.6pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Immediately (i.e. within 48 hours) upon </span></p>
<p style="top:323.4pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">receipt of information </span></p>
<p style="top:337.7pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Other event that in the PI&apos;s judgment, warrants </span></b></p>
<p style="top:351.5pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">reporting or is in the best interest of the subject(s)</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:365.3pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(e.g., because it may affect the safety and/or welfare </span></p>
<p style="top:379.1pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of subjects; it changes the risk level of the study; or </span></p>
<p style="top:392.9pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the frequency of the same event significantly </span></p>
<p style="top:406.7pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">increases) </span></p>
<p style="top:337.7pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">If life-threatening, report within 7 calendar </span></p>
<p style="top:351.5pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">days of receipt of the information.  </span></p>
<p style="top:365.3pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:379.1pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All other events/problems must be reported </span></p>
<p style="top:392.9pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">within 14 calendar days of the investigator&#x2019;s </span></p>
<p style="top:406.7pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">receipt of the information. </span></p>
<p style="top:421.1pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Other unanticipated problems that impact the </span></b></p>
<p style="top:434.9pt;left:75.8pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">conduct or integrity of the study</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> (e.g. FDA Clinical </span></p>
<p style="top:448.7pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">hold or recall, published literature or data and safety </span></p>
<p style="top:462.5pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">monitoring board report impacting risk-benefit ratio, </span></p>
<p style="top:476.3pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FDA Form 483 or warning letter, investigator medical </span></p>
<p style="top:490.1pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">license restriction or suspension, participant is </span></p>
<p style="top:503.9pt;left:75.8pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">incarcerated) </span></p>
<p style="top:427.9pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">If life-threatening, report within 7 calendar </span></p>
<p style="top:441.7pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">days of receipt of the information.  </span></p>
<p style="top:455.5pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:469.3pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All other events/problems must be reported </span></p>
<p style="top:483.1pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">within 14 calendar days of the investigator&#x2019;s </span></p>
<p style="top:496.9pt;left:341.2pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">receipt of the information. </span></p>
<p style="top:516.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:528.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All SAEs will be followed until satisfactory resolution or until the site investigator deems the </span></p>
<p style="top:540.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">event to be chronic or the adherence to be stable.  </span></p>
<p style="top:552.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:566.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sponsor Safety Reporting contact information: </span></p>
<p style="top:578.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name, degree, title:  Austin Stone, MD, PhD </span></p>
<p style="top:590.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Institution Name:      University of Kentucky </span></p>
<p style="top:602.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address:                    760 S Limestone, Suite K401 </span></p>
<p style="top:614.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">                                  Lexington, KY 40536-0284 </span></p>
<p style="top:626.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone Number:          859-218-3065 </span></p>
<p style="top:638.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email:                       </span><i><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#0000ff"> </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">austin.stone@uky.edu </span></p>
<p style="top:652.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FAX:</span><span style="font-family:Arial,sans-serif;font-size:10.0pt">                   </span></p>
<p style="top:652.0pt;left:180.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(859)-323-2412 </span></p>
<p style="top:665.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:679.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Name: Caitlin Conley, PhD </span></p>
<p style="top:693.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Address: 740 S Limestone, Suite K401 </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">35 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:73.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone #: (859) 257-1939 </span></p>
<p style="top:87.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Email: caitlin.whale@uky.edu </span></p>
<p style="top:101.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Fax:  (859) 323-2412 </span></p>
<p style="top:115.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:128.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The reporting of serious adverse events to the study sponsor does not relieve the investigator  </span></p>
<p style="top:142.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">from other regulatory reporting responsibilities. </span></p>
<p style="top:156.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:168.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Investigator reporting to SOBI:  The Sponsor must inform Swedish Orphan Biovitrum (SOBI) in </span></p>
<p style="top:180.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">writing using a SOBI SAE or a MEDWATCH 3500A form of any SAE, independent of </span></p>
<p style="top:192.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">causality. The written report must be completed and supplied to SOBI by e-mail or facsimile </span></p>
<p style="top:204.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">within 24 hours/1 business day of first awareness. The initial report must be as complete as </span></p>
<p style="top:216.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">possible, including an assessment of the causal relationship between the event and the </span></p>
<p style="top:228.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigational product(s), if available. Information not available at the time of the initial report </span></p>
<p style="top:240.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(e.g., an end date for the adverse event or laboratory values received after the report) must be </span></p>
<p style="top:252.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">documented on a follow-up report.  </span></p>
<p style="top:264.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:276.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A final report to document resolution of the SAE is required. A copy of the email transmission of </span></p>
<p style="top:288.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the SAE report to SOBI (drugsafety@sobi.com) should be attached to the SAE and retained with </span></p>
<p style="top:300.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the patient records. </span></p>
<p style="top:312.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:326.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SOBI Safety Reporting contact information: </span></p>
<p style="top:340.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Drug Safety Swedish Orphan Biovitrum SE-112 76 Stockholm, Sweden Fax: 011-46 8 697 32 30 </span></p>
<p style="top:353.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Phone: 011-46 8 697 20 00 (switchboard) e-mail: drugsafety@sobi.com </span></p>
<p style="top:367.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The reporting of serious adverse events to SOBi does not relieve the sponsor from other </span></p>
<p style="top:381.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">regulatory reporting responsibilities. </span></p>
<p style="top:395.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SOBi Safety Reporting contact information: </span></p>
<p style="top:409.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Fax: 011-46 8 697 32 30 </span></p>
<p style="top:422.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">e-mail: drugsafety@sobi.com </span></p>
<p style="top:435.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:451.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.4.3 UNANTICIPATED PROBLEM REPORTING  </span></p>
<p style="top:463.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:475.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Incidents or events that meet the OHRP criteria for UPs require the creation and completion of </span></p>
<p style="top:487.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">an UP report form. It is the site investigator&#x2019;s responsibility to report UPs to their IRB and to the </span></p>
<p style="top:499.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">DCC/study sponsor. The UP report will include the following information:  </span></p>
<p style="top:511.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:523.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; Protocol identifying information: protocol title and number, PI&#x2019;s name, and the IRB project </span></p>
<p style="top:535.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  number;  </span></p>
<p style="top:547.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; A detailed description of the event, incident, experience, or outcome;  </span></p>
<p style="top:559.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; An explanation of the basis for determining that the event, incident, experience, or outcome  </span></p>
<p style="top:571.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  represents an UP;  </span></p>
<p style="top:583.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; A description of any changes to the protocol or other corrective actions that have been  </span></p>
<p style="top:595.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  taken or are proposed in response to the UP.  </span></p>
<p style="top:607.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:619.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">To satisfy the requirement for prompt reporting, UPs will be reported using the following </span></p>
<p style="top:631.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">timeline:  </span></p>
<p style="top:643.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:655.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within of the  </span></p>
<p style="top:667.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  investigator becoming aware of the event.  </span></p>
<p style="top:679.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; Any other UP will be reported to the IRB and to the DCC/study sponsor within of the  </span></p>
<p style="top:691.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  investigator becoming aware of the problem.  </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">36 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; All UPs should be reported to appropriate institutional officials (as required by an  </span></p>
<p style="top:84.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  institution&#x2019;s written reporting procedures), the supporting agency head (or designee), and </span></p>
<p style="top:96.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  OHRP within (insert timeline in accordancy with policy) of the IRB&#x2019;s receipt of the report  </span></p>
<p style="top:108.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  of the problem from the investigator.  </span></p>
<p style="top:120.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:136.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.4.4 EVENTS OF SPECIAL INTEREST  </span></p>
<p style="top:148.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:160.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not applicable. </span></p>
<p style="top:172.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:188.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">8.4.5 REPORTING OF PREGNANCY  </span></p>
<p style="top:201.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:213.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Pregnancy is neither an AE nor SAE.  All subject pregnancy must be reported to their study </span></p>
<p style="top:225.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">doctor or study staff immediately.  Once confirmed, study medication will be stopped and the </span></p>
<p style="top:237.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study site will request permission from the woman to follow her for pregnancy outcomes.  All </span></p>
<p style="top:249.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">confirmed pregnancies will be reported to the study sponsor, FDA, SOBI  and IRB and followed </span></p>
<p style="top:261.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">until resolution (i.e., termination [voluntary or spontaneous] or birth) to assess for pregnancy-</span></p>
<p style="top:273.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">associated AEs or SAEs such as congential anomaly.   </span></p>
<p style="top:285.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:301.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.5 </span></p>
<p style="top:301.7pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">STUDY HALTING RULES  </span></p>
<p style="top:316.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:328.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Administration of study agent will be halted when three grade 3 AEs determined to be &#x201c;probably </span></p>
<p style="top:340.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">related&#x201d; are reported to the FDA/IRB and enrollment screens will stop accepting new study </span></p>
<p style="top:352.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participants. The study sponsor will inform the DSMB members within 24 hours of this </span></p>
<p style="top:364.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">occurrence and will provide the DSMB with AE listing reports. The DSMB will convene an ad </span></p>
<p style="top:376.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">hoc meeting by teleconference or in writing as soon as possible. The DSMB will provide </span></p>
<p style="top:388.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recommendations for proceeding with the study to the study sponsor.  The study sponsor will </span></p>
<p style="top:400.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">inform the FDA of the temporary halt and the disposition of the study. </span></p>
<p style="top:412.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:424.9pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study Stopping Criteria </span></b></p>
<p style="top:436.9pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:448.9pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Local intolerance of the administered Kineret or any sign of allergic response. </span></p>
<p style="top:460.9pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Development of signs and symptoms before the second time point preventing the second </span></p>
<p style="top:472.9pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">administration of the study drug. </span></p>
<p style="top:484.9pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Any patient reported drug related SAE after the first or second administration of the study </span></p>
<p style="top:496.9pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">drug. </span></p>
<p style="top:508.9pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Diagnosis with any condition as outlined in the exclusion criteria during the course of the </span></p>
<p style="top:520.9pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">initial 2 weeks of study enrollment. </span></p>
<p style="top:532.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:544.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:561.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">8.6 </span></p>
<p style="top:561.5pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">SAFETY OVERSIGHT </span></p>
<p style="top:576.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:588.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Monitoring for adverse events will be conducted in real-time by the study investigators and study </span></p>
<p style="top:600.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">coordinators.  Risks involved with this study are considered greater than minimal risk.  For this </span></p>
<p style="top:612.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reason, we will utilize the standing independent Data Safety Monitoring Board (DSMB) as </span></p>
<p style="top:624.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">chartered by the Center for Clinical and Translational Science (CCTS).  The DSMB will meet </span></p>
<p style="top:636.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">semiannually or as needed, and will review subject recruitment, AE&#x2019;s, side effects, laboratory </span></p>
<p style="top:648.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">results, dropouts, protocol violations, and inclusion/exclusion criteria.  More frequent meetings </span></p>
<p style="top:660.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">will take place if side effects or other problems are prevalent.  </span></p>
<p style="top:672.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:684.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">37 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">9 </span></b></p>
<p style="top:76.6pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">CLINICAL MONITORING </span></b></p>
<p style="top:91.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:103.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical site monitoring will be performed by Bluegrass Research Consultants Inc. The monitor </span></p>
<p style="top:115.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">will conduct monitoring to verify that a) the rights and well-being of human subjects are </span></p>
<p style="top:127.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">protected; b) the reported trial data are accurate, complete and verifiable from source documents; </span></p>
<p style="top:139.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">c) the conduct of the trial is in compliance with the currently approved protocol/amendment(s), </span></p>
<p style="top:151.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Food and Drug Administration (FDA) regulations and ICH guidelines d) Provide practical </span></p>
<p style="top:163.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">guidelines for Site Monitors, Study Monitors and Medical Monitors; e) Provide consistent </span></p>
<p style="top:175.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">monitoring procedures across all clinical sites; f) Ensure the quality and integrity of clinical </span></p>
<p style="top:187.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study data; g) Evaluate the progress of the study and ensure completion of the clinical study in a </span></p>
<p style="top:199.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">timely manner.  A monitoring visit report will be provided to the Sponsor within 21 business </span></p>
<p style="top:211.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">days following the completion of a visit. </span></p>
<p style="top:223.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:235.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The first monitoring visit will be conducted within two weeks following enrollment of the first </span></p>
<p style="top:247.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subjects.  Subsequent monitoring visits will be completed based on enrollment and are expected </span></p>
<p style="top:259.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">to occur every four to six weeks. </span></p>
<p style="top:271.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:288.4pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">10 </span></b></p>
<p style="top:288.4pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STATISTICAL CONSIDERATIONS  </span></b></p>
<p style="top:308.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">10.1 STATISTICAL AND ANALYTICAL PLANS </span></p>
<p style="top:323.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:339.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.1.1 GENERAL APPROACH </span></p>
<p style="top:352.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b></p>
<p style="top:364.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Sample Size and Power Analysis</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> - </span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt">The primary outcome aim of the study is to determine if </span></p>
<p style="top:376.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">treatment with the study medication results in greater improvements in patient-reported </span></p>
<p style="top:388.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">outcomes one year following surgery.  We will use the validated Knee Osteoarthritis and injury </span></p>
<p style="top:400.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Outcome Score (KOOS),[27] which is a self-administered, knee-specific instrument that </span></p>
<p style="top:412.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">evaluates the course of knee injury and treatment outcomes. To reduce the risk of an </span></p>
<p style="top:424.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">underpowered RCT, an a priori sample size estimation was calculated from data collected from </span></p>
<p style="top:436.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recent studies of ACL-injured and &#x2013;reconstructed patients.[28-32] The previously published one-</span></p>
<p style="top:448.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">year KOOS Quality of Life Scores are 60.2 &#xb1; 24.2 [31] and the minimal detectable change of this </span></p>
<p style="top:460.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">instrument is 7.2 [32]. Assuming that the standard deviation of the change scores between the </span></p>
<p style="top:472.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">day of surgery and one year postoperative visits will be 20% of the standard deviation of the </span></p>
<p style="top:484.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">standard deviation of the one-year KOOS Quality of Life Scores (.2 x 24.2 = 4.8), a sample size </span></p>
<p style="top:496.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of 16 patients per group (32total) would be at least 80% powered to detect a difference of 7.2 </span></p>
<p style="top:508.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">points between the treatment group and the control group (One-way ANOVA model with alpha </span></p>
<p style="top:520.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">= 0.05, Effect size = 7.2/4.8 = 1.5, G*Power 3.0.10).  This sample size would adequately power </span></p>
<p style="top:532.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the study for the primary outcome variable, but would also adequately power the study for the </span></p>
<p style="top:544.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">second aim of the study. The second aim of the study is to compare chondrodegenerative </span></p>
<p style="top:556.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">biomarkers between groups at the 1 year follow up. We have previously observed large effect </span></p>
<p style="top:568.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">sizes between groups in preliminary studies (ES = 1.34), and a sample size of 32 patients (16 per </span></p>
<p style="top:580.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">group) would be at least 80% powered to detect effect sizes of this magnitude.  However, to </span></p>
<p style="top:592.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">protect against an underpowered study due to patient attrition, we will monitor compliance and </span></p>
<p style="top:604.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">potentially enroll up to 20 patients per group in order to adjust for attrition. Patient costs will not </span></p>
<p style="top:616.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">occur until sample or MRI analysis.  </span></p>
<p style="top:628.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:640.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The power calculations include several caveats. First, for purposes of power calculation, we did </span></p>
<p style="top:652.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">not assume a full repeated measures analysis, but instead analyzed at a single time point (one-</span></p>
<p style="top:664.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">year follow-up). Second, we note that in trials such as this, the power of a non-parametric </span></p>
<p style="top:676.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">analysis is never much lower than its parametric analog (the &#x201c;asymptotic relative efficiency&#x201d; of </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">38 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the Wilcoxon test is at least 0.95), leading us to conclude that our parametrically based power </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">calculations should apply with equal force to a non-parametric analysis.   </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Statistical analyses</span></i></b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> -</span></i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Results from a sample of this size may not be normally distributed. </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Therefore, non-parametric statistical measures may be used.  Primary outcome measures </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">evaluating for change in KOOS will be assessed at multiple points and will be analyzed for </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">change between groups using Friedman two-way ANOVA for repeated measures. Synovial fluid </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">analyses comparing the three groups at five time points will be analyzed using the Wilcoxon </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Signed Rank Sum Test with Hochberg corrections for multiple time points.  Alternatively, if </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">results are normally distributed or can be transformed (e.g., by log transformation) to meet the </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">criteria for normality for parametric analysis, then repeated measures ANOVA will be utilized </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">comparing treatment groups.  P-values of less than or equal to 0.05 will be considered </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">statistically significant. </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">Predicted Results:  </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">IL-1ra, while potent, has had mixed results in the treatment of established </span></p>
<p style="top:252.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">OA, possibly due to it&#x2019;s short half-life in vivo. In this trial, we expect that an early intervention </span></p>
<p style="top:264.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">with IL-1ra will effectively block the deleterious cascade of joint degradation events after joint </span></p>
<p style="top:276.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury.  We expect a significant effect of IL-1ra on post-injury pain and concomitantly an </span></p>
<p style="top:288.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">increase in patient-reported outcomes due to the improved early function </span></p>
<p style="top:300.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:312.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Minimization of bias</span></b><b><i><span style="font-family:Times New Roman,serif;font-size:12.0pt">: </span></i></b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Due to the randomized study design and the blinding of the investigator </span></p>
<p style="top:324.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and patient to the drug used, we hope to eliminate any investigator or subject bias. Using broad </span></p>
<p style="top:336.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and previously established enrollment criteria we hope to reduce selection bias to a minimum </span></p>
<p style="top:348.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">while protecting potentially vulnerable individuals through the exclusion criteria. Procedural bias </span></p>
<p style="top:360.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and measurement bias will be reduced by the multicenter design and the blinded data analysis. </span></p>
<p style="top:372.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">  </span></p>
<p style="top:388.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.1.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S) </span></p>
<p style="top:400.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:412.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A safety review of treatment Groups 1 and 2will be performed.  Safety endpoints will be </span></p>
<p style="top:424.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">monitored at each study visit and at each monitoring visit.  </span></p>
<p style="top:436.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:448.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study Stopping Criteria </span></b></p>
<p style="top:460.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></b></p>
<p style="top:472.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">local intolerance of the administered Kineret or any sign of allergic response. </span></p>
<p style="top:484.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">development of signs and symptoms before the second time point preventing the second </span></p>
<p style="top:496.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">administration of the study drug. </span></p>
<p style="top:508.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Any patient reported SAE after the first or second administration of the study drug. </span></p>
<p style="top:520.6pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">Diagnosis with any condition as outlined in the exclusion criteria during the course of the </span></p>
<p style="top:532.6pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">initial 2 weeks of study enrollment. </span></p>
<p style="top:544.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:560.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.1.3 ANALYSIS OF THE SECONDARY ENDPOINT(S) </span></p>
<p style="top:573.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:585.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not applicable </span></p>
<p style="top:597.1pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:613.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">10.2 MEASURES TO MINIMIZE BIAS </span></p>
<p style="top:630.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:647.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.2.1 ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES </span></p>
<p style="top:659.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:671.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Randomization:  Following informed consent and after successfully being screened into the </span></p>
<p style="top:683.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study, subjects will be randomized to one of three treatment groups.   </span></p>
<p style="top:695.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">39 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 1</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of Anakinra (Kineret&#xae;,  IL-1ra; 150mg) 1-</span></p>
<p style="top:84.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">28 days after ACL injury.  </span></p>
<p style="top:96.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Arial,sans-serif;font-size:12.0pt"> </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">Group 2</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> will receive intra-articular injection of saline placebo 1-28 days after ACL </span></p>
<p style="top:108.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">injury.  </span></p>
<p style="top:120.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Blinding:</span><span style="font-family:Times New Roman,serif;font-size:11.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:12.0pt">To ensure triple-blindness, an uninvolved third party will generate the allocation </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">sequence of the intervention and provide this to the principal investigator.  Allocation of drug or </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">placebo will be by permutated random block size, ensuring that approximately equal numbers of </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subjects will be treated with drug or placebo in the unlikely event that the study will need to be </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">terminated prematurely. </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">If subject discontinues the study for any reason prior to 3-month visit, then the collected data will </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be evaluated but not included in the analysis and a replacement subject will be enrolled in the </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study. </span></p>
<p style="top:240.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:256.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.2.2 EVALUATION OF SUCCESS OF BLINDING  </span></p>
<p style="top:268.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:280.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Not applicable. </span></p>
<p style="top:292.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:308.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">10.2.3 BREAKING THE STUDY BLIND/PARTICIPANT CODE </span></p>
<p style="top:321.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:333.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Breaking the randomization code will be performed by the Principal Investigator and will occur </span></p>
<p style="top:345.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">if  it is necessary for the care of the subjects.  For example, if an AE or SAE occurs with the a </span></p>
<p style="top:357.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subject and knowledge of the drug randomization would be important for clinical care or to </span></p>
<p style="top:369.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">determine appropriate treatment, then the principal investigator will break the code and the </span></p>
<p style="top:381.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">subject will be withdrawn from the study. </span></p>
<p style="top:393.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:405.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Unblinding of a subject(s) dosing will be documented and will include an explanation of why the </span></p>
<p style="top:417.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study medication was unblinded. </span></p>
<p style="top:429.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:441.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Following data lock, subject dosing information can be unblinded and the unblinded information </span></p>
<p style="top:453.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">can be sent to the study participants at the discretion of the principal investigator. </span></p>
<p style="top:465.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:481.7pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">11 </span></b></p>
<p style="top:481.7pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">SOURCE DOCUMENTS AND ACCESS TO SOURCE </span></b></p>
<p style="top:495.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">DATA/DOCUMENTS </span></b></p>
<p style="top:510.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:522.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The principal investigator will maintain appropriate medical and research records for this trial, in </span></p>
<p style="top:534.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">compliance with ICH E6 and regulatory and institutional requirements for the protection of </span></p>
<p style="top:546.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">confidentiality of participants.  The principal investigator will permit authorized representatives </span></p>
<p style="top:558.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of the FDA, Institutional Review Board, Center for Clinical and Translational Science, Bluegrass </span></p>
<p style="top:570.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Research Consultants, Inc. and regulatory agencies to examine (and when permitted by </span></p>
<p style="top:582.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits, </span></p>
<p style="top:594.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and evaluation of the study safety, progress, and data validity.  </span></p>
<p style="top:606.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:618.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Source data are all information, original records of clinical findings, observations, or other </span></p>
<p style="top:630.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples </span></p>
<p style="top:642.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of these original documents and data records include, but are not limited to, hospital records, </span></p>
<p style="top:654.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">clinical and office charts, laboratory notes, memoranda, participant&#x2019;s memory aids or evalulation </span></p>
<p style="top:666.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">checklists, pharmacy dispensing records, recorded audio tapes of counseling sessions, recorded </span></p>
<p style="top:678.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">data from automated instruments, copies or transcriptions certified after verification as being </span></p>
<p style="top:690.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-</span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">40 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">rays, and participant files and records kept at the pharmacy, at the laboratories, and medico-</span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">technical departments involved in the clinical trial.  </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">It is </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">not</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> acceptable for the CRF to be the only record of a patient&#x2019;s participation in the study.  </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This is to ensure that anyone who would access the patient medical record has adequate </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">knowledge that the patient is participating in a clinical trial. </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:160.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">12 </span></b></p>
<p style="top:160.6pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">QUALITY ASSURANCE AND QUALITY CONTROL </span></b></p>
<p style="top:175.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:187.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Quality Control rocedures will be implemented beginning with the data entry system and data </span></p>
<p style="top:199.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">QC checks that will be run on the database will be generated. Any missing data or data </span></p>
<p style="top:211.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">anomalies will be communicated to the site(s) for clarification/resolution.  </span></p>
<p style="top:223.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:235.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Following written SOPs, the monitors will verify that the clinical trial is conducted and data are </span></p>
<p style="top:247.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">generated, documented (recorded), and reported in compliance with the protocol, GCP, and the </span></p>
<p style="top:259.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing </span></p>
<p style="top:271.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Practices (GMP)).  </span></p>
<p style="top:283.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:295.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The investigational site will provide direct access to all trial related sites, source data/documents, </span></p>
<p style="top:307.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local </span></p>
<p style="top:319.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and regulatory authorities. </span></p>
<p style="top:331.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:348.4pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">13 </span></b></p>
<p style="top:348.4pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">ETHICS/PROTECTION OF HUMAN SUBJECTS  </span></b></p>
<p style="top:365.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:382.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">13.1 ETHICAL STANDARD  </span></p>
<p style="top:397.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:409.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The investigator will ensure that this study is conducted in full conformity with Regulations for </span></p>
<p style="top:421.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 </span></p>
<p style="top:433.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">CFR Part 56, and/or the ICH E6. If the study is conducted at international sites, the statement </span></p>
<p style="top:445.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">could be as above and/or could reference compliance with the Declaration of Helsinki, Council </span></p>
<p style="top:457.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">for International Organizations of Medical Science (CIOMS), International Ethical Guidelines </span></p>
<p style="top:469.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">for Biomedical Research Involving Human Subjects (2002), or another country&#x2019;s ethical policy </span></p>
<p style="top:481.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">statement, whichever provides the </span><b><span style="font-family:Times New Roman,serif;font-size:12.0pt">most</span></b><span style="font-family:Times New Roman,serif;font-size:12.0pt"> protection to  human subjects. </span></p>
<p style="top:493.2pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:509.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">13.2 INSTITUTIONAL REVIEW BOARD  </span></p>
<p style="top:525.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:537.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The protocol, informed consent form(s), recruitment materials, and all participant materials will </span></p>
<p style="top:549.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">be submitted to the IRB for review and approval. Approval of both the protocol and the consent </span></p>
<p style="top:561.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">form must be obtained before any participant is enrolled. Any amendment to the protocol will </span></p>
<p style="top:573.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">require review and approval by the IRB before the changes are implemented to the study. All </span></p>
<p style="top:585.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">changes to the consent form will be IRB approved; a determination will be made regarding </span></p>
<p style="top:597.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">whether previously consented participants need to be re-consented. </span></p>
<p style="top:609.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:625.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">13.3 INFORMED CONSENT PROCESS  </span></p>
<p style="top:642.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:654.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Prior to the start of the trial, the investigator should have the IRB&#x2019;s written approval for the </span></p>
<p style="top:666.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">protocol and the written informed consent form(s) and any other written information to be </span></p>
<p style="top:678.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">provided to the participants. </span></p>
<p style="top:690.6pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">41 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:76.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS </span></p>
<p style="top:90.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">PROVIDED TO PARTICIPANTS </span></p>
<p style="top:102.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:114.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Consent forms describing in detail the study agent, study procedures, and risks are given to the </span></p>
<p style="top:126.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participant and written documentation of informed consent is required prior to starting </span></p>
<p style="top:138.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">intervention/administering study product. The following consent materials are submitted with </span></p>
<p style="top:150.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">this protocol. </span></p>
<p style="top:162.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:178.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">13.3.2 CONSENT PROCEDURES AND DOCUMENTATION </span></p>
<p style="top:190.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:202.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Informed consent is a process that is initiated prior to the individual&#x2019;s agreeing to participate in </span></p>
<p style="top:214.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the study and continues throughout the individual&#x2019;s study participation. Extensive discussion of </span></p>
<p style="top:226.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">risks and possible benefits of participation will be provided to the participants and their families. </span></p>
<p style="top:238.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Consent forms will be IRB-approved and the participant will be asked to read and review the </span></p>
<p style="top:250.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">document. The investigator will explain the research study to the participant and answer any </span></p>
<p style="top:262.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">questions that may arise. All participants will receive a verbal explanation in terms suited to their </span></p>
<p style="top:274.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">comprehension of the purposes, procedures, and potential risks of the study and of their rights as </span></p>
<p style="top:286.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">research participants. Participants will have the opportunity to carefully review the written </span></p>
<p style="top:298.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">consent form and ask questions prior to signing. The participants should have the opportunity to </span></p>
<p style="top:310.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">discuss the study with their surrogates or think about it prior to agreeing to participate. The </span></p>
<p style="top:322.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participant will sign the informed consent document prior to any procedures being done </span></p>
<p style="top:334.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">specifically for the study. The participants may withdraw consent at any time throughout the </span></p>
<p style="top:346.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">course of the trial. A copy of the informed consent document will be given to the participants for </span></p>
<p style="top:358.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">their records. The rights and welfare of the participants will be protected by emphasizing to them </span></p>
<p style="top:370.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">that the quality of their medical care will not be adversely affected if they decline to participate </span></p>
<p style="top:382.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">in this study. </span></p>
<p style="top:394.9pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:411.5pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">13.4 PARTICIPANT AND DATA CONFIDENTIALITY  </span></p>
<p style="top:426.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:438.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Participant confidentiality is strictly held in trust by the participating investigators, their staff, </span></p>
<p style="top:450.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological </span></p>
<p style="top:462.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">samples and genetic tests in addition to the clinical information relating to participants. </span></p>
<p style="top:474.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Therefore, the study protocol, documentation, data, and all other information generated will be </span></p>
<p style="top:486.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">held in strict confidence. No information concerning the study or the data will be released to any </span></p>
<p style="top:498.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">unauthorized third party without prior written approval of the sponsor. </span></p>
<p style="top:510.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:522.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study monitor, other authorized representatives of the sponsor, representatives of the IRB or </span></p>
<p style="top:534.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pharmaceutical company supplying study product may inspect all documents and records </span></p>
<p style="top:546.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">required to be maintained by the investigator, including but not limited to, medical records </span></p>
<p style="top:558.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">(office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical </span></p>
<p style="top:570.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study site will permit access to such records.  </span></p>
<p style="top:582.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:594.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study participant&#x2019;s contact information will be securely stored at each clinical site for </span></p>
<p style="top:606.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">internal use during the study. At the end of the study, all records will continue to be kept in a </span></p>
<p style="top:618.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">secure location for as long a period as dictated by local IRB and Institutional regulations.  </span></p>
<p style="top:630.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:642.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Study participant research data, which is for purposes of statistical analysis and scientific </span></p>
<p style="top:654.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reporting will not include the participant&#x2019;s contact or identifying information. Rather, individual </span></p>
<p style="top:666.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">participants and their research data will be identified by a unique study identification number. </span></p>
<p style="top:678.7pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study data entry and study management systems used by clinical sites and by research staff </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">42 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">will be secured and password protected. At the end of the study, all study databases will be de-</span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">identified and archived at the the University of Kentucky.  </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:110.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#233e5f">13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES,SPECIMENS OR DATA </span></p>
<p style="top:122.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:134.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All samples/specimens or data collect will be used for the purpose of this research study only.  </span></p>
<p style="top:146.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">No future use of the samples/specimens or data will be allowed. </span></p>
<p style="top:158.8pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:173.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">13.5 FUTURE USE OF STORED SPECIMENS  </span></p>
<p style="top:188.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff"> </span></b></p>
<p style="top:200.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">N/A </span></p>
<p style="top:212.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff"> </span></b></p>
<p style="top:227.8pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">14 </span></b></p>
<p style="top:227.8pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">DATA HANDLING AND RECORD KEEPING  </span></b></p>
<p style="top:242.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:257.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  </span></p>
<p style="top:272.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:284.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Data collection is the responsibility of the clinical trial staff at the site under the supervision of </span></p>
<p style="top:296.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, </span></p>
<p style="top:308.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and timeliness of the data reported.  </span></p>
<p style="top:320.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:332.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">All source documents should be completed in a neat, legible manner to ensure accurate </span></p>
<p style="top:344.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">interpretation of data. Black ink is required to ensure clarity of reproduced copies. When making </span></p>
<p style="top:356.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">changes or corrections, cross out the original entry with a single line, and initial and date the </span></p>
<p style="top:368.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON </span></p>
<p style="top:380.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">THE ORIGINAL. </span></p>
<p style="top:392.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:404.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Copies of the CRF (CRF) will be provided for use as source documents and maintained for </span></p>
<p style="top:416.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">recording data for each participant enrolled in the study. Data reported in the CRF derived from </span></p>
<p style="top:428.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">source documents should be consistent with the source documents or the discrepancies should be </span></p>
<p style="top:440.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">explained and captured in a progress note and maintained in the participant&#x2019;s official electronic </span></p>
<p style="top:452.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study record.  </span></p>
<p style="top:464.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:476.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and </span></p>
<p style="top:488.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">clinical laboratory data will be entered onto paper CRFs or a eCRF 21 CFR Part 11-compliant </span></p>
<p style="top:500.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">data capture system provided by the Sponsor. The data system includes password protection and </span></p>
<p style="top:512.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">internal quality checks, such as automatic range checks, to identify data that appear inconsistent, </span></p>
<p style="top:524.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">incomplete, or inaccurate. Clinical data will be entered directly from the source documents. </span></p>
<p style="top:536.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:551.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14.2 STUDY RECORDS RETENTION  </span></p>
<p style="top:566.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:578.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Records should not be destroyed without the sponsor&#x2019;s agreement.  Study documents should be </span></p>
<p style="top:590.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">retained for a minimum of 6 years in keeping with local IRB record retension policy.   </span></p>
<p style="top:602.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:617.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14.3 PROTOCOL DEVIATIONS  </span></p>
<p style="top:632.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:644.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP </span></p>
<p style="top:656.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">requirements. The noncompliance may be either on the part of the participant, the investigator, or </span></p>
<p style="top:668.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">the study site staff. As a result of deviations, corrective actions are to be developed by the site </span></p>
<p style="top:680.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and implemented promptly. </span></p>
<p style="top:692.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">43 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">These practices are consistent with ICH E6:  </span></p>
<p style="top:84.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:96.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  </span></p>
<p style="top:96.0pt;left:432.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:108.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; 5.1 Quality Assurance and Quality Control, section 5.1.1  </span></p>
<p style="top:120.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:120.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">&#x2022; 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">It is the responsibility of the site to use continuous vigilance to identify and report deviations </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">within working days of identification of the protocol deviation, or within working days of the </span></p>
<p style="top:168.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">scheduled protocol-required activity. All deviations must be addressed in study source </span></p>
<p style="top:180.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">documents, reported to Program Official and protocol deviations must be sent to the local IRB </span></p>
<p style="top:192.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB </span></p>
<p style="top:204.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">requirements. Further details about the handling of protocol deviations will be included in the </span></p>
<p style="top:216.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">MOP. </span></p>
<p style="top:228.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:243.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">14.4 PUBLICATION AND DATA SHARING POLICY </span></p>
<p style="top:258.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:270.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">This study will comply with the NIH Public Access Policy, which ensures that the public has </span></p>
<p style="top:282.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">access to the published results of NIH funded research. It requires scientists to submit final peer-</span></p>
<p style="top:294.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central </span></p>
<p style="top:306.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">upon acceptance for publication.  </span></p>
<p style="top:318.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:330.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The International Committee of Medical Journal Editors (ICMJE) member journals have adopted </span></p>
<p style="top:342.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical </span></p>
<p style="top:354.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">trial as any research project that prospectively assigns human subjects to intervention or </span></p>
<p style="top:366.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">concurrent comparison or control groups to study the cause-and-effect relationship between a </span></p>
<p style="top:378.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">medical intervention and a health outcome. Medical interventions include drugs, surgical </span></p>
<p style="top:390.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">procedures, devices, behavioral treatments, process-of-care changes, and the like. Health </span></p>
<p style="top:402.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">outcomes include any biomedical or health-related measures obtained in patients or participants, </span></p>
<p style="top:414.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">including pharmacokinetic measures and adverse events.  </span></p>
<p style="top:426.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:438.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The ICMJE policy, and the Section 801 of the Food and Drug Administration Amendments Act </span></p>
<p style="top:450.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">of 2007, requires that all clinical trials be registered in a public trials registry such as </span></p>
<p style="top:462.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">ClinicalTrials.gov, which is sponsored by the National Library of Medicine. Other biomedical </span></p>
<p style="top:474.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">journals are considering adopting similar policies. For interventional clinical trials performed </span></p>
<p style="top:486.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">under NIH IC grants and cooperative agreements, it is the grantee&#x2019;s responsibility to register the </span></p>
<p style="top:498.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">trial in an acceptable registry, so the research results may be considered for publication in ICMJE </span></p>
<p style="top:510.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">member journals. The ICMJE does not review specific studies to determine whether registration </span></p>
<p style="top:522.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">is necessary; instead, the committee recommends that researchers who have questions about the </span></p>
<p style="top:534.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">need to register err on the side of registration or consult the editorial office of the journal in </span></p>
<p style="top:546.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">which they wish to publish. </span></p>
<p style="top:558.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:570.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FDAAA mandates that a &quot;responsible party&quot; (i.e., the sponsor or designated principal </span></p>
<p style="top:582.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigator) register and report results of certain &quot;applicable clinical trials&quot;:  </span></p>
<p style="top:594.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I </span></p>
<p style="top:606.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">investigations, of a product subject to FDA regulation  </span></p>
<p style="top:618.0pt;left:90.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span><span style="font-family:SymbolMT,sans-serif;font-size:12.0pt">&#x2022;</span><span style="font-family:Times New Roman,serif;font-size:12.0pt"> Trials of Devices: Controlled trials with health outcomes of a product subject to FDA </span></p>
<p style="top:630.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">regulation (other than small feasibility studies) and pediatric postmarket surveillance </span></p>
<p style="top:642.0pt;left:108.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">studies.  </span></p>
<p style="top:654.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:666.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">NIH grantees must take specific steps to ensure compliance with NIH implementation of </span></p>
<p style="top:678.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">FDAAA. </span></p>
<p style="top:690.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">44 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:75.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">15 </span></b></p>
<p style="top:75.0pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">STUDY ADMINISTRATION </span></b></p>
<p style="top:90.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:102.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:117.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">15.1 STUDY LEADERSHIP </span></p>
<p style="top:132.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:144.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The study leadership will be comprise of the sponsor and site principal investigators. </span></p>
<p style="top:156.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:171.0pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">16 </span></b></p>
<p style="top:171.0pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">CONFLICT OF INTEREST POLICY </span></b></p>
<p style="top:186.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:198.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">The independence of this study from any actual or perceived influence, such as by the </span></p>
<p style="top:210.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">pharmaceutical industry, is critical. Therefore any actual conflict of interest of persons who have </span></p>
<p style="top:222.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed </span></p>
<p style="top:234.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">and managed. Furthermore, persons who have a perceived conflict of interest will be required to </span></p>
<p style="top:246.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">have such conflicts managed in a way that is appropriate to their participation in the trial. The </span></p>
<p style="top:258.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">study leadership in conjunction with the has established policies and procedures for all study </span></p>
<p style="top:270.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">group members to disclose all conflicts of interest and will establish a mechanism for the </span></p>
<p style="top:282.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">management of all reported dualities of interest. </span></p>
<p style="top:294.0pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:310.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">17  </span></b></p>
<p style="top:310.6pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">LITERATURE REFERENCES  </span></b></p>
<p style="top:325.8pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:339.6pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Cambria,serif;font-size:12.0pt">References: </span></b></p>
<p style="top:351.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">1.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heineg&#xe5;rd D, Jordan JM, Kepler TB, </span></p>
<p style="top:362.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lane NE, Saxne T, Tyree B, Kraus VB; Osteoarthritis Biomarkers Network. Classification of osteoarthritis </span></p>
<p style="top:372.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006 Aug;14(8):723-7. Epub 2006 Jun 2. </span></p>
<p style="top:381.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Review. PubMed PMID: 16733093. </span></p>
<p style="top:392.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Boks SS, Vroegindeweij D, Koes BW, Bernsen RM, Hunink MG, Bierma-Zeinstra SM.  Clinical </span></p>
<p style="top:402.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">consequences of posttraumatic bone bruise in the knee. Am J Sports Med.  2007 Jun;35(6):990-5. Epub </span></p>
<p style="top:411.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2007 Feb 16. PubMed PMID: 17307889.   </span></p>
<p style="top:422.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">3.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Brown TD, Johnston RC, Saltzman CL, Lawrence MJ, Buckwalter JA. Posttraumatic OA: A First Estimate </span></p>
<p style="top:432.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of Incidence, Prevalence, and Burden of Disease. J Ortho Trauma 2006; 20(10): 739-744 </span></p>
<p style="top:441.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">4.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bruyere O, Collette J, Kothari M, Zaim S, White D, Genant H, Peterfy C, Burlet N, Ethgen D, Montague T, </span></p>
<p style="top:452.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dabrowski C, Reginster JY. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one </span></p>
<p style="top:462.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">year prospective study. Ann Rheum Dis. 2006 Aug;65(8):1050-4. Epub 2006 Jan 5. PubMed PMID: </span></p>
<p style="top:471.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">16396978; PubMed  Central PMCID: PMC1798262.   </span></p>
<p style="top:482.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">5.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY. </span></p>
<p style="top:491.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee </span></p>
<p style="top:501.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">osteoarthritis. J Rheumatol. 2003 May;30(5):1043-50. PubMed PMID: 12734904.   </span></p>
<p style="top:512.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">6.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Catterall JB, Stabler TV, Flannery CR, Kraus VB.Changes in serum and synovial fluid biomarkers after </span></p>
<p style="top:521.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">acute injury Arthritis Res Ther. 2010;12(6):R229. Epub 2010 Dec 31.PMID:21194441 </span></p>
<p style="top:531.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">7.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Chaudhari AM, Briant PL, Bevill SL, Koo S, Andriacchi TP. Knee kinematics, cartilage morphology, and </span></p>
<p style="top:542.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">osteoarthritis after ACL injury. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Med Sci Sports Exerc. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Feb 2008;40(2):215-222. </span></p>
<p style="top:551.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">8.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, </span></p>
<p style="top:561.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL,  Esdaile JM. Association of biomarkers </span></p>
<p style="top:572.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based </span></p>
<p style="top:581.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study. Arthritis Rheum. 2009 May;60(5):1372-80. PubMed PMID: 19404937.   </span></p>
<p style="top:591.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">9.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Costa-Paz M, Muscolo DL, Ayerza M, Makino A, Aponte-Tinao L. Magnetic resonance imaging followup </span></p>
<p style="top:602.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study of bone bruises associated with anterior cruciate ligament ruptures. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Arthroscopy. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">May </span></p>
<p style="top:611.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2001;17(5):445-449. </span></p>
<p style="top:621.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">dunn </span></p>
<p style="top:632.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">11.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Faber KJ, Dill JR, Amendola A, Thain L, Spouge A, Fowler PJ. Occult osteochondral lesions after anterior </span></p>
<p style="top:641.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cruciate ligament rupture. Six-year magnetic resonance imaging follow-up study. Am J Sports Med. 1999 </span></p>
<p style="top:651.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Jul-Aug;27(4):489-94. PubMed PMID: 10424219.   </span></p>
<p style="top:662.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">12.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Felson DT. Validating markers in osteoarthritis. Acta Orthop Scand Suppl. 1995 Oct;266:205-7. Review. </span></p>
<p style="top:671.9pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PubMed PMID: 8553853.   </span></p>
<p style="top:681.9pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">13.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Frobell RB, Le Graverand MP, Buck R, et al. The acutely ACL injured knee assessed by MRI: changes in </span></p>
<p style="top:692.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">joint fluid, bone marrow lesions, and cartilage during the first year. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Osteoarthritis Cartilage. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Feb </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">45 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2009;17(2):161-167. </span></p>
<p style="top:82.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">14.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Granan LP, Bahr R, Lie SA, Engebretsen L. Timing of anterior cruciate ligament reconstructive surgery </span></p>
<p style="top:92.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and risk of cartilage lesions and meniscal tears: a cohort study based on the Norwegian National Knee </span></p>
<p style="top:102.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ligament Registry. Am J Sports Med. 2009 May;37(5):955-61. Epub 2009 Feb 26. PubMed PMID: </span></p>
<p style="top:112.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">19251674.   </span></p>
<p style="top:122.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">15.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Hanypsiak BT, Spindler KP, Rothrock CR, Calabrese GJ, Richmond B, Herrenbruck  TM, Parker RD. </span></p>
<p style="top:132.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Twelve-year follow-up on anterior cruciate ligament reconstruction: long-term outcomes of prospectively </span></p>
<p style="top:142.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studied osseous and articular injuries. Am J Sports Med. 2008 Apr;36(4):671-7. Epub 2008 Mar 7. PubMed </span></p>
<p style="top:152.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PMID: 18326830.   </span></p>
<p style="top:162.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">16.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Hewett TE, Torg JS, Boden BP. Video analysis of trunk and knee motion during  non-contact anterior </span></p>
<p style="top:172.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cruciate ligament injury in female athletes: lateral trunk and knee abduction motion are combined </span></p>
<p style="top:182.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">components of the injury mechanism. Br J Sports Med. 2009 Jun;43(6):417-22. Epub 2009 Apr 15. </span></p>
<p style="top:192.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PubMed PMID: 19372088. </span></p>
<p style="top:202.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">17.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Hunter DJ, Li J, LaValley M, et al. Cartilage markers and their association with cartilage loss on magnetic </span></p>
<p style="top:212.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Arthritis Res Ther. </span></i></p>
<p style="top:222.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2007;9(5):R108. </span></p>
<p style="top:232.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">18.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Hunter DJ, Lavalley M, Li J, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D,  Guermazi A, Gale D, </span></p>
<p style="top:242.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Totterman S, Felson DT. Biochemical markers of bone turnover  and their association with bone marrow </span></p>
<p style="top:252.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lesions. Arthritis Res Ther. 2008;10(4):R102. Epub 2008 Aug 29. PubMed PMID: 18759975; PubMed </span></p>
<p style="top:262.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Central PMCID: PMC2575616.   </span></p>
<p style="top:272.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">19.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Johnson DL, Bealle DP, Brand JC Jr, Nyland J, Caborn DN. The effect of a geographic lateral bone bruise </span></p>
<p style="top:282.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">on knee inflammation after acute anterior cruciate ligament rupture. Am J Sports Med. 2000 Mar-</span></p>
<p style="top:292.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Apr;28(2):152-5. PubMed PMID: 10750989.   </span></p>
<p style="top:302.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">20.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Johnson DL, Urban WP Jr, Caborn DN, Vanarthos WJ, Carlson CS. Articular cartilage changes seen with </span></p>
<p style="top:312.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">magnetic resonance imaging-detected bone bruises associated with acute anterior cruciate ligament rupture. </span></p>
<p style="top:322.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Am J Sports Med. 1998 May-Jun;26(3):409-14. PubMed PMID: 9617404.   </span></p>
<p style="top:332.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">21.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kuhne SA, Neidhart M, Everson MP, et al. Persistent high serum levels of cartilage oligomeric matrix </span></p>
<p style="top:342.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">protein in a subgroup of patients with traumatic knee injury. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rheumatol Int. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">1998;18(1):21-25. </span></p>
<p style="top:352.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">22.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lahm A, Uhl M,Erggelet C,Haberstroh J, Mrosek E. Articular cartilage degeneration after acute </span></p>
<p style="top:362.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">subchondral bone damage: an experimental study in dogs with histopathological grading. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Acta Orthop </span></i></p>
<p style="top:372.1pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Scand.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 2004 Dec;75(6):762-7. </span></p>
<p style="top:382.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">23.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lewis PB, Parameswaran AD, Rue JP, Bach BR Jr. Systematic review of single-bundle anterior cruciate </span></p>
<p style="top:392.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ligament reconstruction outcomes: a baseline assessment for consideration of double-bundle techniques. </span></p>
<p style="top:402.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Am J Sports Med. 2008 Oct;36(10):2028-36. Epub 2008 Aug 29. Review. PubMed PMID: 18757764.   </span></p>
<p style="top:412.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">24.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lohmander LS, Ostenberg A, Englund M, Roos H. High prevalence of knee osteoarthritis, pain, and </span></p>
<p style="top:422.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">functional limitations in female soccer players twelve  years after anterior cruciate ligament injury. Arthritis </span></p>
<p style="top:432.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rheum. 2004 Oct;50(10):3145-52. PubMed PMID: 15476248.   </span></p>
<p style="top:442.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">25.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lohmander LS, Felson D. Can we identify a &apos;high risk&apos; patient profile to determine who will experience </span></p>
<p style="top:452.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rapid progression of osteoarthritis? Osteoarthritis Cartilage. 2004;12 Suppl A:S49-52. Review. PubMed </span></p>
<p style="top:462.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PMID: 14698642.   </span></p>
<p style="top:472.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">26.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament </span></p>
<p style="top:482.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and meniscus injuries: osteoarthritis. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Am J Sports Med. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Oct 2007;35(10):1756-1769. </span></p>
<p style="top:492.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">27.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Marlovits S, Singer P, Zeller P, Mandl I, Haller J, Trattnig S. Magnetic resonance observation of cartilage </span></p>
<p style="top:502.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">repair tissue (MOCART) for the evaluation of autologous chondrocyte transplantation: determination of </span></p>
<p style="top:512.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">interobserver variability and correlation to clinical outcome after 2 years. Eur J Radiol. 2006 Jan;57(1):16-</span></p>
<p style="top:522.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">23. Epub 2005 Oct 3 </span></p>
<p style="top:532.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">28.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Myer GD, Ford KR, Divine JG, Wall EJ, Kahanov L, Hewett TE. Longitudinal assessment of noncontact </span></p>
<p style="top:542.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anterior cruciate ligament injury risk factors during maturation in a female athlete: a case report. J Athl </span></p>
<p style="top:552.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Train. 2009 Jan-Feb;44(1):101-9. PubMed PMID: 19180226; PubMed Central PMCID: PMC2629034.   </span></p>
<p style="top:562.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">29.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Oda H, Igarashi M, Sase H, Sase T, Yamamoto S. Bone bruise in magnetic resonance imaging strongly </span></p>
<p style="top:572.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">correlates with the production of joint effusion and with knee osteoarthritis. J Orthop Sci. 2008 Jan;13(1):7-</span></p>
<p style="top:582.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">15. Epub 2008 Feb 16. PubMed PMID: 18274849.   </span></p>
<p style="top:592.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">30.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Pollard TC, Gwilym SE, Carr AJ. The assessment of early osteoarthritis. J Bone Joint Surg Br. 2008 </span></p>
<p style="top:602.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Apr;90(4):411-21. Review. PubMed PMID: 18378911.   </span></p>
<p style="top:612.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">31.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Suggestion of nonlinear or phasic progression of knee </span></i></p>
<p style="top:622.0pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years.</span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt"> </span></p>
<p style="top:632.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Arthritis Rheum. 2004; 50(8):2479-2488 </span></p>
<p style="top:642.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">32.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Shelbourne KD, Gray T. Minimum 10-year results after anterior cruciate ligament reconstruction: how the </span></p>
<p style="top:652.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">loss of normal knee motion compounds other factors related to the development of osteoarthritis after </span></p>
<p style="top:662.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery. Am J Sports Med. 2009 Mar;37(3):471-80. Epub 2008 Dec 4. PubMed PMID: 19059893.   </span></p>
<p style="top:672.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">33.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Spindler KP, Schils JP, Bergfeld JA, Andrish JT, Weiker GG, Anderson TE, Piraino DW, Richmond BJ, </span></p>
<p style="top:682.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Medendorp SV. Prospective study of osseous, articular, and meniscal lesions in recent anterior cruciate </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">46 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:72.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ligament tears by magnetic resonance imaging and arthroscopy. Am J Sports Med. 1993 Jul-</span></p>
<p style="top:82.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Aug;21(4):551-7. PubMed PMID: 8368416.   </span></p>
<p style="top:92.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">34.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Sumer EU, Schaller S, Sondergaard BC, Tank&#xf3; LB, Qvist P. Application of biomarkers in the clinical </span></p>
<p style="top:102.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers. 2006 </span></p>
<p style="top:112.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nov-Dec;11(6):485-506. Review. PubMed PMID: 17056470.   </span></p>
<p style="top:122.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">35.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Wegrzyn J, Chouteau J, Philippot R, Fessy MH, Moyen B. Repeat revision of anterior cruciate ligament </span></p>
<p style="top:132.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reconstruction: a retrospective review of management and outcome of 10 patients with an average 3-year </span></p>
<p style="top:142.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">follow-up. Am J Sports Med. 2009 Apr;37(4):776-85. PubMed PMID: 19336620.   </span></p>
<p style="top:152.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">36.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Wislowska M, Jablonska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and </span></p>
<p style="top:162.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">knee osteoarthritis. </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clin Rheumatol. </span></i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Jun 2005;24(3):278-284. </span></p>
<p style="top:172.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">37.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Wright RW, Phaneuf MA, Limbird TJ, Spindler KP. Clinical outcome of isolated  subcortical trabecular </span></p>
<p style="top:182.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fractures (bone bruise) detected on magnetic resonance imaging in knees. Am J Sports Med. 2000 Sep-</span></p>
<p style="top:192.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Oct;28(5):663-7. PubMed PMID: 11032221.  </span></p>
<p style="top:202.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">38.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nahata MC, Morosco RS, Sabados BK, Weber TR. College of Pharmacy, Ohio State University, </span></p>
<p style="top:212.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Columbus, USA., Stability and compatibility of anakinra with ceftriaxone sodium injection in 0.9% sodium </span></p>
<p style="top:222.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">chloride or 5% dextrose injection. J Clin Pharm Ther. 1997 Jun;22(3):167-9 </span></p>
<p style="top:232.0pt;left:90.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">39.</span></i><i><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span></i><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-</span></i></p>
<p style="top:242.1pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with </span></i></p>
<p style="top:252.1pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011 May; 70(5):747-754.(8) </span></i></p>
<p style="top:262.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">40.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report </span></i></p>
<p style="top:272.1pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb; 63(2):545-555. </span></i></p>
<p style="top:282.1pt;left:108.0pt;line-height:10.0pt"><i><span style="font-family:Times New Roman,serif;font-size:10.0pt">(7)</span></i><b><span style="font-family:Times New Roman,serif;font-size:10.0pt">  </span></b></p>
<p style="top:292.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">41.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-</span></p>
<p style="top:302.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic </span></p>
<p style="top:312.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">arthritis. Arthritis Rheum. 2008 May; 58(5):1505-1515. </span></p>
<p style="top:322.0pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">42.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Haines KA. Juvenile idiopathic arthritis: therapies in the 21st century. Bulletin of the NYU hospital for </span></p>
<p style="top:332.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">joint diseases. 2007; 65(3):205-211. </span></p>
<p style="top:342.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">43.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">  Havemose-Poulsen A, Sorensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral </span></p>
<p style="top:352.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, </span></p>
<p style="top:362.1pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and rheumatoid arthritis. J Periodontol. 2005 Dec; 76(12):2276-2285. </span></p>
<p style="top:372.1pt;left:90.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">44.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> Horneff G. [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile </span></p>
<p style="top:382.0pt;left:108.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">idiopathic arthritis (JIA)]. Z Rheumatol. 2005 Jun; 64(5):317-326. </span></p>
<p style="top:392.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">45.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Sanders TL, Maradit Kremers H, Bryan AJ, Larson DR, Dahm DL, Levy BA, Stuart MJ, Krych AJ. </span></p>
<p style="top:402.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Incidence of Anterior Cruciate Ligament Tears and Reconstruction: A 21-Year Population-Based Study. </span></p>
<p style="top:412.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Am J Sports Med. 2016 Jun;44(6):1502-7. doi: 10.1177/0363546516629944. Epub 2016 Feb 26. PubMed </span></p>
<p style="top:422.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">PMID: 26920430. </span></p>
<p style="top:432.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">46.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Genemaras AA, Reiner T, Huang CY, Kaplan L. Early intervention with Interleukin-1 Receptor Antagonist </span></p>
<p style="top:442.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Protein modulates catabolic microRNA and mRNA expression in cartilage after impact injury. </span></p>
<p style="top:452.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Osteoarthritis Cartilage. 2015 Nov;23(11):2036-44. doi: 10.1016/j.joca.2015.05.010. PubMed PMID: </span></p>
<p style="top:462.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">26521750.  </span></p>
<p style="top:472.0pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">47.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Furman BD, Mangiapani DS, Zeitler E, Bailey KN, Horne PH, Huebner JL, Kraus VB, Guilak F, Olson </span></p>
<p style="top:482.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SA. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of </span></p>
<p style="top:492.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther. 2014 Jun </span></p>
<p style="top:502.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">25;16(3):R134. doi: 10.1186/ar4591. PubMed PMID: 24964765; PubMed Central PMCID: PMC4229982.    </span></p>
<p style="top:512.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">48.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular </span></p>
<p style="top:522.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injection of interleukin 1 receptor antagonist in  patients with painful knee osteoarthritis: a multicenter </span></p>
<p style="top:532.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study. J Rheumatol. 2005 Jul;32(7):1317-23. PubMed PMID: 15996071. </span></p>
<p style="top:542.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">49.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Lattermann C, Jacobs CA, Bunnell MP, Jochimsen KN, Abt JP, Reinke EK, Gammon LG, Huebner JL, </span></p>
<p style="top:552.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kraus VB, Spindler KP. Logistical challenges and design considerations for studies using acute anterior </span></p>
<p style="top:562.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cruciate ligament injury as a potential model for early posttraumatic osteoarthritis. J Orthop Res. 2016 Jun </span></p>
<p style="top:572.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">9. doi: 10.1002/jor.23329. [Epub ahead of print] PubMed PMID: 27279368. </span></p>
<p style="top:582.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">50.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Struglics A, Larsson S, Kumahashi N, Frobell R, Lohmander LS. Changes in Cytokines and Aggrecan </span></p>
<p style="top:592.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ARGS Neoepitope in Synovial Fluid and Serum and in C-Terminal Crosslinking Telopeptide of Type II </span></p>
<p style="top:602.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Collagen and N-Terminal Crosslinking Telopeptide of Type I Collagen in Urine Over Five Years After </span></p>
<p style="top:612.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Anterior Cruciate Ligament Rupture: An Exploratory Analysis in the Knee Anterior  Cruciate Ligament, </span></p>
<p style="top:622.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Nonsurgical Versus Surgical Treatment Trial. Arthritis Rheumatol. 2015 Jul;67(7):1816-25. doi: </span></p>
<p style="top:632.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">10.1002/art.39146. PubMed PMID: 25914389. </span></p>
<p style="top:642.1pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">51.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd, Garrett WE, Toth AP. Effects </span></p>
<p style="top:652.0pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial </span></p>
<p style="top:662.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(NCT00332254). Osteoarthritis Cartilage. 2012 Apr;20(4):271-8. doi: 10.1016/j.joca.2011.12.009.  Epub </span></p>
<p style="top:672.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">2012 Jan 10. PubMed PMID: 22273632.  </span></p>
<p style="top:682.0pt;left:89.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">52.</span><span style="font-family:Arial,sans-serif;font-size:10.0pt"> </span><span style="font-family:Times New Roman,serif;font-size:10.0pt">Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. </span></p>
<p style="top:692.1pt;left:107.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Orthopedics. 2010 Dec 1;33(12):877. </span></p>
</div>
<div id="page0" style="width:612.0pt;height:792.0pt">
<p style="top:37.2pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">EASI ACL </span></p>
<p style="top:37.2pt;left:498.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">Version 7.0 </span></p>
<p style="top:47.5pt;left:72.0pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:47.5pt;left:489.5pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt">3 March 2020 </span></p>
<p style="top:723.2pt;left:301.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt">47 </span></p>
<p style="top:745.4pt;left:72.0pt;line-height:10.0pt"><span style="font-family:Calibri,sans-serif;font-size:10.0pt"> </span></p>
<p style="top:70.4pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
<p style="top:86.5pt;left:72.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">18  </span></b></p>
<p style="top:86.5pt;left:108.0pt;line-height:12.0pt"><b><span style="font-family:Times New Roman,serif;font-size:12.0pt;color:#ffffff">APPENDIXES  </span></b></p>
<p style="top:103.3pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">Figure 3 &#x2013; Pain VAS &#x2013; Initial Visit </span></p>
<p style="top:117.1pt;left:72.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt"> </span></p>
</div>
